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THE IMMUNE SYSTEM. 
The immune system is an organization of cells and molecules that is specialized in defending 
the organism against pathogens such as bacteria, viruses, worms, fungi, and yeasts. In addition, 
the immune system is also capable of eradicating malignant cells. To fight these pathogens 
and malignant cells, two fundamentally different immune responses work intimately together: 
the innate (natural) immune response, and the acquired (adaptive) immune response.
The innate immune response is the first line defense that readily takes action after infection 
and causes an inflammatory reaction. The innate immune system consist of all the immune 
cells that lack immunological memory such as: phagocytic cells (neutrophils, macrophages, 
and monocytes); cells that release inflammatory cytokines (basophils, mast cells, and 
eosinophils); and natural killer cells. The innate immune response is mediated by germ-line 
encoded receptors and is therefore genetically predetermined. These receptors have defined 
specificity and recognize conserved structures, so called pathogen-associated molecular 
patterns that are shared between large groups of micro-organism (1). The best known 
pattern-recognition receptors that can bind these conserved structures and subsequently 
activate the immune system are the Toll-Like Receptors (2,3) of which already 11 receptors 
have been characterized in mice (4,5). 
The adaptive immune response possesses immunological memory and consists of 
B- and T cells. By means of unique recombination processes, it has been estimated that 
B- and T cells are capable of producing about 1015 different unique receptors from only 400 
different genes, each. With this extremely diverse repertoire, the acquired immune response 
ensures specific recognition of any foreign antigen. The main action of B cells is to excrete 
neutralizing antibodies to clear viruses and bacteria (humoral response). T cells recognize 
small protein fragments (peptide) from extracellular or intracellular proteins and T cells can 
either provide help in the induction of an immune response or can kill infected or malignant 
cells (cellular response). The ligand for T cells is peptides that are presented as a complex 
with the major histocompatibility complex molecules on the cell surface. 
Upon activation, B- and T cells dvide, rapidly increase in numbers and acquire effector 
mechanisms that endow them to clear infections or malignant cells. When the infection is 
cleared, immunological memory is established that will ensure rapid activation of the immune 
system upon re-challenge.
General introduction
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WHAT DO T CELLS RECOGNIZE?
CD4+ and CD8+ T cells.
Naive T cells can be subdivided into two classes: CD4+ and CD8+ T cells. CD4+ T cells can 
be further subdivided into T helper 1 (Th1), Th2 and T regulatory (Treg) T cells. Th cells 
recognize predominantly extracellular Antigen (Ag) in Major Histocompatibility Complex 
(MHC) class II molecules presented by professional Antigen Presenting Cells (APC), 
such as Dendritic Cells (DC) and B lymphocytes. Th2 cells can activate B cells to produce 
antibodies (Ab), while Th1 cells can have several functions for instance: activation of DC 
via CD40-CD40Ligand (CD40L) ligation; they are great sources of inflammatory mediators 
(cytokines); or activation of macrophages to clear intracellular pathogens. The function 
of Treg cells is to dampen the immune response to prevent over activation and to avoid 
auto-immunity. 
CD8+ Cytotoxic T Lymphocytes (CTL) are killer T cells that recognize small peptides 
presented in MHC class I molecules that are expressed on all nucleated cells of the body. 
These peptides are derived from intracellular proteins and the CD8+ T cells can thereby 
recognize infected or malignant cells. Killing of these target cells is mediated by targeted 
release of granzymes, perforins or activation of a death receptor on the target cells (Fas) that 
subsequently induces apoptosis (6). 
Cytotoxic T lymphocytes recognize short linear peptide sequences presented on the cell 
surface.
Until the publication of Townsend et al. 1984 (7) it was generally thought that the CD8+ 
T cells recognized Ag in their native conformation on the cell surface of target cells. In an 
elegant system - in which they transfected fibroblast cells with either the Hemagglutinin 
or the Nucleoprotein (NP) DNA of influenza virus - they showed that cells that expressed 
native glycoprotein Hemagglutinin on the cell surface were not recognized and lysed by 
CTLs. Only cells that expressed the intracellular NP were susceptible for CTL lysis. Most 
importantly, the NP positive cells that were recognized by the CTL did not express any 
surface native NP protein at all. Townsend et al. suggested that proteins were proteolytically 
degraded in the cytosol and that these fragments were presented on the cell surface that could 
then be recognized by CTLs (7,8). In 1986 they actually demonstrated that CTLs recognized 
short linear peptide sequences instead of the 3-dimensional protein structure (9) and by fine 
mapping of the protein they revealed that the CTL sequence was about 16 amino acid (a.a.) 
in length (9). 
13
T cell epitope prediction.
In order to determine the exact peptide length and peptide sequence, the group of Rammensee 
used acid-elution to elute peptides from the MHC class I molecules (10-12). They showed 
that the minimal sequence of MHC class I was not 11-16 a.a., as was published by Townsend 
et al. (8), but was much shorter - 8 a.a in length (11). They found that, despite different 
genetic background of the cells, similar peptides of a given protein are presented if these cells 
share a MHC class I molecule. This provided evidence that the MHC class I molecule is the 
main factor that determines which peptide of a given protein is presented on the cell surface. 
Sequencing of all the eluted peptides revealed that there are MHC allele-specific motifs that 
determine which peptides will (strongly) bind to the MHC class I molecules (13). 
The knowledge of the restriction patterns of peptides for MHC class I binding resulted in 
the rapid identification of CTL epitopes. Straightforward scanning of the protein sequences 
revealed: i) the first bacterial CTL epitope from Listeria Monocytogenes (14), ii) the dominant 
epitope of the chicken egg Ovalbumin (OVA) OVA
257-264
 (15), and iii) epitopes for the hen 
egg lysozyme protein (16). However, identification of the primary a.a. sequence turned out 
to be not sufficient per se, as different peptides were found that did not meet the criteria (16) 
or predicted CTL epitope sequences that did not induce any CTL responses (17). 
ANTIGEN PRESENTATION BY DENDRITIC CELLS TO T CELLS
Antigen scavenging and antigen presentation by Dendritic Cells.
Immature DC are the gatekeepers of the body and are therefore lined in the periphery at the 
barriers of the body –such as skin and mucosa (in the lungs and gut) – places that are easily 
accessed by invading pathogens. Immature DC are specialized to bind and engulf all kinds 
of pathogens and Ag formulations (18). Upon endocytosis of pathogens, the immature DC 
will be activated and migrates to the draining LN (dLN) where it enters the paracortical area 
where the T cells reside (19). During that migration the ability of the DC to take up Ag is 
decreased while on the other hand the machinery to process Ag is enhanced (18). 
Proteins from ingested pathogens, dying virally infected cells, or tumor cells are degraded 
by the DC’s endosomal and lysosomal proteases and results in the production of small 
peptides (20). When the endocytic compartments fuse with the lysosomal compartments, 
the peptides can associate with newly synthesized MHC class II molecules, which are 
subsequently transported to the cell surface for presentation to CD4+ Th cells. 
CD8+ T cells recognize peptides that are bound to MHC class I molecules. Because most 
viruses do not infect DC and most of the exogenous Ag from dying cells is presented in 
the MHC class II route, activation of CD8+ T cells requires a different mechanism called 
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cross-presentation (21). Ag that is taken up by the DC via endocytosis can leave the 
endosomal compartment and enters the cytosol. In the cytosol the proteins are proteolitically 
cleaved by the proteasome into small peptide fragments that are subsequently transported 
via the Transporters of Ag Processing to the Endoplasmatic Reticulum (ER). In the ER these 
peptides are further trimmed to allow exact binding into the groove of the MHC class I 
molecule after which the peptide:MHC class I complex is transported to the cell surface. This 
route ensures presentation of Ag from the periphery such as self proteins, proteins derived 
from pathogens (e.g. viruses), and aberrantly expressed proteins or neo-proteins from tumor 
cells, to CD8+ T cells in the dLN (22).
Dendritic Cell activation and maturation.
DC can be activated in several distinct ways. The commonly shared structures of pathogens 
(pathogen-associated molecular patterns) can interact with its cognate receptor and thereby 
activate the DC. These pathogen-associated molecular patterns can consist for instance 
of DNA (23), RNA (24-26), lipoproteins and cell wall proteins of the pathogen (27-30). 
Additionally, uric acid is a major endogenous danger signal that is released from injured or 
dying (cancer) cells and can also induce DC activation (31). Moreover, activation via CD40 
receptor ligation by CD40L on Ag-specific Th cells in the dLN (32,33) or by agonistic CD40 
Ab to activate DC (34-36) will endow the DC with the ability to cross-present exogenous Ag 
to CD8+ T cells (37). Finally, DC can be activated by soluble inflammatory mediators such 
as TNFα, IL-1β, and PGE-2 whose secretion is triggered by invading pathogens (18,38). 
Following activation, DC enhance the Ag processing pathways, increase MHC class I and 
II presentation and induce co-stimulatory molecules on the surface of the DC to facilitate 
optimal T cell activation and T cell expansion (38). 
The requirements for T cell activation. 
Naïve T cells that enter the LN from the blood and subsequently migrate to the paracortical 
area to scan DC for their cognate Ag, require three signals from the DC for optimal priming 
(Fig. 1 and reviewed in (39)): i) peptide:MHC complexes on the APC that interact with the 
TCR on the T cell, ii) co-stimulatory molecules on the APC such as B7 that ligate with 
the CD28 receptor on the T cell, and iii) additional cytokines such as  IL-12 and IFNα/β 
that function as a third signal to enhance T cell survival (40,41). Although efficient T cell 
activation can occur in the absence of co-stimulation, it will require high concentrations of 
Ag to overcome the lack of co-stimulation (42,43). Co-stimulation, however, reduces the 
need for high amount of peptide/MHC complexes in order to activate naïve T cells and in 
addition, it results in the stabilization of IL-2 mRNA to allow transcription into IL-2 protein 
15
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Figure 1. Three signal model for T cell activation. T cells require three signals for optimal activation: 1) TCR 
triggering on the T cell by MHC/peptide complex presented by the APC, 2) CD28 ligation on the T cell by the 
co-stimulatory molecules B7.1 and/or B7.2 on the APC, and 3) cytokines like IL-12 and IFNα/β secreted by the 
APC to enhance T cell survival.
IL-12/
IFNα/βMHC
APC
naive T cell
TCR
B7.1/2
CD28
1 2 3
(44-46) - an important growth hormone required by CD8+ T cells (47,48). 
In the absence of strong inflammatory responses the DC will not upregulate co-stimulatory 
molecules, nor produce the necessary inflammatory cytokines. Ag presentation in the absence 
of co-stimulatory molecules will therefore result in the incomplete activation of the T cell 
and will lead to either a state of specific unresponsiveness termed anergy (associated with 
impaired intracellular signaling) or will lead to apoptosis (programmed cell death) (49); 
collectively called peripheral tolerance (50). 
THE IMMUNE SYSTEM, CANCER, AND PEPTIDE VACCINATION
The role of the immune system in tumor clearance.
The first indication that the immune system could be induced to fight cancerous tissue was 
seen in the 18th century. Spontaneous tumor regression was sporadically observed in patients 
that had high fever. Occasionally complete remission could be induced by deliberately 
infecting cancer patients with the bacteria Streptococcus pyogenes, also know as Coley’s 
toxin (51). In the 1950s the role of the immune system in cancer was further explored. It 
was shown that unknown items of the tumor - tumor associated Ag (TAA) - were recognized 
by T cells. Mice could be rendered immune against syngenic transplanted carcinogenic 
tumors when the primary (carcinogenic) tumor was excised and the mice were challenged 
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with the parental tumor (52-55). By the use of depleting Antibodies (Ab), it was shown that 
several immune cell type such as: natural killer cells (56), neutrophils (56), macrophages 
(56), eosinophils (57), CD4+ Th2 cells (57), or CD8+ T cells (58,59) have the ability to clear 
malignant cells. Eventually, in the 1990s the first immunogenic human and mouse TAA were 
identified (60-64). This knowledge about what the T cells actually recognize, resulted in a 
gain in momentum in the applicability of tumor specific immunological therapies, of which 
peptide vaccinations is one of the best explored so far. 
Synthetic peptide vaccines.
The first synthetic peptide vaccine that induced virus-specific CD8+ T cells in vivo was a 
peptide derived from lymphocytic choriomeningitis virus (LCMV) (65). Soon two papers 
followed that showed that peptide vaccination protected mice against a lethal virus challenge 
of either Sendai virus (66) or LCMV (67). In addition, peptide vaccination also protected 
mice against a lethal tumor challenge of a Human Papilloma Virus (HPV) type 16 positive 
tumor (68), or enhanced the survival of mice in a spontaneous metastasis model (69). 
The immunogenicity of a peptide is determined by the affinity of the peptide for its MHC 
molecule (70-73) and its dissociation constant (74). Together these parameters influence the 
duration of Ag presentation on the APC and thereby the time of TCR triggering. Most TAA 
have relatively low affinity and higher dissociation constants for the MHC class I molecule 
compared to most viral Ag and are therefore less immunogenic. Using site directed substitution 
of specific a.a. positions in the peptide, the affinity of the peptide can be enhanced and the 
dissociation can be reduced for the MHC class I molecule, resulting in higher half-life of 
the peptide:MHC complex. Vaccination with these enhanced binding affinity peptides were 
shown to give protection against a subsequent lethal tumor challenge in two different Ag 
systems in mice (75) and were reported to increase T-cell immunity in melanoma patients 
vaccinated with a modified gp100 peptide (76-80). 
Tolerance induction after synthetic peptide vaccination.
Although minimal CTL peptide vaccines were reported to induce CTL responses and give 
protection against lethal tumor challenges, there were also publications about the lack of 
CTL responses and even data showing the induction of CD8+ T cell tolerance. For instance, 
vaccination with the minimal CTL peptide of the Murine leukemia virus (MuLV) did not 
protect mice against a subsequent MuLV+ tumor challenge (81). Moreover, multiple high 
dose of minimal CTL (GP
33-41
) peptide vaccination of the GP33 protein of LCMV resulted 
in the induction of CD8+ T cell tolerance (82) or the deletion of GP
33-41
 specific Transgenic 
CD8+ T cells (83). Although multiple vaccinations with high doses of GP
33-41
 peptide seemed 
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to be required IN the LCMV system to induce tolerance (82,83), Toes et al. demonstrated 
that in the Adenovirus system, already a single injection of low Ag dose with the minimal 
Adenovirus CTL peptide was sufficient to induce CD8+ T cell tolerance or to enhance 
tumor outgrowth (84,85). Despite these potential dangerous effects of minimal CTL peptide 
vaccination, many clinical trials have been initiated, so far with limited immunological and 
clinical responses (86).
Help for the Cytotoxic T Lymphocyte.
The low magnitude of CD8+ T cell responses can be enhanced by inclusion of a Th epitope in 
the same vaccine. This helper mechanism is versatile, CD4+ T cells; i) can secrete the growth 
hormone IL-2 (87), ii) can activate the APC via CD40-CD40L interactions (34-36) that can 
subsequently license (88) the CD8+ T cell to kill its target cell (Fig. 2) and, iii) are required for 
the induction of CD8+ T cell memory (89). The first synthetic peptide vaccine that protected 
against a lethal challenge with LCMV (65) not only contained a CD8+ T cell epitope, but also 
a CD4+ T cell epitope (90). Deletion of the CD4+ T cells almost completely abrogated this 
protective effect, showing the importance of the concomitant activation of CD4+ and CD8+ 
T cells. Accordingly, addition of a Th peptide to a minimal CTL peptide enhanced the CTL 
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Figure 2. Licensing of the Antigen Presenting Cell. Immature APC can take up pathogens that will activate 
the APC via triggering of the TLR (left). Proteins derived from the pathogen are presented in the context of 
MHC class I and II. Ag-speciﬁc CD4+ T cells are activated by the APC and subsequently activate the DC via 
CD40-CD40L interactions (left). This “licensed” APC can activate naive CD8+ T cells to kill their target cells 
(right).
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response in a malaria vaccination system (91). Similarly, the addition of the MuLV Th peptide 
in combination with the minimal MuLV CTL peptide protected mice against a subsequent 
MuLV+ tumor challenge, while mice vaccinated with just the minimal CTL peptide died 
from the tumor (81). Although it was claimed that the T helper response had to be tumor 
Ag-specific (81), this tumor specific Th-dependence theory has been challenged by others 
(92). Most likely the differences in peptide binding affinity of these specific or unspecific Th 
peptides were the cause of the enhanced tumor clearance; resulting in enhanced CD4+ T cell 
responses and cytokine secretion, rather than that the Th peptides had to be derived from the 
tumor Ag. 
Help can also be provided in the form of an agonistic CD40 Ab that triggers the 
CD40 receptor on the DC (34-36). Using CD40 agonistic Ab, a prophylactic vaccine 
- HPV16 E7 minimal CTL peptide - was altered into a vaccine with therapeutic tumor potency 
(93). Also for the minimal CTL peptide of the E1A protein of Adenovirus (84,85) addition of 
CD40 agonistic Ab enhanced the Ag-specific CD8+ T response (94). 
Increased peptide length.
Zwaveling et al. have published that the use of a long peptide based vaccine of the HPV16 
E7 protein, induced a more robust CTL response capable of eradicating a pre existing 
tumor compared to the minimal CTL peptide (95).  In this paper it was hypothesized that 
the additional advantage of the use of long peptide-based vaccines compared to minimal 
CTL peptide-based vaccines might be the differences in dependency of Ag processing. While 
minimal CTL peptide can exogenously bind to any cell that contains MHC class I molecules, 
it was suggested that long peptides are taken up and processed by professional APC in order 
to be presented in the context of MHC class I molecules. In addition, the T cell epitopes in 
long peptides are protected by the N- and C-terminal flanking a.a. from direct proteolytically 
degradation and thereby prevent destruction of the epitope. Finally, the enhanced CTL 
response in the long HPV16 E7 peptide could have been due to the existence of a Th epitope 
in the peptide (95), as co-delivery of the Th and CTL epitope to the same APC results in APC 
activation (36) and has been shown to be more effective than vaccination with the minimal 
Th and CTL epitopes as a mix (96,97). 
Toll Like Receptor ligands as adjuvant.
Besides APC activation by CD4+ T cell via CD40-CD40L interactions, pathogens possess 
strong immune stimulatory molecules that can trigger Toll Like Receptors (TLR). These 
TLR are widely expressed on immune cells, especially on APC. Except for TLR9, which 
is in humans restricted to plasmacytoid DC and B cells, the expression of TLR3, 4, 7, and 
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8 is broadly expressed on myeloid DC in both human and mouse DC (98-100). These TLR 
ligands can be made synthetically and can be used in various vaccination forms to enhance 
the (vaccine induced) immune response by ways of: mixing a TLR ligand with the Ag of 
interest (101,102), using TLR ligand-cream mixed with peptides (103), or covalently linking 
the TLR ligands to the Ag of interest (104-107). Besides that covalently linking the TLR 
ligand to the Ag results in enhanced uptake of the Ag-TLR complex (104-107), another great 
advantage of covalently linkage is the simultaneous delivery of Ag and the activation signal to 
the same APC, comparable to physically linking of the Th and the CTL epitopes (96,97,108). 
Therefore, these chemically designed and well defined vaccines hold great promises for a 
variety of vaccine formulations against multiple diseases. 
SCOPE OF THIS THESIS
In this thesis we have explored the mechanisms of minimal and extended CTL peptide-based 
vaccines to induce an optimal immune response, without the risk for tolerance induction. 
Minimal CTL peptide vaccinations are widely used to induce a CD8+ T cell response in 
cancer patients, however, without the expected success. 
In chapter 2 the work is described on the difference between long and short-peptide based 
vaccinations. We have used the Ovalbumin (OVA) antigenic system to investigate the 
long-term effects of minimal CTL peptide vaccination after application in oil-in-water 
formulation; Incomplete Freund’s Adjuvant (IFA). The reason we chose for this type 
of adjuvant is that it is the most standard vehicle used in clinical vaccinations strategies. 
Vaccination with the minimal (8 a.a.) CTL peptide-based vaccine in IFA induced a transient 
CD8+ T cell response that is readily tolerized at day 30. Tolerance induction could, however, 
be prevented by the addition of a minimal Th peptide or using an extended (30 a.a.) CTL 
peptide that was CD4+ T cell independent.
In Chapter 3 the mechanisms is discussed of the enhanced immunogenicity of extended 
peptide-based vaccines compared to their minimal counterparts in the OVA system after 
vaccination in combination with the TLR9 ligand CpG (in saline). The use of an extended 
peptide resulted in an increased duration of in vivo Ag presentation and induced a greater 
CTL response compared to the minimal CTL peptide. In addition, the extended peptide was 
presented predominantly by DC in the local draining LN, whereas the minimal CTL peptide 
was presented by DC, B and, T cells in the dLN and was transported by B and T cells to 
non-draining LN. Furthermore, B cells turned out to be important APC in the induction of 
CD8+ T cells after minimal CTL peptide-based vaccination.
In chapter 4, a head-to-head comparison of different TLR compounds and a CD40 agonistic 
Ab is discribed using the HPV16 E7 extended peptide-based vaccination model (95). We 
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have compared the differences in potency of inducing CD8+ T cell responses with enhanced 
in vivo effector function using these adjuvants. Only the addition of MPL, CpG, or CD40 
agonistic Ab to the vaccine (in saline) was able to induce comparable high magnitudes of 
the CD8+ T cell response. However, CpG was the only adjuvant that induced fully functional 
CTL that correlated with the simultaneous induction of Ag-specific CD4+ IFNγ+ T cells. 
In the 5th chapter the work is described on delineating the underlying molecular and cellular 
mechanisms of the superior working mechanism of a TLR2 or TLR9 ligand coupled to an 
extended peptide, compared to the uncoupled TLR ligands and peptide. We have shown that 
Ag coupling to a TLR ligand enhanced immune activation and showed that this required 
endosomal acidification and proteasomal cleavage. Surprisingly, the enhanced uptake of the 
TLR-ligand peptide conjugate was independent of expression of the cognate TLR. Together, 
these data show that simultaneous entry of antigen and delivery of a maturation signal to the 
same DC is responsible for the improved action of the TLR-ligand peptide conjugates. 
In chapter 6 we have described the anti-cancer potential of a mouse line deficient for Cbl-b. 
Cbl-b is a member of the mammalian family of Cbl E3 ubiquitin ligases and functions as a 
negative regulator of antigen-specific T cell activation. Cbl-b is consequently upregulated in 
T cells that are stimulated in the absence of co-simulation and Cbl-b is therefore a critical 
mediator of T cell anergy. Cbl-b deficient mice spontaneously reject a lethal dose of HPV16 
E7 positive tumors and CD8+ T cells were identified as the key players. Loss of Cbl-b not 
only enhanced the anti-tumor reactivity of CD8+ T cells but also uncoupled in vivo anti-tumor 
immunity from CD4+ T cell help. Importantly, therapeutic transfer of naïve Cbl-b-/- CD8+ T 
cells was sufficient to mediate rejection of established tumors.
Finally, an overall view of the design and development of synthetic peptide vaccines is 
discussed in chapter 7.
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CD8+ CTL priming by exact peptide-epitopes 
in Incomplete Freund’s Adjuvant induces a 
vanishing CTL response, whereas long peptides 
induce sustained CTL reactivity
Abstract. Therapeutic vaccination trials, in which patients with cancer were vaccinated with 
minimal CTL peptide in oil-in-water formulations, have met with limited success. Many of 
these studies were based on the promising data of mice studies, showing that vaccination 
with a short synthetic peptide in IFA results in protective CD8+ T-cell immunity. By use of 
the highly immunogenic Ovalbumin CTL peptide in IFA as a model peptide-based vaccine 
we investigated why minimal CTL peptide vaccines in IFA performed so inadequate in order 
to allow full optimization of peptide vaccination. 
Injection of the minimal MHC class I-binding OVA
257-264
 peptide in IFA transiently activated 
CD8+ effector T-cells, which eventually failed to undergo secondary expansion or to kill 
target cells, as a result of a sustained and systemic presentation of the CTL peptides gradually 
leaking out of the IFA depot without systemic danger signals. Complementation of this 
vaccine with the MHC class II-binding T-helper peptide (OVA
323-339
) restored both secondary 
expansion and in vivo effector functions of CD8+ T-cells. Simply extending the CTL peptide 
to a length of 30 amino acids also preserved these CD8+ T-cell functions, independent of 
T-cell help, because the longer CTL peptide was predominantly presented in the locally 
inflamed draining lymph node. Importantly, these functional differences were reproduced in 
two additional model-antigen systems. 
Our data clearly show why priming of CTL with minimal peptide-epitopes in IFA is suboptimal 
and demonstrates that the use of longer versions of these CTL peptide-epitopes ensures the 
induction of sustained effector CD8+ T-cell reactivity in vivo.  
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INTRODUCTION
Tumor cells express tumor associated antigens (TAA) on their cell surface in the context 
of MHC class I molecules. These TAA can be recognized by CD8+ T-cells, which are the 
essential players in the clearance of tumor cells in vivo (1,2). In recent years many epitopes 
have been identified (3,4), providing the option to apply these minimal MHC class I restricted 
CD8+ T-cell peptide-epitopes in vaccination strategies for the immunotherapy of solid tumors 
(3,4). Unfortunately, these minimal CTL peptide-based vaccines in oil-in-water formulations 
(e.g. IFA or Montanide) have in general met with limited immunological and clinical success 
(4,5). 
The use of minimal CTL peptide-based vaccines was based on murine studies demonstrating 
that prophylactic vaccinations with minimal CTL peptides in IFA induced protective CD8+ 
T-cell (anti-tumor) immunity (6-9). However, other reports show that vaccination with 
the minimal CD8+ T-cell epitopes can also result in the induction of CD8+ T-cell tolerance 
(8,10-14). While in some of these studies tolerance was the result of repetitive vaccination 
with high dose of Ag (8,13,14), others reported that even after a single subcutaneous 
vaccination, tolerance could be induced (11,12). In these studies the injection of mice with 
low amounts of Adenovirus E1A (11) or E1B (12) minimal CTL peptide emulsified in 
IFA resulted in functional impairment of activated CD8+ T-cells, as was evident from the 
enhanced outgrowth of tumors (11,12). Intravenous co-injection of agonistic CD40 antibody 
(FGK), in order to activate and to mature dendritic cells (DC) (15,16), resulted in a transient 
adenovirus-specific CD8+ effector T-cell response, detectable 10 days after vaccination but 
not at 30 days after vaccination, and did not protect mice against a tumor challenge (17). 
These data indicate that an initial proper activation of the CD8+ T-cell response by minimal 
CTL peptide vaccines in IFA does not ensure long-term effectiveness of these CD8+ T-cells. 
Such long-term effectiveness is particularly important to control chronic diseases such as 
cancer. 
So far it is unclear what the common long-term result is with respect to immunological 
outcome of injection with minimal CTL peptides. Therefore, we have thoroughly studied 
different peptide vaccinations strategies using the highly immunogenic model Ag Ovalbumin 
(OVA) (18-22), containing the MHC class I restricted CD8+ T-cell epitope OVA
257-264 
(OVA8) 
and the CD4+ T helper (Th) cell epitope OVA
323-339 
(ThOVA17). Peptides were mixed in IFA, 
as oil-in-water formulations are standard vehicles for peptide vaccination in clinical trials. 
The efficacy of the different peptide vaccine formulations was tested by the analysis of the 
following three important parameters: i) the magnitude of the CD8+ T-cell response, ii) the 
ability of CD8+ T-cells to undergo secondary expansion upon antigen challenge in vitro (23), 
and iii) the in vivo killing capacity of the CD8+ T-cells. These parameters were tested at 
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either day 10 (peak of the response) or at day 30 after vaccination - the time point where 
adenovirus-specific CD8+ T-cells were tolerized after injection with E1A-peptide in IFA (17). 
Furthermore, we investigated how to formulate a peptide-based vaccine that triggers CTL 
immunity without the risk for exhaustion/tolerance.
Here, we report that vaccination with immunogenic OVA8 peptide in IFA also results in 
the activation of effector CD8+ T-cells which eventually ceased to expand or to kill target 
cells. This cessation of T-cell function was associated with long-term systemic presentation 
of the minimal CTL peptide in vivo but could be prevented by either complementation with 
a minimal T helper peptide or by extension of the minimal CTL peptide to a 30 amino acid 
long peptide. These data clearly shows the potential hazard of using minimal CTL peptide 
vaccines, and the benefits of long peptide vaccines for the induction of an effective CD8+ 
T-cell response. 
MATERIALS AND METHODS
Mice. C57BL/6 (B6; H-2b) and MHC Class II knock out mice (class II-/-) mice were purchased 
from Charles River (St. Germain sur l’Arbresle, France). CD90.1 mice were bred at TNO-
PG (Leiden, the Netherlands). CD45.1 OT-1 (24) and OT-2 (25) mice are CD8+ T-cell and 
CD4+ T-cell TCR transgenic (Tg) mice expressing the TCR α-chain and β-chain recognizing 
OVA
257–264 
in H2-Kb and OVA
323-339
 in I-Ab, respectively and were bred at the Leiden University 
Medical Centre animal facility. All mice were kept at the Leiden University Medical Centre 
animal facility and used at 8–14 weeks of age in accordance with national legislation and 
under supervision of the animal experimental committee of the University of Leiden. 
Cell lines. EG7 (EL4-OVA) (26) tumor cells were cultured in IMDM (Invitrogen Life 
Technologies, Rockville, MD) supplemented with 8% (v/v) FCS (Greiner), 50 µM 
2-mercaptoethanol, 2 mM glutamine, 100 IU/ml penicillin (complete medium) and 400 ug/
ml Geneticin (Gibco). 
Peptides and peptide vaccination. Peptides were generated as described before (6). The 
following dominant minimal CTL peptides were used: OVA
257-264
 SIINFEKL (OVA8), 
HPV16E7 peptide E7
49-57
 RAHYNIVTF (HPV9) (6) and the Adenovirus protein E1A
234-243
 
SGPSNTPPEI (E1A10) (11). The minimal Th peptide sequence of OVA was the following; 
OVA
323-339
 ISQAVHAAHAEINEAGR (ThOVA17). In addition the following long peptides 
deduced from the natural sequence of each protein were used: CTL peptide OVA
241-270
 SML
VLLPDEVSGLEQLESIINFEKLTEWTS (OVA30). Note that this peptide does not contain 
CD8+ T cell tolerance
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the C-terminal Th epitope OVA
265-280
 (27). Th peptide OVA
317-347
 SSAESLKISQAVHAAH
AEINEAGREVVGSAE (ThOVA31), CTL peptide of HPV protein E7
43-77
 GQAEPDRAH
YNIVTFCCKCDSTLRLCVQSTHVDIR (HPV35) (28), CTL peptide of protein E1A
223-252
 
RECNSSTDSCDSGPSNTPPEIHPVVRLCKK (E1A30). Mice were s.c. vaccinated with 40 
nmol of (each) peptide admixed in PBS or in PBS and IFA (Difco Laboratories, Detroit, 
USA) (50% v/v) in a total volume of 200 µl. 
Antibody treatment. Agonistic CD40 Ab (FGK45) (50 ug) was provided intravenously 
(i.v.) in the tail vein on day 0, 1 and 2 in 200 µl of PBS. Complete CD4+ T-cell depletion 
was obtained by i.p. injection of 25 µg of anti-CD4 (clone GK1.5) in PBS three days and 
one day before vaccination and once a week throughout the experiment. CD4 depletion was 
regularly checked by Facs analysis and showed that the mean percentage of CD4+ T-cells 
was ≤ 0.003% ± 0.005%  in the mice receiving GK1.5,  while naïve mice displayed  13,8% 
± 2% of CD4+ T-cells.
CFSE labeling and adoptive transfer of Tg T-cells. Single cell suspension was made from 
spleen and peripheral lymph nodes of CD45.1 OT-1 mice or OT-2 mice. Erythrocytes were 
lysed by ammonium chloride treatment and 10*106 cells/ml were incubated at 5 µM CFSE 
end concentration in PBS 0.1%/BSA at 37º C for 15 minutes. The reaction was blocked with 
10% v.v. of pure FCS. The cells were washed 2 times with PBS and 1-2 x 106 Tg T cells were 
injected into the tail vein in 200 µl of  PBS. 
Ex vivo detection of Ag. Mice were vaccinated with either OVA8, OVA30, ThOVA17 or 
ThOVA31 mixed in IFA. Two days later the dLN (inguinal and axillary) and the ndLN 
(mesenteric) were isolated. A single cell suspension was made using a 70µm cell strainer. To 
detect the CTL epitope ex vivo 0,5*106 LN cells were plated in a 96 wells plate and to detect 
the Th epitope, 1*106 LN cells were plated in a 96 wells plate. Purified and CFSE-labeled 
OT-1 (1*105) or OT-2 (2*105) Tg cells were added to these wells, respectively. Three days 
later division of OT-1 Tg T cells was measured by flow cytometry by gating on CD45.1+ and 
CD8+ lymphocytes. In the case of OT-2 cells, four days later division was determined by 
gating on Va2+ and CD4+ lymphocytes. Ag presentation was determined by the dilution of 
the CFSE of the Tg T cells.  
In vivo cytotoxicity assay. Erythrocytes of B6/CD45.2 splenocytes were lysed and the 
splenocytes were split into two equal fractions. Cells were differentially labeled with CFSE 
to either 5 (target) or 0.5 (control) uM end concentration (see CFSE labeling). The target 
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cell population was pulsed with 1.0 ug/ml of OVA
257-264
 and the control population with 1.0 
ug/ml of p53 peptide (H2-Kb, p53
158-166
) at 37º C in complete medium for 60 minutes. The 
cells were washed four times with PBS before the two populations were mixed in a 1:1 ratio 
and a total of 8*106 cells was injected i.v. Either 1 or 2 days after injection of the target cells 
(day 10 or day 30 after vaccination, respectively) spleens were removed and analyzed for 
specific killing. The ratio of CFSElo/CFSEhi cells was determined by flow cytometry by 
gating on CD45.1+ lymphocytes. Specific killing of OVA
257−264 
pulsed (CFSEhi) target cells 
was calculated as follows: (1-[(CFSEhi/CFSElo)
vaccinated
*(CFSElo/CFSEhi)
naive
])*100%.
In vitro stimulation. EG7 cells were incubated with 50 ug/ml of mitomycin C (Kyowa) in 
complete medium at 37º C for 1 hour. Subsequently, the cells were washed 4 times and then 
irradiated (4000 RAD). 1*106 EG7 cells were incubated with 10*106 splenocytes (V
tot
=2 ml). 
After seven days viable splenocytes were isolated over a ficoll gradient and stained for H-2Kb 
Tetramer (TM)-OVA
257-264
, CD8b2, and Propidium Iodide (to exclude dead cells).
Overnight Intracellular Cytokine Staining. Splenocytes were incubated for 1 hour 
with 1 µM of ThOVA17 or ThOVA31 peptide or no peptide (background) before 1 µg/ml 
Golgiplug (containing Brefeldin A; BD Pharmingen) was added. The next day cells were 
permeabilized and stained using the Cytofix/Cytoperm Plus kit (BD Pharmingen), according 
to manufacturer’s instructions and stained for CD4 and intracellular IFNγ.
Flow cytometry. Single cell suspensions of spleens or lymph nodes were stained in PBS 
0.1% BSA. The Abs that were used were the following: directly allophycocyanin-conjugated; 
TM-OVA
257-264
; CD45.1 (A20, eBioscience); IFNγ (XMG1.2, Pharmingen); CD90.2 (53-2,1, 
Pharmingen); CD8a (53-6.7, Pharmingen) and PE-conjugated; CD8b2 (53-5,8, Pharmingen), 
CD4 (RM4-5, Pharmingen). Data acquisition and analysis was done on a BD Biosciences 
FACScan (San Jose, CA, USA) with CellQuest software.
Statistical analysis. Statistical analysis was done using GraphPad InStat software (version 
3.0) and GraphPad Prism 4 (GraphPad Software, San Diego, CA). A two-tailed t test with 
Welch correction was applied for the statistical analysis of the samples, except for Fig. 1A 
OVA8 (IFA) d=10 vs. d=30 (non-parametric 2-tailed Mann-Whitney test) and Fig. 7 and 8 
(Kruskal Wallis test non-parametric ANOVA).
CD8+ T cell tolerance
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RESULTS
Vaccination with the minimal CTL peptide OVA
257-264 
in IFA induces a transient and 
then functionally impaired CTL response.
To explore the short and long-term outcome of the CD8+ T-cell response after peptide 
vaccination with the minimal MHC class I binding peptides, mice were vaccinated with 
OVA8 in IFA and subsequently the secondary expansion potential of the CD8+ T-cells in 
vitro as well as the in vivo effector function were determined, either 10 days (short-term) or 
30 days after vaccination (long-term). In addition a strong DC stimulus was provided by i.v. 
injection of FGK in order to systemically activate APC in vivo (15,16,29).
Figure 1. Minimal CTL peptide in IFA induces only transient CTL immunity. Mice were vaccinated s.c. with 
the minimal OVA8 CTL peptide mixed in IFA (black bars) or in PBS (white bars) in the presence or absence of 
50 µg of FGK administered i.v. on day 0, 1 and 2. A, Enumeration of TM-OVA+ CD8+ T-cells by ﬂowcytometry. 
Ten or 30 days after vaccination, splenocytes were harvested and stimulated in vitro with OVA-expressing tumor 
cells for seven days before analyzing the presence of TM-OVA+ CD8+ T cells (OVA8 (IFA) d=10 vs. d=30, p<0.01; 
OVA8+FGK (IFA) d=10 vs. d30, p<0.001). The data are depicted as mean ± SEM (n=5-7). B, In vivo cytotoxicity 
assay. Nine or 28 days after vaccination, CFSE-labeled CD45.1+ target cells were injected and cytotoxicity was 
measured in the spleen at day 10 or day 30, respectively by FACS analysis (OVA8 (IFA) d10 vs. d30, p<0.01; 
OVA8+ FGK (IFA) d10 vs. d30, p<0.01). Cells were gated on CD45.1+ lymphocytes. The data are depicted as 
mean ± SEM (n=6-10). Representative Facs plots of the experiment are shown below in the ﬁgure.
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Splenocytes were collected 10 days after vaccination and stimulated with OVA-expressing 
APC in vitro. The OVA-specific CD8+ T-cells in these cultures were capable of undergoing 
secondary expansion  in vitro, as measured by high numbers of TM-OVA+ CD8+ T-cells 
(Fig. 1A, left). In order to determine whether vaccination resulted in effector CD8+ T-cells, an 
in vivo cytotoxicity assay was performed (30). Both groups of mice vaccinated with OVA8 
peptide in IFA (+/- FGK) displayed a similar capacity to kill target cells in vivo 10 days after 
vaccination (Fig. 1B, left). 
When splenocytes were isolated 30 days after vaccination, OVA-specific CD8+ T-cells 
displayed a strongly decreased capacity to undergo secondary expansion since only low 
numbers of OVA8-specific (TM-OVA+) CD8+ T-cells could be observed after stimulation in 
vitro (Fig. 1A). Accordingly, mice showed a markedly reduced capacity to kill target cells 
in vivo at day 30 (Fig. 1B), indicating that the ability to undergo secondary expansion in 
vitro correlated with the ability to lyse target cells in vivo. Provision of a DC stimulatory 
signal by FGK, although enhancing CTL levels at day 10, was unable to preserve the CTL 
response at day 30 (Figs 1A+B). Interestingly, when the OVA8 peptide was applied in PBS 
in combination with systemic administration of FGK, the CD8+ T-cell response was not lost 
over 30 days as indicated by their ability to expand after in vitro stimulation (Fig. 1A) and 
their capacity, albeit at lower levels, to kill target cells in vivo (Fig. 1B). Thus, vaccination 
with the minimal OVA8 CTL peptide in IFA induces a transient effector CD8+ T-cell response, 
followed by functional impairment of these activated CD8+ T-cells. 
Peptide vaccination in IFA induces long-term presentation of the minimal CTL 
peptide.
The major difference between PBS and IFA is the capacity of the latter formulation to 
function as a depot for the peptides. To test whether the OVA8 peptide in IFA was presented 
for a long term in vivo, mice were vaccinated with the OVA8 peptide in IFA and after either 
30 or 60 days, CFSE-labeled OT-1 CD8+ T-cells were adoptively transferred into C57BL/6 
mice as probes to detect antigen presentation in vivo. Extensive proliferation of OT-1 T-cells 
was observed both at day 30 and day 60 (Fig. 2A) in the dLN of vaccinated mice, indicating 
that the minimal OVA8 CTL peptide was still presented 60 days after vaccination. In contrast, 
when the peptide was applied in PBS, no proliferation of OT-1 CD8+ T-cells was observed 
at day 30 (Fig. 2A). This indicated that vaccination with the OVA8 peptide in PBS was 
associated with relatively short duration of Ag presentation, while vaccination in IFA induced 
long-term Ag presentation in vivo.
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Addition of Th OVA
323-339
 peptide to the CTL/IFA vaccine retains CD8+
 
T-cell function.
Provision of FGK for APC activation (15,16), was unable to prevent CD8+ T-cell tolerance 
induction after vaccination with OVA8 peptide in IFA. As a dose of monoclonal Ab is generally 
rapidly cleared from the system (31,32), long-term presentation of OVA8 peptide beyond this 
period (Fig. 2) occurs in the absence of a potent APC activating agent. Since CD4+ T-cells can 
also activate APC via CD40-CD40L interaction (33), the minimal Th peptide ThOVA17 was 
mixed into the same IFA depot as the OVA8 peptide. Adoptively transferred CFSE-labeled 
OT-2 cells into ThOVA17 vaccinated mice, showed that also the ThOVA17 peptide in IFA is 
presented for at least day 60  in vivo in the dLN (Fig. 2B). 
We therefore tested if vaccination with ThOVA17 peptide in IFA was able to induce 
long-lasting OVA
323-339
-specific CD4+ T-cell responses in C57BL/6 mice. Indeed, OVA
323-339
 
specific IFNγ+ CD4+ T-cells could be detected in all mice when tested directly ex vivo, 30 days 
after vaccination with the ThOVA17 peptide in IFA (Fig. 3A). Subsequently, we examined if 
addition of the ThOVA17 peptide to the IFA depot could rescue the function of OVA8 induced 
CD8+ T-cells. As shown in figure 3B, s.c. vaccination of mice with a combination of OVA8 
and ThOVA17 peptide in IFA resulted in the detection of similar percentages of TM-OVA+ 
CD8+ T-cells following in vitro stimulation, both at day 10 and day 30 after vaccination. 
Moreover, the combination with the ThOVA17 peptide retained the cytolytic capacity of 
these CD8+ T-cells at day 30 (compare Fig 3C and Fig 1B, respectively).The addition of 
an extra DC-stimulatory signal, FGK, slightly enhanced the expansion of the OVA-specific 
CD8+ T-cell response (Fig.3B+C). 
Figure 2. IFA promotes extended duration of minimal CTL and minimal Th peptide presentation in vivo. 
Mice were vaccinated s.c. with the minimal OVA8 CTL (A) or minimal ThOVA17 (B) peptide mixed in IFA. A, 
Either 30 or 60 days later, 1-2*106 CFSE-labeled CD8+ CD45.1+ OT-1 T-cells were i.v. injected into C57BL/6 
mice. Three days later the dLN (inguinal) was harvested and proliferation was determined by ﬂow cytometry 
analysis. Cells were gated on CD45.1+ CD8+ cells. B, Either at day 30 or 60, 1*106 CFSE-labeled CD4+ CD90.2+ 
OT-2 T-cells were i.v. injected into CD90.1+ recipient mice. Four days later the dLN (inguinal) was harvested and 
proliferation was determined by FACS analysis. Cells were gated on CD90.2+ CD4+ T cells. As a control, peptides 
were administered in PBS and antigen presentation was analyzed on day 30. The data are representative of 4 
mice per time point and per vaccine.
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Injection of OVA8 and ThOVA17 in PBS, in combination with systemic injection of FGK, 
resulted in an OVA8-specific CD8+ T-cell response with a strong capacity to undergo 
secondary expansion but with only a moderate to kill target cells in vivo (Fig. 3B+C). 
Direct ex vivo analysis shows that at this time point the CD8+ T-cell response has contracted 
(% TM+ CD8+ cells; 0.13±0.03 vs. naïve 0.12±0.04, data not shown), with too low numbers of 
circulating T-cells to exert a direct strong in vivo measurable cytotoxic response. In contrast 
to the T-cells that were formed after vaccination with OVA8 in IFA, delivery of OVA8 + FGK 
± ThOVA17 in PBS did not affect their potential to expand in vitro following one round of 
stimulation (Fig. 1+3). 
In conclusion, simultaneous activation of T-helper cells for the sustained deliverance of 
license to kill signals (34), prevented premature termination of the CD8+ T-cell response that 
is observed otherwise after vaccination with OVA8 in IFA.
CD8+ T cell tolerance
Figure 3. Long-term immunity after minimal CTL peptide plus minimal Th peptide vaccination in IFA. Mice 
were vaccinated s.c. with the minimal OVA8 CTL peptide and minimal ThOVA17 peptide mixed in IFA (black 
bars) or in PBS (white bars) in the presence or absence of 50 µg of FGK (i.v. day 0, 1 and 2). A, Enumeration 
of CD4+ IFNγ+ T-cells by intracellular cytokine staining. Thirty days after vaccination mice were sacriﬁced and 
the splenocytes were stimulated overnight in the presence or absence of the minimal ThOVA17 peptide and 
golgiplug. The next day the cells were stained for the surface marker CD4 and for intracellular IFNγ (n=5; 
naïve vs. vaccinated mice p<0.01). B, Enumeration of TM-OVA+ CD8+ T-cells by FACS. Ten or 30 days after 
vaccination, splenocytes were harvested and stimulated in vitro with OVA-expressing tumor cells (EL4-OVA) for 
seven days and then analyzed for the presence of CD8+ T-cells capable of binding TM-OVA (n=5-8). C, In vivo 
cytotoxicity assay. Nine or 28 days after vaccination, target cells were injected and cytotoxicity was measured in 
the spleen at day 10 or day 30, respectively. Cells were gated on CD45.1+ lymphocytes. The data are depicted 
as mean ± SEM (n=6).
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Long CTL peptide induces long-lasting CD8+ T-cell immunity independent of CD4+ 
T-cell help.
We have recently shown that long peptide-vaccination (35 a.a. long peptide) was superior 
to a minimal CTL peptide, with respect to the induction of the magnitude and functionality 
of the CD8+ T-cell response when vaccinated in PBS in combination with CpG-ODN (28). 
To study whether the functional impairment of the CD8+ T-cell response induced by the 
minimal OVA8 CTL peptide in IFA can be prevented by the use of  a longer peptide in IFA, 
a long CTL peptide OVA30 and the long ThOVA31 peptide were designed, using the natural 
OVA protein flanking residues to extend the minimal CTL and Th peptides. By use of TCR 
transgenic detector T-cells OT-1 (CD8) and OT-2 (CD4), we confirmed that also the extended 
CTL (OVA30) and Th (ThOVA31) peptides were presented at least for 60 days in vivo in the 
dLN, when administered in IFA (Fig. 4A+B). 
To ensure that vaccination with the ThOVA31 peptide also resulted in the induction of 
OVA-specific CD4+ T-cells, we enumerated the number of IFNγ producing CD4+ T-cells 
30 days after vaccination by FACS analysis. The magnitude of the OVA-specific CD4+ 
T-cell response induced by the ThOVA31 peptide was comparable to what was observed after 
vaccination with the ThOVA17 peptide (Fig. 5A). To assess whether the use of long peptides 
in IFA prevented the induction of CD8+ T-cell tolerance at day 30, mice were vaccinated 
with the OVA30 peptide in the absence or the presence of the ThOVA31 peptide with or 
without i.v. injection of FGK (Fig. 5). In contrast to what we observed with OVA8, all the 
vaccine combinations with OVA30 resulted in high numbers of TM-OVA+ CD8+ T-cells after 
Figure 4. IFA promotes extended duration of long CTL peptide and long Th peptide presentation in vivo. 
Mice were vaccinated s.c. with either the long CTL peptide OVA30 or with the long Th peptide ThOVA31 mixed 
in either IFA or PBS. A. Either 30 or 60 days later, 1-2*106 CFSE labeled CD8+CD45.1+ OT-1 T-cells were i.v. 
injected into C57BL/6 recipient mice. Three days later the dLN (inguinal) was harvested and proliferation was 
determined by FACS analysis gating on CD45.1+ and CD8a+ lymphocytes. B, Either 30 or 60 days later, 1*106 
CFSE labeled CD4+ CD90.2+ OT-2 T-cells were injected i.v. into CD90.1+ recipient mice. Four days later the dLN 
(inguinal) was harvested and proliferation was determined by FACS analysis. Cells were gated on CD90.2+ and 
CD4+ lymphocytes. As a control, peptides were administered in PBS and antigen presentation was analyzed on 
day 30. Representative ﬁgure is shown of 4 mice per time point and per vaccine.
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stimulation in vitro at day 30, indicating that the CD8+ T-cells were capable of undergoing 
extensive secondary expansion in vitro (compare Fig. 5B with Fig. 1A, right hand side). 
Addition of the ThOVA31 peptide to the OVA30 peptide/IFA bolus enhanced the CD8+ 
T-cell response (Fig. 5B) compared to OVA30 peptide alone (mean TM-OVA+ 28% vs. 
13%, respectively). An additional, albeit small increase in the number of CD8+ T-cells was 
observed in mice that received the OVA30, ThOVA31 peptide in IFA in combination with 
systemic FGK (Figure 5B). 
Subsequently, the effector function of the CD8+ T-cells was tested in an in vivo cytotoxicity 
assay at day 30. Vaccination with OVA30 in IFA resulted in strong in vivo lytic activity 
(Fig. 5C). To warrant that the effect seen by OVA30 does not rely on CD4+ T-cell help, by 
unknown cryptic helper sequences that may have been present in the long OVA30 peptide, 
the mice were depleted for CD4+ T-cells prior to vaccination and once every week throughout 
the experiment to maintain complete CD4+ T-cell depletion (≤0.01 % CD4+ T-cells) or MHC 
class II-/- mice were used. The absence of CD4+ T-cells during the priming and effector phase 
did not demonstrably affect the OVA30 induced CD8+ T-cell killing of target cells. Nor did 
the absence of MHC class II strongly influence the killing capacity of OVA30 induced CTL 
(Fig. 5C). Although the numbers of OVA-specific CD8+ T-cells were higher when the OVA30 
peptide was complemented with either systemic FGK, the ThOVA31 peptide, or both, it was 
not possible to measure a potential increase in effector function since the percentage of in 
vivo killed target cells in mice vaccinated with OVA30 in IFA was high already  (Fig. 5C). 
The cytolytic activity of these CD8+ T cells was preserved over time, as a comparable killing 
capacity was observed at day 90 (Fig. 5D).
Similar to what was observed with the injection of OVA8 and ThOVA17 in PBS, the injection 
of the long peptide(s) in PBS in combination with systemic FGK resulted in an OVA-specific 
CD8+ T-cell response which was contracted at day 30 (%TM+ CD8+ cells; OVA30+FGK 
0.13±0.05. OVA30+ThOVA31+FGK 0.13±0.03, vs. naïve 0.12±0.04, data not shown) and 
of which the number of circulating T-cells was too low to measure direct in vivo effector 
function (Fig. 5C). However, these vaccine-induced T-cells were still capable of undergoing 
secondary expansion in vitro (Fig. 5B) to a similar extend as seen with OVA30 in IFA. In 
contrast, higher numbers of circulating OVA-specific cytotoxic CD8+ T-cells were detected 
in mice vaccinated with the long OVA30 CTL peptide in IFA (%TM+CD8+ cells; 0.83±0.61, 
data not shown).
In conclusion, despite the fact that vaccination with the OVA8 peptide or the  OVA30 peptide 
in IFA resulted in a comparable long Ag presentation in vivo, extension of the minimal OVA8 
peptide to the OVA30 peptide prevented the functional impairment of activated CD8+ T-cells 
and instead induced a CTL response that was sustained over a long period. 
CD8+ T cell tolerance
40
Figure 5. Long CTL peptide induces long-lasting CTL immunity independent of CD4+ T-cell help. Mice 
were vaccinated s.c. with the long CTL peptide OVA30 with or without the long Th peptide ThOVA31 mixed 
in IFA (black bars) or in PBS (white bars) in the presence or absence of 50 ug of FGK (i.v. on day 0, 1 and 2). 
A, Enumeration of CD4+ IFNγ+ T-cells by intracellular cytokine staining. Thirty days after vaccination mice were 
sacriﬁced and the splenocytes were stimulated overnight in the presence or absence of the ThOVA31 peptide 
and golgiplug. The next day the cells were stained for the surface marker CD4 and for intracellular IFNγ (n=5; 
naïve vs. vaccinated mice p<0.001). B, After 30 days the spleen was harvested and cells were stimulated in 
vitro with OVA-expressing tumor cells (EL4-OVA)  for seven days and then analyzed for the presence of CD8+ 
T-cells capable of binding TM-OVA (n=4;  OVA30 (IFA) vs. OVA30+ThOVA31 (IFA) p=0.06; OVA30+FGK (IFA) 
vs. OVA30+ThOVA31+FGK (IFA), p=0.09]. In vivo cytotoxicity assay C, day 30 and D, d90. Target cells were 
injected at day 28 (C) or day 88 (D) and two days later cytotoxicity was measured in the spleen by FACS 
analysis. Cells were gated on CD45.1+ lymphocytes. The data are depicted as mean ± SEM (n=5-10; C+D: IFA 
vaccination vs. PBS vaccination, p<0.01). Mice that were depleted for CD4+ T helper cells (GK1.5, light grey bar) 
received 25 ug i.p. of depleting aCD4 at 3 days and one day before vaccination and once every week during the 
experiment. The dark grey bar indicates MHC class II knock-out mice (Class II-/-; n=6).
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Dominant negative effect of the OVA8 CTL peptide on induction of effector CD8+ 
T-cells by an immunogenic vaccine.
In addition to the vaccine draining lymph nodes, also the non-draining lymph nodes of mice 
injected with either OVA8, OVA30, ThOVA17 or ThOVA31 were analyzed for the presentation 
of these peptides. In contrast to the long peptides, which were presented predominantly in the 
draining lymph node, presentation of the OVA8 peptide was also observed in non-draining 
lymph nodes indicating that this peptide spreads systemically (Fig. 6). Despite the fact that 
sustained presentation of the ThOVA17 peptide is readily detected in vivo (Fig.2B), we were 
not able to detect presentation of the ThOVA17 peptide ex vivo (Fig. 6B) suggesting that the 
MHC class II off-rate of this peptide is too high to allow direct ex vivo detection. This must 
be related to the affinity of this peptide for MHC class II I-Ab, which is probably lower than 
for the MHC class II molecule I-Ad which was first found to present this peptide (35).
Importantly, systemic presentation of OVA8 CTL peptide is associated with the functional 
impairment of the CD8+ T-cell response (Fig. 1B) while the predominant local presentation 
of the OVA30 peptide results in immunity. Therefore, we wondered what effect of OVA8 
vaccination has on a concomitant immunogenic vaccination (OVA30, Fig. 5C). To test this, 
mice were vaccinated with the OVA8 peptide, the OVA30 peptide or both peptides mixed 
in IFA and the in vivo killing capacity was determined at day 30. As shown in figure 7, 
vaccination with OVA8 was unable to induce effector CD8+ T-cells at day 30, while 
Figure 6. Location of Ag presentation. Mice were vaccinated with the indicated peptide mixed in IFA. 
Two days later the dLN (inguinal and axillary) and a ndLN (mesenteric) were isolated. A, Ex vivo detection of 
the OVA8 epitope was performed by incubation of 0.5*106 LN cells with 100,000 OT-1 CFSE-labeled Tg CD8+ T 
cells for 3 days. B, Ex vivo detection of the Th epitope was performed by incubation of 1*106 LN cells together 
with 200,000 CFSE-labeled OT-2 cells for 4 days. Dilution of CFSE was measured by gating on CD45.1+ CD8+ 
lymphocytes for OT-1 cells, or Vα2+ CD4+ lymphocytes for OT-2 cells.
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vaccination with the OVA30 peptide resulted in a CTL response. When the OVA8 peptide 
was mixed with the OVA30 peptide in the same IFA depot, a significant reduction in the in 
vivo effector function of OVA-specific CD8+ T-cell reactivity was observed (Fig 7). These 
data show that vaccination with the minimal OVA8 peptide has a dominant negative effect 
on the effector functions of CD8+ T-cell induced by an immunogenic peptide vaccine such as 
OVA30 CTL peptide.
Figure 7. Dominant negative effect of the minimal OVA CTL peptide on immunogenic vaccination with the 
long OVA30 CTL peptide.  Mice were vaccinated s.c. with the minimal CTL peptide (white bars), the long CTL 
peptide (black bars), or both peptides (blocked bars) mixed in IFA. Thirty days later mice were subjected to an in 
vivo cytotoxicity assay (n=4-6). (p<0.01, Kruskal Wallis test non-parametric ANOVA).
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Failure to induce long-lasting CTL immunity is a more general characteristic of 
vaccination with minimal CTL peptide epitopes but can be overcome by the use of long 
peptides.
Because injection of the dominant minimal CTL peptide OVA8 of the model Ag OVA results 
in the functional impairment of CD8+ T cells when injected s.c. at a low dose in IFA, and 
as such acts similar to the earlier described adenoviral E1A (E1A10) (11,17) and E1B (12) 
minimal CTL peptides, the impact of minimal and extended CTL epitope vaccines was 
compared in two additional antigenic systems.
First we tested the HPV16 E7 minimal CTL peptide (HPV9) and the extended CTL peptide 
(HPV35) (28). As shown in Fig. 8A, vaccination with the HPV9 peptide resulted in marginal 
killing (8%) of HPV peptide loaded target cells in vivo 30 days after vaccination whereas 
the use of the HPV35 peptide resulted in 45% specific killing of target cells (Fig. 8A). The 
enhanced effector response induced by HPV35 in IFA was independent of CD4+ T-cell help 
(Fig. 8A). 
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Similarly, vaccination with the minimal CTL peptide of the Adenovirus E1A protein E1A10, 
known to tolerize the CD8+ T-cell response (11,17), failed to induce CD8+ T-cell effector 
function 30 days after vaccination (3% killing) (Fig. 8B). In contrast, when the extended 
CTL peptide E1A30 was used 52% of the target cells were lysed 30 days after vaccination, 
independently of the presence of CD4+ T-cell help (Fig. 8B). These results indicated that the 
use of extended CTL peptide vaccines may prevent T cell tolerance (E1A10 peptide) and, 
in general, induce a sustained in vivo CD8+ effector T-cell response, when compared to their 
minimal CTL peptide counterparts.
Figure 8. Failure to induce long-lasting CTL immunity is a general feature for minimal CTL peptides. 
Mice were vaccinated s.c. with peptides mixed in IFA with either the minimal CTL peptide (white bars), the long 
CTL peptide (black bars), or the long CTL peptide in which mice where depleted for CD4+ T-cells with GK1.5 
Ab (light grey bars). Mice that were depleted for CD4+ T-cells received three and one day prior to vaccination, 
25 ug of CD4 depleting Ab GK1.5 (i.p.) and thereafter once every week 25 ug to maintain complete CD4+ 
T-cell depletion. Thirty days later mice were subjected to an in vivo cytotoxicity assay. A, HPV peptides (n=10) 
(HPV9 vs. HPV35 with or w/o GK1.5, p<0.001, Kruskal Wallis test non-parametric ANOVA) B, E1A peptides 
(n=5) (E1A10 vs. E1A30 with or w/o GK1.5, p<0.001, Kruskal Wallis test non-parametric ANOVA). The data are 
depicted as mean ± SEM. 
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DISCUSSION
In this study we showed that vaccination with a low dose of a highly immunogenic exact 
MHC class I binding peptide (OVA
257-264
) can result in the activation of CD8+ effector 
T-cells which eventually cease to expand or to kill target cells, provided that this peptide 
is administered in IFA. The injection of a minimal CTL peptide in IFA did not immediately 
impair the responding CD8+ T-cells but was preceded by induction of a complete functional 
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CD8+ T-cell response that was still present at day 10 but absent at 30 days after vaccination. 
APC activation by co-administration of FGK was unable to rescue the responding CD8+ 
T-cells from their fate. The basis for this dominant negative effect lies in the duration of 
antigen presentation in vivo, the location where these peptides are presented and the absence 
of sustained systemic danger signals.  
When the minimal CTL peptide is administered in PBS, this antigen is presented to CD8+ 
T-cells for less than 30 days. In contrast, when the peptide is mixed with IFA, the CTL peptide 
was still presented at 60 days after vaccination. FGK is likely to be cleared rapidly from the 
system, similar to other Ab (31,32), and as such can only temporarily activate APC. When 
systemic presentation of the minimal CTL peptide ensues in the absence of a continuous 
helper/danger signal (36), it is likely that this will result in CD8+ T-cell tolerance (Fig. 1, Fig. 
2 and (17)). In order to provide continuous helper signals we included the minimal ThOVA17 
peptide in the CTL/IFA bolus to activate APC via CD40-CD40L interactions (15,16,33), 
and showed that also the Th peptide was presented for more than 60 days (Fig. 2). As both 
peptides are continuously leaking out of the IFA depot, activation of APC, CD4+ and CD8+ 
T-cells will take place simultaneously. The induction of CD4+ T-cells not only enhanced the 
CD8+ T-cell response (Fig. 3) as was previously reported (37,38), but our experiments also 
show that it prevented the impairment of CD8+ T-cell reactivity, resulting in the preservation 
of long-term CD8+ T-cell immunity (Fig. 3). 
Recently, we found that the activation of CD8+ T-cells by minimal CTL peptide vaccines 
strongly depended on the presence of non-professional APC (Bijker, manuscript in 
preparation). Indeed, minimal MHC class I binding peptides are known to bind directly 
to their restriction elements at the cell surface of MHC class I expressing cells, including 
non-professional APC. However, our experiments teach us that CD8+ T-cells responding to 
minimal CTL peptides injected in PBS (and FGK) can become fully activated and as well 
form memory CD8+ T cells that are able to expand upon secondary antigen stimulation in 
vitro, to a similar extend as when the longer peptide is injected (compare figures 1A and 5B, 
day 30, open bars). Thus, even while suboptimal presentation may occur, this not necessarily 
leads to the activation of CTL that subsequently fail to expand or survive. This implies that 
at least other factors, such as the long term systemic presentation of the OVA8 peptide, may 
play a role in the detrimental outcome of minimal CTL peptide vaccines in IFA. 
Despite the fact that both the long OVA30 CTL peptide and the minimal OVA8 CTL peptide 
were presented for at least 60 days in vivo when applied in IFA (Fig. 4A and 2A, respectively), 
vaccination with the OVA30 peptide did not result in an eventual impairment of CD8+ T-cell 
reactivity and did not require CD4+ T-cell help to preserve the CD8+ T-cell response (Fig. 5). 
This was not only the case for OVA, but could be generalized for 3 Ag systems (Figs 1,5,8). 
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Extension of the minimal CTL peptide of either the OVA, HPV or E1A protein induced 
CD8+ T-cells with potent in vivo killing function until at least 30 days after vaccination. 
Furthermore, increasing the length of the minimal E1A10 CTL peptide to a 30 a.a. long 
peptide, prevented the induction of CD8+ T-cell tolerance that was previously observed when 
the minimal CTL peptide was used (11). 
In contrast to the minimal CTL peptides - which spread systemically to non-draining and 
non-inflamed LNs (17,29,39) where antigen probably is presented in a tolerizing fashion 
(40) - the longer peptides are predominantly presented by APC in the vaccine dLN (Fig. 6). 
As IFA induces a local inflammatory response (41,42) it will thereby provide the necessary 
danger signals (36,43) that are needed to activate the local APC that have ingested the long 
peptide vaccine. Together, this can explain why vaccination with long peptides in IFA does 
not result in a functionally impaired CD8+ T-cell response and why CD4+ T-cell help is not 
required. 
So, why did many papers report that minimal peptide vaccination in IFA induces an effective 
CD8+ T-cell response (6-9) instead of CD8+ T-cell tolerance? At one hand the outcome of 
vaccination was studied shortly after peptide vaccination when the CD8+ T-cells are not 
expected to be tolerized as shown here (Fig. 1A+B). On the other, many of the peptides used 
were much longer than the minimal CTL sequence, reaching up to 27 a.a. in length (2,6,7,44-
48), and/or contained a Th sequence (45,49). In view of the current results, this might explain 
why these so called “short synthetic peptides” performed so well compared to the exact 
minimal CTL peptides used here, or in clinical trials (4).
In addition, it should be noted that vaccination with minimal CTL peptide represses the 
induction of CD8+ effector T-cells generated in response to concomitant proper antigen 
presentation (Fig. 7). One can envisage that such an effect is highly undesirable in cancer 
patients that receive minimal CTL peptide vaccination after chemotherapy or radio therapy. 
In these cases, large amounts of Ag are released and cross presented by DC (50), which may 
result in the activation of tumor-specific CD8+ T cells that recognize the same sequences also 
present in the minimal CTL peptide vaccines in IFA. As a result such T-cell responses may be 
functional impaired following vaccination. 
In conclusion, our data clearly answers the question why vaccines consisting of minimal 
CTL peptides in oil-in-water emulsions (e.g. IFA) may have only limited immunological 
and clinical success in cancer patients. These vaccines need to be complemented at least by 
T-helper epitopes in order to sustain effective CD8+ T-cell reactivity. In case that specific 
CD4+ T-cell help is not readily available, extension of CTL peptides to longer variants may 
form an excellent alternative. Vaccine trials should be performed in order to confirm our 
results in a human setting. 
CD8+ T cell tolerance
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Superior induction of anti-tumor CTL 
immunity by extended peptide vaccines involves 
prolonged, DC-focused antigen presentation
Abstract. Anti-tumor vaccines consisting of extended CTL peptides in combination with CpG 
are superior to those comprising minimal CTL epitopes and CpG, in that they elicit stronger 
effector CTL responses with greater tumoricidal potential. This superiority is primarily due 
to the focusing of CTL epitope presentation to activated DC in the inflamed lymph nodes 
draining the vaccination site. In the case of vaccination with minimal peptides, additional 
APC including T- and B-cells are also loaded with CTL epitopes and, once loaded, can 
circulate through the lymphoid system. Consequently, epitopes are presented in non-inflamed 
lymphoid organs distal from the vaccination site, in the absence of potent costimulatory 
signals required for efficient CTL priming. The resulting blend of pro-immunogenic and 
tolerogenic signals, which results in suboptimal activation of the CTL response, is avoided 
by vaccinating with extended CTL peptides. An additional advantage of extended CTL 
peptide vaccines is an increased duration of in vivo epitope presentation, which is particularly 
apparent for vaccines comprising epitopes with weaker MHC class I binding.
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INTRODUCTION
The immune system has evolved to fight a diversity of invading pathogens, but is not 
optimally equipped to combat most cancer types (1). An important reason for this is that 
tumors arise slowly from single cell precursors and thereby fail to efficiently activate the 
immune system, due to the lack of strong pro-inflammatory signals (2,3). The immune system 
can be forced to respond against tumor-associated antigens (TAAs) by means of vaccination 
(reviewed in (4)). Peptide-based vaccines are intensively studied as a means for enhancing 
anti-cancer immunity, in particular T-cell responses. Their development was sparked by 
the identification of MHC-bound peptides, derived from various TAA, that are presented 
at the surface of murine and human tumor cells (5-7). Peptide-based vaccines constitute 
an attractive platform for immune intervention against cancer, because synthetic peptides 
with defined sequences can be readily produced in clinical-grade quality (4). Furthermore, 
synthetic peptides are molecularly defined, in that they do not contain antigenic components 
other than the epitopes of interest that could divert the attention of the immune response, or 
potentially pathogenic remnants of micro-organisms that could compromise the safety of their 
use in patients. Moreover, synthetic peptides constitute ‘off the shelf’ components that can be 
used to compose multi-peptide vaccines tailored to the antigen-content of the tumor and the 
HLA-type of the patient. Finally, the known antigen-content of peptide-based vaccines 
facilitates evaluation of antigen-specific immunity pre- and post-vaccination and, thereby, 
systematic analysis of vaccine-induced T-cell immunity in relation to clinical efficacy.
The vast majority of pre-clinical and clinical vaccination studies involving peptide-based 
vaccines have employed formulations comprising short peptides that match the exact, 
minimal sequences of MHC class I-binding CD8+ T-cell epitopes (8-14). Their apparent 
efficacy in eliciting protective anti-tumor T-cell immunity in mouse tumor models (9,14) has 
resulted in the testing of this concept in a considerable number of clinical studies involving 
cancer patients. However, the clinical and immunological impact of these vaccines can be 
considered disappointing (reviewed in (15,16)). In hindsight, this lack of therapeutic efficacy 
was to be expected. Although studies in multiple mouse models have shown that prior 
immunization of mice with vaccines comprising minimal CTL epitopes can protect against 
outgrowth of subsequently transplanted tumors, such vaccines were rarely found to elicit 
truly therapeutic T-cell immunity capable of clearing pre-existing tumors (reviewed in (4)). 
In our previous work, we have demonstrated this feature with a peptide vaccine comprising 
a CD8+ T ell epitope derived from the human papillomavirus type 16 E7 oncoprotein that is 
presented in the context of MHC class I (H-2Db) of HPV16-transformed murine tumor cells. 
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Even though administration of a vaccine comprising this minimal peptide epitope can protect 
mice against a subsequent challenge with HPV16-positive tumor cells (9), this vaccine fails 
to elicit therapeutic T-cell immunity in mice with pre-existing tumors (17). Importantly, we 
have found that the therapeutic efficacy this HPV16E7 peptide can be significantly increased 
by either combining it with a systemic dose of agonistic anti-CD40 antibody (18), or by 
extending the length of the peptide with natural flanking sequences (17). In the former case, 
in vivo ligation of CD40 was shown to replace the need for CD4+ T-cell help in mediating 
efficient CTL priming through the activation of antigen-presenting dendritic cells (DC) 
(18). In the latter case, the superior anti-tumor immunity induced by the extended peptide 
vaccine was shown to relate, at least in part, to the presence of a CD4 T-helper epitope in 
this peptide (17). This resulted in the induction of HPV16E7-specific T-helper responses 
and enhanced CTL-responses, where the enhancement of CTL immunity by these T-helper 
responses depended on CD40-mediated interactions with professional APC. Importantly, the 
extended HPV16E7 peptide vaccine also resulted in superior induction of CTL immunity 
in settings where the contribution of CD4+ T-cell help was excluded. If the minimal and 
extended peptides were administered in combination with the potent DC-activating agent 
CpG ODN, the extended peptide elicited much higher CTL responses, in a manner that did 
not depend on CD40-mediated interactions with professional APC.
In view of the potential of more effective, long-peptide based vaccines for immunotherapeutic 
use, we further investigated the mode of action of these vaccines, in particular the importance 
of peptide length on vaccine performance. The use of the chicken Ovalbumin (OVA) antigen 
and the corresponding OVA257-264-specific OT-1 TCR transgenic CD8+ T-cell system allowed 
detailed analysis of the impact of peptide length on epitope presentation and CTL activation. 
We compared the minimal CTL peptide OVA257-264 (OVA8) to a peptide that was extended 
at the N  and C terminus with the natural flanking residues of the OVA protein OVA241-270 
(OVA30). Because the OVA epitope is highly immunogenic (19,20), while many epitopes 
derived from TAA may have less optimal characteristics (20), we also compared minimal and 
extended OVA peptides that, due to a point mutation in an anchor residue, displayed weaker 
MHC binding (21). The results of our studies showed that the induction of therapeutic anti-
tumor CTL immunity critically depends on the use of extended peptide vaccines, in particular 
when the target epitope concerned is suboptimal. Our data furthermore demonstrate that the 
superiority of vaccines comprising extended peptides relies on an increased duration of 
antigen presentation that is focused on CD11c+ dendritic cells in the lymph node draining 
the vaccination site. 
Pharmacokinetics of short and long peptide-based vaccines
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MATERIALS AND METHODS
Mice. C57BL/6 (B6; H-2b) mice were purchased from IFFA Credo. B-cell-deficient uMT 
H-2Kb mice were purchased from Charles River (St. Germain sur l’Arbresle, France). OT 1, 
CD45.1  mice, expressing the OVA-specific, H2-Kb -restricted T-cell receptor (22) were bred 
at the Leiden University Medical Centre animal facility. All mice were used at 8–12 wk of 
age in accordance with national legislation and under supervision of the animal experimental 
committee of the University of Leiden. 
Peptides and vaccination. Peptides were generated, purified, dissolved and 
stored as described previously (9).  We have used the following peptides; OVA8 
(OVA257-264, SIINFEKL), OVA30 (OVA241-270 (SMLVLLPDEVSGLEQLESIINFEKLTEW
TS), OVA8LI (SIINFEKI) and OVA30LI  (SMLVLLPDEVSGLEQLESIINFEKITEWTS)
. The extended OVA peptides do not contain the known T-helper epitope OVA265-280 (23), 
nor any cryptic helper epitopes (24). Mice were vaccinated s.c. in the flank with 40 nmol 
of peptide (40 ug for 8-mer peptides; 140 ug for 30-mer peptides) admixed with 20 ug of 
CpG-ODN (25) in a total volume of 200 ul PBS.
Tumor cells and their use for in vitro stimulation and tumor challenge experiments. 
EG7 tumor cells expressing the full length OVA antigen (26) were cultured in IMDM 
(Invitrogen Life Technologies, Rockville, MD) supplemented with 8% (v/v) FCS (Greiner), 
50 µM 2-ME, 2 mM glutamine, 100 IU/ml penicillin (complete medium) supplemented 
with 400 ug/ml G418 (Gibco). EG7 cells were used for in vitro stimulation of splenocytes 
from immunized animals as follows. Three weeks after vaccination, spleens were removed 
and single spleen cell suspension of 10*106 cells/ml were made. EG7 cells were incubated 
with 50 ug/ml of mitomycin C (Kyowa) in complete medium at 37º C for 1 hour, washed 
4 times with medium, irradiated (4000 RAD) and resuspended and used as stimulator cells. 
Splenocytes were incubated in a 10:1 ratio with EG7 cells. Seven days later, viable cells 
were isolated over a ficoll gradient and were stained with H-2Kb Tetramer (TM)-OVA257-264 
complexes and CD8. Propidium Iodine was used to exclude dead cells. 
B16-OVA cells, which express the OVA antigen (27) were cultured in complete medium 
supplemented with Non essential amino acids (1:100) (Gibco), 1mM Sodium Pyruvate 
(Gibco), 60 ug/ml Hygromycin B (Invitrogen) and 1000 ug/ml G418 (Gibco ). For therapeutic 
vaccination experiments, mice were challenged with 5*104 B16-OVA tumor cells in the left 
flank. The following day, mice were vaccinated on the right flank with peptide vaccine and 
boosted two weeks later. Tumor size was measured with a capillary in 3 dimensions three 
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times a week. Mice were sacrificed when the tumor exceeded 1000 mm3 in accordance 
with national legislation. The group size was n=15 for the naïve groups and n=10 for the 
vaccinated groups.
In vivo cytotoxicity assay.  In vivo cytolytic activity was determined with peptide-loaded 
B6/CD45.1 splenocytes as target cells that were differentially labeled with the fluorescent dye 
CFSE (Molecular Probes). First erythrocytes were lysed by ammonium chloride treatment 
(3 min at room temperature). Splenocytes were then split into two fractions: i) target 
population and ii) internal control population. The target cell population was pulsed with 
1.0 ug/ml of OVA257-264 peptide and the internal control population with 1.0 ug/ml of p53 
peptide (H2-Kb, p53158-166) in complete medium at 37º C for 60 minutes. Subsequently, the 
cells were washed three times with PBS 0.1% BSA to remove excess of free peptide. The 
target population was labeled with 5 µM (CFSEhi) and the internal control population with 
0.5 µM (CFSElo) of CFSE for 20 minutes. The cells were washed two times with PBS 
before the populations were mixed in a 1:1 ratio and a total of 8*106 cells in 200 µl PBS 
was injected i.v. The next day spleens were removed and single cell suspension was made. 
The ratio of CFSElo/CFSEhi cells was determined by flow cytometry by gating on CD45.1+ 
lymphocytes. Specific killing of OVA257−264 pulsed (CFSEhi) target cells was calculated as 
follows: (1 [(CFSEhi/CFSElo)vaccinated*(CFSElo/CFSEhi)naive ] )*100%.
CFSE labeling of Tg T cells and adoptive T cell transfer. Single cell suspension was made 
from spleen and peripheral lymph nodes of OT-1 CD45.1+ mice. Erythrocytes were lysed by 
ammonium chloride treatment (3 min at room temperature). Cells were labeled with CFSE 
(28) as described above (5uM). OT-1 CD8+ T cells (2 x 106 in 200 ul PBS) were injected into 
the tail vein or used for in vitro experiments (in complete medium).
Ex vivo Ag detection. Lymph nodes were isolated and incubated for 30 minutes with 
Collagenase IV (250 U/ml; Sigma-Aldrich, St. Louis, MO) and DNAse (50 ug/ml; Sigma-
Aldrich) at 37º C. Single cell suspension was made and the cells were incubated with Abs 
against CD11c (DC), CD19 (B cells) and CD3 (T cells) and sorted on a FACSort. These 
sorted cells were used as stimulator cells in co-cultures with naïve CFSE-labeled OT-1 CD8+ 
T cells for three days, after which proliferation of the OT-1 cells was evaluated by flow 
cytometry on basis of CSFE-dilution. Co-cultures contained 1*105 OT-1 cells and one of 
the following stimulator cells: CD11c+ 5*104; CD19+ cells 4*105, CD3+ cells 8*105, We 
have used 5*104 CD11c+ cells, because only limited amounts of these cells could be isolated 
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from the draining lymph nodes (dLN). The numbers of CD19+ and CD3+ cells used for this 
experiment, were based on their ratio to the CD11c+ cells found in the dLN; 8 fold more 
CD19+ cells, and 16 fold more CD3+ cells.  
Flow cytometry. Single cell suspensions of spleens were stained in PBS 0.1% BSA. The 
Abs used, were the following: directly allophycocyanin-conjugated; H-2Kb Tetramer 
OVA257-264; CD45.1 (A20, eBioscience), CD19 (1D3, Pharmingen); PE conjugated; CD8b2 
(53-5,8, Pharmingen), CD11c (HL3, Pharmingen) and, Va2 (clone B20.1, Pharmingen); 
FITC-conjugated CD3 (145-2C11, Pharmingen). Data acquisition and analysis was done on 
a BD Biosciences FACScan (San Jose, CA, USA) with CellQuest software. 
Statistical analysis. Statistical analysis was done using GraphPad InStat software (version 
3.0) and GraphPad Prism 4 (GraphPad Software, San Diego, CA). A two-tailed t test with 
Welch correction was used for Fig. 1,4 and 5. For the comparison of survival curves in 
Fig. 2, the Logrank test was applied.
RESULTS
Magnitude and anti-tumor efﬁcacy of the CD8+ T cell response is determined by peptide 
afﬁnity and length.
In order to validate whether the OVA epitope constitutes a suitable model for evaluating 
the mode of action of peptide vaccines containing extended CTL epitopes (17), mice were 
vaccinated with the minimal peptide OVA8 (OVA257-264) or the extended peptide OVA30 
(OVA241-270). Because our study focused on the impact of peptide length on vaccine 
performance, both peptides were administered in combination with CpG. In this setting, CTL 
priming is independent of CD4+ T-cell help (17). Analysis of the number of OVA-specific 
CTLs by means of flow cytometry revealed only a modest difference between mice immunized 
with the minimal and extended peptides (Fig. 1). The lack of correspondence of these results 
with our previously published data concerning minimal and extended peptides containing 
the HPV16 E7 CTL epitope (17) could be explained by the fact that the OVA8 epitope is a 
highly immunogenic epitope that strongly binds to MHC class I, while the HPV16E7 epitope 
is a subdominant epitope that displays intermediate MHC binding (8,20). In view of this, 
we repeated our analyses with minimal and extended peptides comprising a modified OVA 
epitope, in which the secondary anchor residue   Leucine at position 264   was substituted for 
an Isoleucine (OVA8LI and OVA30LI). This substitution was reported to result in decreased 
MHC binding without altering its interaction with the T cell repertoire (21). Importantly, 
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comparison of the CTL numbers induced by minimal and extended peptides comprising this 
modified CTL epitope did reveal a clear superiority of the extended peptide vaccine (Fig. 1), 
in agreement with our previous results for peptides comprising the HPV16 E7 epitope (17).
To test if the capacity of the OVA peptide vaccines to increase CTL numbers corresponded 
with their capacity to elicit therapeutic anti-tumor immunity, groups of mice were challenged 
with tumorigenic doses of B16-OVA cells and subsequently vaccinated with the peptide 
vaccines under examination. Interestingly, vaccination with extended peptides did not only 
result in superior anti-tumor immunity in the case of the wild type OVA epitope, but also in the 
case of its modified counterpart (Fig 2A,B). In line with these findings, the in vivo cytolytic 
activity against peptide-loaded splenocytes was significantly stronger in mice immunized 
with extended peptides as compared to mice immunized with the corresponding minimal 
peptides (Fig. 2C, D). For vaccines comprising the wild type OVA peptide, this difference was 
already apparent after a single vaccine dose (Fig. 2C), while induction of detectable cytolytic 
activity with vaccines comprising the modified OVA peptides required two subsequent doses 
of vaccines (Fig 2D). Overall, the levels of in vivo cytolytic activity induced by prime-boost 
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Figure 1. The magnitude of the CD8+ T cell response is determined by peptide afﬁnity and length. 
Mice (>15/group) were vaccinated s.c. with either OVA8, OVA30, OVA8LI, or OVA30LI peptide (40 nmol) in 
combination with CpG (20ug). Three weeks afterwards, splenocytes were isolated and stimulated in vitro with 
OVA-expressing tumor cells for 7 days before analyzing the frequency of TM-OVA+ CD8+ T cells. The data are 
depicted as mean values ± SEM. Results with OVA and OVALI peptides are shown with black and grey bars 
respectively (OVA8 vs. OVA30, p=0.058; OVA8LI vs. OVA30LI, p<0.01). In addition, representative FACS plots 
are shown.
58
Figure 2. Improved therapeutic efﬁcacy of anti-tumor vaccines comprising extended CTL peptides. 
A. Mice were challenged s.c. with 5*104 B16-OVA tumor cells in the left ﬂank (day -1).  The following day 
(d0), the mice (n=15) were left untreated or vaccinated in the right ﬂank with either OVA8 or OVA30 peptides 
(40 nmol) in combination with CpG (20 ug) and boosted 2 weeks later (10 mice/group). Tumor size was measured 
3 times per week and mice were sacriﬁced when the tumors exceeded 1000mm3. B. Mice were challenged with 
B16-OVA tumor cells as in A, and left untreated or vaccinated with either OVA8LI, or OVA30LI peptide in 
combination with CpG and boosted 2 weeks later (10 mice/group). The graphs depict the percentages of tumor 
free mice (signiﬁcant improvement of tumor free mice as compared to untreated mice: †, p<0.0002; ‡, p<0.03; 
#, p<0.03).  C, D: Analysis of antigen-speciﬁc in vivo cytolytic activity in mice vaccinated with one (C; day 0) 
or two (D; days 0 and 14) doses of vaccines containing the indicated peptides. Mice (6/group) received a 1:1 
mixture of OVA-peptide loaded and control peptide-loaded, CSFE-labeled splenocytes as target cells at day 
9 (C) or day 19 (D). The relative amounts of OVA- and control peptide-loaded target cells in the spleen were 
evaluated by ﬂow cytometry. Data are depicted as mean percentage of OVA-speciﬁc target cell killing ± SEM.
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regimens (Fig 2D) correspond well with the protective effect observed in tumor challenge 
experiments (Fig 2A, B), in accordance with the fact that also the latter experiments involved 
prime-boost vaccination.
Taken together, our data indicate that the capacity of CTL peptide vaccines to induce CTL 
effector responses is greatly enhanced by the use of extended peptide sequences. Even though 
this is particularly critical for vaccines comprising suboptimal CTL epitopes, this concept 
also applies to vaccines that comprise highly immunogenic CTL epitopes. Notably, such 
differences in vaccine efficacy may be overlooked when enumeration of antigen-specific 
CTL by flow cytometry is used as a read out (Fig 1).
Increased duration of antigen presentation after vaccination with extended CTL 
peptides.
Several studies have demonstrated that duration of antigen presentation is an important 
parameter in determining the magnitude of the CTL response (29-31). We therefore tested the 
impact of peptide length on longevity of antigen presentation after vaccination, as detected 
by naïve CFSE-labeled OT-1 CD8+ T cells (32). OT-1 T cells can be used to detect the 
presentation of both wild type and modified OVA peptides, because the CTLs respond to 
these peptides in vitro and in vivo with comparable efficiency (Fig. 3A, B). 
To test the duration of antigen presentation in vivo, naïve CFSE-labeled OT-1 T cells were 
infused 2, 6, or 10 days after vaccination with the minimal and extended OVA peptides 
(Fig. 3C). For peptides comprising the wild type OVA epitope, peptide length had only a 
modest impact on duration of antigen presentation. Even tough OVA peptide was presented 
up to 10 days after vaccination with either OVA8 or OVA30, antigen presentation at day 
10 was still maximal in mice immunized with OVA30, while being in decline in mice 
immunized with OVA8. The impact of peptide length was much more profound in case of 
the modified OVA peptides, in that most antigen presentation was already lost within 2 days 
after vaccination with the short OVA8LI peptide, while being constant for at least 10 days in 
case of the extended OVA30LI peptide.
Our data on longevity of antigen presentation are in striking correspondence with those on 
the induction of in vivo effector CTL responses, in that the use of extended peptides is critical 
for good performance of vaccines comprising the suboptimal OVA epitope, while being less 
essential (but still important) for vaccines comprising the optimal OVA epitope.
The short in vivo duration of antigen presentation of the minimal CTL peptide OVA8LI 
(Fig.3C) correlated with its poor capacity to elicit CTL responses (Fig. 1&2). We therefore 
analyzed whether increasing the duration of antigen presentation by repeated administration 
of the OVA8LI peptide would improve its capacity to elicit CTL immunity. Indeed, such 
Pharmacokinetics of short and long peptide-based vaccines
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Figure 3. Increased duration of antigen presentation after vaccination with extended CTL peptides.  
A. Ex vivo recognition of OVA8 and OVAL8I peptides by OT-1 T-cells. Naïve CFSE-labeled OT-1 T-cells 
(1*105) were incubated in vitro with the indicated amounts of OVA8 or OVA8LI peptide. Three days afterwards, 
proliferation was determined by measuring CFSE dilution. Representative histograms of duplicate experiments 
are shown. B. In vivo recognition peptide antigens by OT-1 T-cells. Mice were infused with naive CFSE-labeled 
OT-1 T cells (2*106) and were vaccinated s.c. on the same day with the indicated peptides in combination with 
CpG. Three days later, the extent of T-cell proliferation in the dLN (inguinal) was analyzed by ﬂow cytometry. 
C. In vivo longevity of antigen presentation. Mice were vaccinated s.c. with the indicated peptides in combination 
with CPG. Two, 6, or 10 days afterwards, naive CFSE-labeled OT-1 T cells (2*106) were infused. Three days 
later, proliferation of OT-1 T cells in the dLN was evaluated by ﬂow cytometry. Each histogram depicts data 
representative of 4 mice. 
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repeated administration resulted in significantly increased numbers of OVA-specific CD8+ T 
cells as detected by MHC-tetramers (Fig. 4A). However, testing of this vaccine regimen for 
its potential to clear B16-OVA tumors revealed that, in spite the high levels of CD8+ T cells 
induced by this vaccine (Fig. 4A), no enhanced tumor clearance was observed compared to the 
naïve mice (Fig. 4B). These data suggest that the therapeutic impact of vaccines comprising 
extended CTL peptides is not merely due to prolonged antigen presentation.
Antigen presentation after vaccination with extended peptides is predominantly focused 
to DC in the draining lymph node.
Efficient induction of CTL immunity requires strong costimulatory signals in addition to the 
antigenic signal. Of all APC types, DC are best equipped to provide naïve CTLs with both 
types of signals, provided that they are activated by CD4 T-helper cells through CD40 and/
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or by pathogen-associated molecular patterns (PAMPs) through Toll-like receptors (TLRs). 
Therefore, one would expect to achieve optimal antigen presentation after vaccination if 
this presentation is restricted to DC in the inflamed lymph node(s) draining the vaccination 
site. To evaluate the localization of - and APC-types involved in - epitope presentation after 
vaccination, mice were vaccinated in the flank with minimal versus extended OVA peptides in 
combination with CpG and two days afterwards, the draining (inguinal and axillary) and non-
draining (mesenteric) lymph nodes were isolated. The cells from the dLN were separated into 
CD11c+ DC, CD19+ B cells, and CD3+ T-cells, while the cells of the ndLN were separated 
into CD11c+ DC and CD11c- cells. The resulting cell populations were subsequently tested 
for their capacity to stimulate proliferation of naive CFSE-labeled OT-1 T-cells. As shown in 
figure 5A, vaccination with the minimal OVA8 peptide resulted in antigen presentation by 
CD11c+ DC, B-cells and T-cells in the dLN, as well as by the CD11c-negative cells in the 
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Figure. 4. Extending in vivo antigen presentation by repeated injection of minimal peptide does not 
enhance effector CTL responses. A. Mice (13/group) were vaccinated s.c. with a single dose (day 0, grey 
bars) of OVA8LI (40 nmol) and CpG (20 ug) or were subsequently boosted with OVA8LI without CpG on days 3, 
6, 9 (checkered bars). Three weeks afterwards, splenocytes were stimulated in vitro with OVA-expressing tumor 
cells for seven days, after which the frequencies of TM-OVA+ CD8+ T cells were analyzed by ﬂow cytometry. 
Histograms show mean values ± SEM (OVA8LI vs. 4*OVA8LI, p<0.013). In addition, representative FACS plots 
are shown.  B. Mice were challenged s.c. with 5*104 B16-OVA tumor cells on the left ﬂank (day -1). The next day 
(d0), mice were either left untreated (n=15) or were vaccinated (n=13) with 4 consecutive doses of OVA8LI at 
days 0, 3, 6 and 9 (see above), and boosted at day 14. Tumor size was measured 3 times per week and mice 
were sacriﬁced when the tumors exceeded 1000 mm3. The untreated group is the same as shown in Fig. 2B. 
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ndLN. In contrast, clearly detectable antigen presentation after vaccination with the extended 
OVA30 peptide was focused to the CD11c+ DC in the dLN, while no antigen presentation 
could be detected by cells isolated from the ndLN. These results are in line with the notion 
that uptake of exogenous antigen, such as extended peptides, and processing of the CTL 
epitopes contained into MHC class I is restricted to DC (33), while minimal peptide epitopes 
can be exogenously loaded into MHC class I molecules at the surface of various types of 
professional and non-professional APC. The finding that DC-mediated antigen presentation 
is limited to the dLN is in accordance with the expectation that activation of DC at the 
vaccination site, by the adjuvant CpG, will result in DC migration to the dLN and not in 
DC circulation throughout the body. Systemic migration after antigen uptake can, however, 
be envisioned for lymphoid APC, such as B and T-cells. We therefore tentatively conclude 
that the antigen presentation in ndLN by CD11c-negative cells, as detected after vaccination 
with the minimal OVA8 peptide, is mediated by circulating lymphocytes that have been 
exogenously loaded with peptide epitope in the dLN.
The analyses of antigen presentation by the different APC populations in dLN versus ndLN 
were also performed after vaccination with the minimal OVA8LI and extended OVA30LI 
peptides (Fig 5B). The levels of antigen presentation detected in these experiments were 
much lower. This is most likely the result of the weaker binding of the modified OVA CTL 
epitope to H-2Kb, which decreases the on-rate and increases the off-rate and thereby the 
level at which peptide/MHC complexes accumulate at the cell surface (21,34). Furthermore, 
the higher off-rate is expected to result in loss of MHC/peptide complexes over time after 
isolation from the lymph nodes, and thereby to negatively affect the detection of such 
MHC/peptide complexes in in vitro assays. In spite of the latter, also the experiment with the 
modified OVA peptides, clearly show that epitope presentation after immunization with the 
extended peptide is focused to the CD11c+ DC in the dLN (Fig. 5B).
Taken together, our data argue that vaccination with extended peptides plus CpG results 
in high-quality CTL epitope presentation that is focused to activated DC in the inflamed, 
draining lymph node.  In comparison, vaccination with minimal peptides plus CpG results in 
CTL epitope presentation by DC and other APC including B- and T-cells. Epitope presentation 
by the latter APC is expected to be tolerogenic, because it is not accompanied by sufficient 
costimulatory signals (33,35,36). Notably, this tolerogenic antigen presentation is not limited 
to the inflamed draining lymph node, but also takes place in the absence of pro-inflammatory 
signals in non-inflamed lymph nodes distal to the vaccination site. 
In view of the magnitude of CTL epitope presentation by B-cells isolated from mice 
immunized with the minimal OVA8 peptide (Fig 5A), and the abundance of this cell type in the 
hematopoietic system, we examined the importance of B-cell mediated epitope presentation 
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Figure 5. Antigen presentation after vaccination with extended peptides is predominantly focused to 
DC in the draining lymph node.A,B. Mice were vaccinated s.c. with the indicated peptides in combination 
with CpG. Two days afterwards, the draining (inguinal and axillary) and non-draining LN (mesenteric) were 
isolated. The dLN cells were sorted into CD11c+ DC, CD19+ B cells and CD3+ T-cells while the ndLN cells were 
sorted into CD11c+ DC and CD11c- cells. The resulting cell fractions CD11c+ cells 5*104; CD19+ cells 4*105; 
CD3+ cells 8*105; CD11c- cells 8*105) were used as stimulator cells in a 3-day co-cultures with 1*105 naïve 
CFSE-labeled OT-1 T cells. Proliferation of OT-1 T cells was measured as dilution of CFSE by ﬂow cytometry. 
C. Antigen presentation on B-cells is important for CTL-priming after minimal CTL peptide vaccination. B cell 
deﬁcient mice (n=7) were vaccinated s.c. with either OVA8 or OVA30 peptide in combination with CpG. Three 
weeks later, splenocytes were stimulated in vitro with OVA-expressing tumor cells for seven days, after which 
the frequencies of TM OVA+ CD8+ T cells were evaluated. Histograms show mean values ± SEM (OVA30 vs. 
naïve, p<0.03). In addition, representative FACS plots are shown. 
OVA8
CD3+CD19+CD11c+
dLN
A
CD11c-CD11c+
ndLN
OVA30
CFSE
C
ou
nt
s
OVA8LI
CD3+CD19+CD11c+
dLN
B
na
ive
OV
A8
OV
A3
0
0
1
2
3
4
5
6
%
TM
+ 
C
D
8+
of
to
ta
lC
D
8+
C
CD11c-CD11c+
ndLN
OVA30LI
CFSE
C
ou
nt
s
OVA8
naive
CD8
TM
-O
V
AOVA30
0.2%
0.4%
4.7%
64
for CTL priming in mice immunized with minimal versus extended OVA peptides. Mice 
deficient for B cells were vaccinated with either of these peptides plus CpG and stimulated 
in vitro, after which the frequencies of OVA-specific CD8+ T cells were determined by flow 
cytometry. This experiment showed that B-cell deficientcy profoundly affected CTL priming 
after minimal OVA8 peptide vaccination, while leaving CTL priming by vaccination with 
the extended OVA30 peptide largely intact (Fig. 5C). These findings support our notion that 
antigen presentation by B-cells plays a prominent role in T-cell priming by minimal CTL 
epitope vaccines .
In conclusion, the focused antigen presentation on activated DC in inflamed, draining lymph 
nodes (Fig 5), together with the increased longevity of antigen presentation (Fig 3) can 
readily explain why vaccination with extended CTL peptides results in superior CTL effector 
responses as compared to vaccination with minimal CTL peptides.
DISCUSSION 
In the present study, we addressed the question why peptide-based vaccines comprising 
extended CTL peptides, in particular the HPV16E7-specific anti-tumor vaccine on which we 
reported previously (17), elicit superior T-cell immune responses as compared to vaccines 
consisting of minimal peptide epitopes. Our experiments, in which we used the chicken 
Ovalbumin (OVA) CTL epitope as a model antigen, showed that vaccination with extended 
CTL peptides resulted in increased duration of antigen presentation, especially in the case 
of a peptide vaccine that comprises a modified OVA epitope with suboptimal MHC-binding 
characteristics. Although this correlation between duration of in vivo antigen presentation 
and vaccine performance is in line with previous observations by others (29,30),it cannot 
fully account for the different capacities of minimal and extended peptide vaccines to elicit 
CTL immunity. Because maintenance of in vivo antigen presentation through repeated 
administration of short peptides, although resulting in the priming of higher CTL frequencies, 
failed to elicit tumoricidal CTL effector responses. A plausible explanation for this failure is 
offered by the outcome of further experiments, in which we evaluated the location of antigen 
presentation and the APC-types involved after vaccination with minimal versus extended 
peptides. These data revealed that antigen presentation after vaccination with extended CTL 
peptides is focused to the DC in the draining lymph nodes, while vaccination with minimal 
peptides can result in antigen presentation on multiple APC types in both the draining lymph 
nodes and in distal lymphoid organs. As a consequence, vaccination with extended peptides 
primarily results in pro-immunogenic presentation of CTL epitopes by DC, in the context 
of strong costimulatory signals and in an inflamed lymph node. In contrast, vaccination 
with minimal CTL peptides, although resulting in this pro-immunogenic mode of antigen 
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presentation, also leads to presentation of CTL epitopes by cell types that cannot provide 
T-cells with the costimulatory signals required for optimal T-cell activation, such as T- and 
B-cells. Importantly, the latter antigen presentation takes place in non-inflamed lymph nodes, 
distal from the source of adjuvant, and thereby in the absence of a pro-inflammatory context. 
It is conceivable that the resulting blend of T-cell activating and tolerizing signals does not 
constitute an optimal setting for mobilization of potent effector CTL responses. This notion is 
supported by our finding that vaccination with minimal peptide vaccines, although increasing 
the numbers of antigen-specific CTLs, fails to launch potent effector CTL immunity capable 
of therapeutic efficacy against tumors.
Our recent data do not only provide insight into the mode of action of minimal and extended 
peptide vaccines in pre-clinical models, but may also explain the lack of therapeutic efficacy 
of minimal CTL epitope vaccines in the clinic, in particular with respect to two recent studies 
in which melanoma patients were vaccinated with minimal CTL peptides derived from 
gp100 and MART-1 (12,13). In both cases, peptide vaccination resulted in significant levels 
of circulating, antigen-specific CTLs that exhibited clear antigen-specific reactivity in vitro. 
However, there was no correlation between the CTL frequencies detected in peripheral blood 
and the clinical impact of vaccination. In fact, clinical impact was similarly poor as that of 
previous peptide vaccination studies (15,16). As such, the results of these clinical vaccination 
studies bear a strong resemblance to those of our mouse studies with minimal CTL peptide 
vaccines. Interestingly, one of these studies tested whether complementation of the minimal 
peptide vaccine with CpG would increase the potency of the vaccine, and concluded that 
addition of this adjuvant enhanced CTL frequencies but not the anti-tumor efficacy (13). 
In view of our data, this lack of true improvement can be explained by the fact that CpG, 
although activating the DC in the draining lymph node, does not empower the other antigen-
loaded APC, such as B-cells and T-cells, in draining and non-draining lymphoid organs to 
efficiently activate CTLs, and therefore does not improve the overall quality of the antigen 
presentation.
Our observation that extended peptide length is especially important for greater duration of 
in vivo antigen presentation in case of the modified OVA epitope (Fig. 3), which displays 
weaker MHC-binding, argues that vaccination with extended peptides creates an antigen 
depot that compensates for loss of surface expressed epitope. Although the nature of this 
depot awaits further investigation, it is likely to constitute an extracellular depot rather than 
storage of antigen within the DC. This is suggested by our observation that ex vivo detection 
of antigen presentation on DC isolated from draining lymph nodes of OVA30LI vaccinated 
mice is rather difficult. If the DC are used in co-cultures with OT-1 T-cells, a modest level of 
T-cell proliferation reflecting antigen presentation can be observed (Fig. 5A, B). However, 
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this antigen presentation is lost if the DC are not rapidly isolated and immediately used for 
the co-cultures (data not shown). Nevertheless, in vivo antigen presentation as detected by 
proliferation of OT-1 T-cells can be observed for at least 10 days after vaccination with the 
OVA30LI8 peptide (Fig 3C). We have previously shown that such a depot can also be created 
for minimal peptide vaccines by administrating these peptides with oil-in-water formulations, 
such as an emulsion with IFA. Importantly, the resulting prolonged presentation fails to 
induce an effective CD8+ T cell response and eventually result in T-cell tolerance through 
exhaustion of the antigen-specific T-cells (24,37). Our cumulative data indicate that the 
tolerance induced by this peptide in IFA vaccine results from prolonged systemic presentation 
of antigen in the absence of sufficient costimulation, because it can be overcome, by addition 
of a CD4+ T-helper epitope to the vaccine, or by extending the length of the peptide (24)  In 
case of the CD4+ T-helper epitope, the helper signal to the DC improves the net quality of 
antigen presentation and thereby the immunogenic potential of the vaccine (38,39), while the 
use of extended peptides focuses antigen presentation to the DC in the inflamed lymph nodes 
draining the vaccination site.
In conclusion, our studies strongly support the use of vaccines comprising extended instead 
of minimal CTL peptides, as this results in a prolonged in vivo antigen presentation as well 
as in a better quality of the antigenic signal that is confined to activated DC in the inflamed 
lymph nodes.
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Multiple CD4 and CD8 T-cell activation 
parameters predict vaccine efficacy in vivo 
mediated by individual DC-activating agonists.
Abstract. A systematic comparison of the immunostimulatory capacity of TLR 2, 3, 4, 5, 7 
and 9 agonists and an agonistic CD40-specific antibody was performed in a single long peptide 
vaccination model. All adjuvants activated DC in vitro but not all induced a strong functional 
T-cell response in vivo. Optimal clonal CD8(+) T-cell expansion depended on the capacity of 
agonists to mature pro-inflammatory DC and the duration of their in vivo stimulatory effect. 
Strong agonists promoted the induction of both antigen-specific IFNgamma-producing 
CD4(+) T-helper cells and high numbers of IFNgamma producing CD8(+) effector T-cells 
that killed target cells in vivo. Importantly, the capacity of an agonist to function as an adjuvant 
depended on the vaccine strategy used. Collectively, the multi-parameter system presented 
here can be used as a general road map to develop therapeutic vaccines.
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INTRODUCTION
Dendritic cell (DC) activation is key to the induction of an effective cytotoxic T-cell (CTL) 
response (1). In effective natural immune responses CD4+ T-helper cells can fully activate 
DC through the CD40/CD40L signaling pathway (2, 3). Other DC activation signals that can 
support induction of powerful CTL responses involve the innate immune receptors and include 
the molecularly defined agonists for Toll-like receptors (TLR), which is a family of pattern 
recognition receptors that recognize structural components of bacteria, viruses and fungi  (4-6).
The use of these TLR agonists in vaccine formulations may permit the development of 
effective therapeutic vaccine strategies for the immunotherapy of cancer. Several reports 
show an improved efficiency of vaccines in mice, when antigen delivery is combined with 
a TLR 9 agonist. In a C57BL/6 mouse model, the combined injection of the TLR 9 agonist 
CpG-ODN1628 and an HPV16-specific long peptide comprising CD4+ and CD8+ T-cell 
epitopes resulted in a strong expansion of HPV16-specific CD8+ T-cells and the subsequent 
eradication of established HPV16+ TC-1 tumors (7). However, the distribution of TLR 9 
differs substantially between human beings and mice. While in C57BL/6 mice TLR 9 is 
broadly expressed on all types of DC (8, 9), the expression of TLR 9 in humans is restricted 
to the plasmacytoid DC (9-11). Importantly, the expression pattern of the other TLRs is 
similar in both humans and mice. TLR 2, 3, 4, 5 and 7 are broadly expressed on several DC 
types of both species (9, 10, 12). However, only few studies have reported the use of TLR 
agonists other than TLR 9 as adjuvants for vaccines. In some mouse studies TLR 3, 4 and 7 
agonists showed a weak capacity to activate antigen-specific CD8+ T-cell responses whereas 
in other studies activation of these TLR resulted in a strong CD8+ T-cell response (13-18). 
Combinations of immunostimulatory molecules are expected to enhance the therapeutic 
potential of anti-tumor vaccines as it was shown that agonists for TLRs synergized with 
CD40 triggering and stimulated a 10-20 fold greater expansion of antigen-specific CD8+ 
T-cells than either agonist alone (17). 
Because the above-mentioned studies were all carried out in different mouse models, we 
performed a systematic comparison in which the adjuvanticity of TLR 2, 3, 4, 5, 7 and 9 
agonists as well as an agonistic CD40-specific antibody was tested in a single long peptide 
vaccination model. Our experiments show that profound differences exist between these 
agonists with respect to a) the efficacy to activate DC in vitro; b) the capacity to induce the 
production of inflammatory cytokines by DC; c) their capacity to sustain T-cell expansion 
in vivo; and d) their ability to trigger direct T-cell effector function as measured by IFNγ 
production, in vivo cytotoxicity, T-cell migration and protection against the outgrowth of 
established tumors. Collectively, these data provide key information regarding the expected 
features and design of potent therapeutic vaccines.
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MATERIAL AND METHODS
Mice. Female C57BL/6 (B6, H-2b) mice were purchased from Charles River (Paris, France). 
Mice were maintained under specific pathogen-free conditions and used at 6-10 weeks of age. 
OT-1 Rag-/- CD45.1 mice were bred at the LUMC animal facility under specific pathogen-
free conditions. These mice were used as a source of OVA-specific CD8+ T-cells for adoptive 
transfer studies.
Cells and cell lines. The tumor cell line 13.2 was derived from B6 mouse embryo cells (B6 
MECs) transformed with adenovirus type 5-derived E1 protein in which the H-2Db E1A 
epitope was replaced with the HPV16-E7
49-57
 CTL epitope (19). Notably, no HPV16-specific 
T-helper epitopes are present in this cell line. TC-1 was derived from primary epithelial cells 
of C57BL/6 mice co-transformed with HPV-16 E6 and E7 and c-Ha-ras oncogenes (a kind 
gift of dr. T.C. Wu). Both tumor cell lines were cultured in IMDM (BioWhittaker, Verviers, 
Belgium) and 10% FCS (Greiner, Alphen aan de Rijn, The Netherlands) (19). Primary bone-
marrow-derived DC cultures (BM-DC) were generated as described previously (20). Both 
floating and adherent DC were used for the experiment and the purity of the cultured cells 
was determined by flow cytometry using the following antibodies: APC-conjugated anti-
CD45R/B220 (clone RA3-6B2; BD Pharmingen, San Diego, CA, USA), FITC-conjugated 
anti-CD11b (clone M1/70; BD Pharmingen) and PE-conjugated anti-CD11c (clone HL3; BD 
Pharmingen).  
Antigens and peptides. As human papillomavirus (HPV)-specific antigens the H-2Db-
restricted CTL epitope HPV16-E7
49-57
 (RAHYNIVTF) and the HPV16 E7
43-77
 35-residue 
long peptide QAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIR, covering both the CTL 
epitope (in bold) and the T-helper (Th) epitope (underlined), were used. In addition, we used 
a 32-mer long OVA peptide LPDEVSGLEQLESIINFEKLTEWTSSNVMEER that encodes 
the H-Kb-restricted CTL epitope SIINFEKL (in bold), which is recognized by the T-cell 
receptor transgenic OT-1 cells. The purity of the peptides was determined by RP-HPLC and 
was found to be routinely over 90%. Peptides were dissolved in 0.5% DMSO in PBS and, if 
not used immediately, stored at –20°C.  The recombinant HPV16-E7 protein was produced in 
recombinant Escherichia coli transformed with Pet-19b-HPV16-E7 and purified as described 
previously (21). 
Molecularly defined adjuvants. The following agonists for the different murine Toll-like 
receptor (TLR) were used: Palmitoyl-Cys(CRS)-2,3-di(palmitoyloxy)-propyl (PAM
3
CSK
4
; 
EMC Echaz Microcollections, Tübingen, Germany) for TLR 2. Poly I:C
12
U (Ampligen; 
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Bioclones, Sandton, South Africa; kindly provided by dr. M. Adams, Cardiff, UK) for 
TLR 3. Monophosphoryl lipid A (MPL; detoxified LPS) was kindly provided by Corixa 
Corporations (Seattle, WA, USA) for TLR 4. Flagellin (FliC protein from Salmonella 
enterica serovar Typhirium, kindly provided by dr. JC Sirard, INSERM, Lille, France) 
for TLR 5. R848 (InvivoGen, San Diego, CA, USA) for TLR 7 and CpG (ODN1826:
TCCATGACGTTCCTGACGTT, kindly provided by dr. G. Lipford (Coley Pharmaceutical 
Group, Wellesley, MA, USA) for TLR 9. In addition, the agonistic CD40 antibody FGK-45 
was used (22). As a standard we used incomplete Freund’s adjuvant (IFA).
In vitro DC stimulating experiments. Activated DC are characterized by cytokine production 
and the up-regulation of accessory and co-stimulatory molecules expressed at the cell 
surface, including CD40, CD80, CD86 and CD83 as well as MHC class II molecules (23). 
Therefore, 10-days cultured BM-DC were incubated at 40,000 cells/well in a flat-bottom 
96-well plate for 48 h with a concentration range (in 2 to 5-fold stepwise dilutions from 50 
μg/ml down to 0.5 ng/ml for all adjuvants except for flagellin which had to be tested in a 
broader range namely from 50 μg/ml  down to 1 pg/ml) of the various adjuvants to activate 
these antigen-presenting cells. Supernatants of all the cultures were harvested after 24 h 
and 48 h to analyze the cytokine profile (IL-6, TNF-α, and IL-10) by cytometric bead array 
(CBA; BD Pharmingen). As an universal marker for activation of all DC subsets present in 
BM-DC (8) we determined the concentration of mouse IL-12p40 in the supernatants by a 
standard sandwich ELISA using rat anti-mouse IL-12p40 (clone C15.6; BD Pharmingen) for 
catching and biotinylated rat-anti mouse IL-12p40 (clone C17.8; BD Pharmingen) for the 
detection. Streptavidin-HRP and ABTS (Sigma-Aldrich, St. Louis, MO, USA) were used as 
enzyme and substrate, respectively. At 48 h of culturing the cells were harvested and stained 
for the activation markers with PE-labeled anti-CD40 (clone 3/23; BD Pharmingen), FITC-
labeled anti-CD80/B7.1 (clone 16-10A1; BD Pharmingen) and PE-labeled anti-CD86/B7.2 
(clone GL-1; BD Pharmingen) and analyzed by flow cytometry. 
Vaccination of mice. Mice were vaccinated subcutaneously (s.c.) in the right flank with 
200 µl of the vaccine, consisting of 150 µg of long HPV16 E7 peptide or 150 µg of long 
OVA peptide, respectively, admixed with or without 50 µg PAM
3
CSK
4
, 20 µg Poly I:C
12
U 
(Ampligen), 10 µg MPL, 50 µg R848 or 50 µg CpG per mouse, respectively. In case of 
CD40 ligation 100 µg FGK-45 per mouse was subcutaneously injected the day after peptide 
vaccination. After 10 days mice were sacrificed and spleen cells were isolated.
The used doses of the various adjuvants were either advised by the provider but also 
demonstrated to be effective (PAM
3
CSK
4
, MPL, CpG (7, 24)) or deduced from a dose finding 
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pilot experiment (range 10–50 µg adjuvant/mouse). Although R848 was successfully used at 
a concentration of 17 µg per mouse (25) and Poly I:C
12
U (Ampligen) at 25-50 µg/mouse (17, 
26, 27) we first tested these components in the dose finding experiment. The dose with the 
relatively highest number of tetramer positive CD8+ T-cells was used for further vaccination 
experiments. The amount of FGK-45 used was based on previous work of our group (22).
Tumor challenge experiments. Mice were injected with 25,000 TC-1 tumor cells in the 
left flank (the tumor take was 100%).  At day 9-10, when the tumors were palpable, mice 
were vaccinated at the right flank with indicated vaccines. Fourteen days later, these mice 
received a booster injection with the vaccine. Tumor growth was monitored every 2-3 days 
and followed for approximately 80 days.
In vivo cytotoxicity analysis. Mice were vaccinated as described above. After 9 days 
peptide-loaded Thy 1.1+ (CD90.1) target cells differentially labeled with CFSE were injected 
intravenously (i.v.) into Thy 1.2+ (CD90.2) mice. At day 10 mice were sacrificed to obtain 
both draining lymph node cells and spleen cells. For target cells the spleen and lymph nodes 
were obtained from a naïve mouse (28). After a red blood cell lysis the cells were purified 
for T-cells by nylon wool column and resuspended at 10 x 106 cells per ml in medium. Then, 
the obtained number of cells were split into two equal amounts and incubated for 90 minutes 
at 37°C either with 0.5 µg/ml of the HPV16 E7
49-57
 peptide (RAHYNIVTF as specific target 
peptide) or OVA
257-264
 peptide (SIINFEKL as non-specific target or control peptide). After 4 
wash steps the specific target cells were labeled with a final concentration of 5 µM CFSE 
and the non-specific target cells with 0.5 µM CFSE for 10 minutes at 37°C. Both target cells 
were resuspended at 50x106 cells/ml, mixed at a 1:1 ratio, and injected i.v. at a volume of 
200 µl per mouse. By flow cytometry the amount of remaining/non-killed specific (CFSEhigh) 
and non-specific (CFSElow) target cells were established by gating on Thy1.1+ cells (clone 
H1551; BD Biosciences). The percentage of specific killing was calculated according to the 
following formula: (1-(% of specific peptide-loaded target cells / % of control peptide-loaded 
target cells)) x 100%.
Analysis of HPV16-E7-specific T-cells. The spleen cells were either analyzed directly by 
tetramer staining as described below or after expansion of the T-cells by culturing spleen 
cells (4x106 cells/well of a 24-wells plate) in complete medium in the presence of 5x105 
HPV16 E7
49-57
-expressing cells (tumor cell line 13.2). Cultures were maintained at 37°C in 
humidified air containing 5% CO
2
. No exogenous IL-2 was added thereby enabling the in 
vivo generated memory T-cells to undergo a secondary expansion in vitro, which is a well 
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known hallmark of a proper immune response (29).  On day 6, dead cells were removed from 
the culture by centrifugation over a Ficoll density gradient and remaining viable cells were 
seeded in 24-wells plates at 1.5x106 cells/well. On day 7, tetramer staining or intracellular 
cytokine staining was performed.
PE-labeled H-2Db epitope E7
49-57
 (RAHYNIVTF)-containing tetramers were constructed 
and used for the analysis of peptide-specific CTL-immunity as described earlier (19). 
FITC-labeled anti-CD8b.2 (Ly-3.2) antibody (clone 53-5.8; BD Pharmingen), APC-labeled 
anti-CD4 (clone RM4-5; BD Pharmingen) and PE-labeled anti-IFNγ (clone XMG1.2; BD 
Pharmingen) were used for the analysis of antigen-specific IFNγ production of HPV16 
E7-specific CD8+ and CD4+ T-cells as described previously (19, 30).
Adoptive transfer of T-cell receptor transgenic CD8+ T-cells. To determine the fate of 
T-cells primed by antigen-presenting DC, which have been stimulated by the various 
adjuvants, mice were vaccinated s.c. with 150 µg long OVA peptide with or without the 
DC stimulating agent in a total volume of 200 µl. After 4 days, T-cell receptor transgenic, 
SIINFEKL-specific CD8+ T-cells (OT-1 cells) were isolated from spleen and lymph nodes 
of naïve OT-1 mice and after lysis of red blood cells, labeled with 5 µM CFSE for 10' at 37 
degrees Celsius, and injected i.v. at a dose of  1-2 x 106. After 5 days mice were sacrificed and 
the CFSE dilution of the labeled OT-1 cells was analyzed by flow cytometry. Gates were set 
based on CD45.1 (clone  A20; BD Pharmingen) and CD8α (clone  53-6.7; BD Pharmingen) 
expression.
RESULTS
In vitro activation of antigen presenting cells by adjuvants.
The induction of potent tumor-specific T-cell immunity by anti-tumor vaccination critically 
depends on the proper conditioning and activation of DC that take up and process the 
delivered antigens. Fully activated DC that display a Th1 polarizing profile exert optimal 
CTL-inducing activity (31). Therefore, the efficacy to activate and polarize DC of the 
TLR-agonists PAM
3
CSK
4 
(TLR 2), Poly I:C
12
U (TLR 3), MPL (TLR 4), Flagellin (TLR 5), 
R848 (TLR 7) and CpG (TLR 9), as well as that of the agonistic CD40 antibody FGK-45, was 
systematically compared in vitro. As a source of DC bone-marrow derived DC (BM-DC) were 
used as they are considered to be a proper source for physiological relevant DC (32) and they 
behave functionally very similar to DC in vivo (33). The minimum required concentration 
to activate ≥ 50% of BM-DC, as indicated by the increased expression of the cell surface 
markers CD40 and CD86 (23) differed per adjuvant (Table 1). On a molar basis Flagellin 
77
(<1 picomolar) was the most potent activator of BM-DC, followed by PAM
3
CSK
4
, MPL, 
CpG and FGK-45 of which concentrations in the 20-80 nanomolar range were sufficient to 
mature DC. Poly I:C
12
U and R848 were less effective in that 2-3 micromolar of these TLR 
agonists was needed to mature DC. 
Supernatants from DC-cultures incubated with the minimal required concentration of each 
agonist to activate ≥ 50% of DC were collected and the amount of cytokine produced 
was measured in order to analyze the polarization of matured DC. BM-DC produced the 
pro-inflammatory cytokines IL-12p40, IL-6 and TNFα when incubated with the compounds 
PAM
3
CSK
4
, MPL, R848 and CpG. Poly I:C
12
U and the agonistic CD40 antibody FGK-45 
displayed only a moderate capacity to trigger the production of such cytokines. In contrast, 
BM-DC incubated with Flagellin were not able to develop a T-helper type 1 (Th1) polarizing 
profile because they did not produce any of the pro-inflammatory cytokines. However, 
flagellin-triggered DC produced the regulatory cytokine IL-10 instead (Table 1), which is 
 Table 1: In vitro activation of bone marrow derived dendritic cells and their cytokine proﬁle
BM-DC were cultured in the presence of a range of 2-5 fold diluted concentrations (0.5 ng/ml – 50 μg/ml, except 
for ﬂagellin which was tested in a range of 1 pg/ml – 50 μg/ml) of the indicated DC agonists for 48 hours, after 
which the cells were harvested and analyzed for cell surface expression of CD40 and CD86 by ﬂow cytometry. 
On the basis of these analyses the minimal required concentration of each agonist (indicated in µg/ml and Molar) 
that resulted in  a strong increase in the expression of these markers in at least 50% of the DC was determined 
for each compound. Supernatants of the DC’s incubated with the minimal required concentration of each agonist 
to activate ≥50% DC were analyzed for the presence of the cytokines (pg/ml) listed. The <20 pg/ml indicates that 
the values were lower than the detection limit of the assays used.
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Receptor Compound TLR ≥50%maturation Cytokine profile
µg/ml M
IL-12
p40
IL-6 TNFα IL-10
- None - - - 32 <20 30 <20
TLR2 PAM3CSK4 2 0.05 3.10
-8 774 2790 >5000 <20
TLR3 poly I:C12U 3 10 1.10
-6 176 46 <20 <20
TLR4 MPL 4 0.1 6.10-8 252 >5000 717 <20
TLR5 Flagellin 5 0.0001 2.10-12 30 <20 <20 61
TLR7 R848 7 1 3.10-6 840 1340 880 <20
TLR9 CpG1628 9 0.5 8.10-8 850 >5000 1456 <20
CD40 FGK-45 - 2.5 2.10-8 392 79 <20 <20
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well known to be non-supportive for induction of cytotoxic T-cell (CTL) responses. 
In conclusion, all the tested adjuvants were able to activate C57BL/6 mouse-derived 
BM-DC in accordance with the presence of TLR on these cells (9, 10, 12).  Striking differences 
were found with respect to the amount of each compound required to mature DC and activate 
the production of pro-inflammatory cytokines. PAM
3
CSK
4
, MPL, CpG and FGK-45, are 
expected to function as potent adjuvants in vaccines that aim at the induction of effective Th1 
and CTL responses, as nanomolar concentrations of these compounds are able to stimulate 
DC to produce pro-inflammatory cytokines.
The efﬁcacy of DC activator agents to induce HPV-speciﬁc T-cell responses in vivo. 
The marked differences between the concentrations of DC-activating agents that were needed 
to mature DC in vitro prompted us to evaluate these compounds, and in particular those 
agents that promoted the development of DC secreting pro-inflammatory cytokines, for their 
efficacy to stimulate the induction of HPV16-specific T-cell responses in vivo. The HPV16 
E7
43-77
 peptide that contains both a CTL epitope and a Th epitope (7) was used as vaccine. 
Mice received a single dose of this peptide-antigen in combination with one of the indicated 
DC agonists (see M&M). Splenocytes were isolated 10 days after vaccination, stimulated 
in vitro for 7 days with 13.2 tumor cells, and the secondary expansion capacity of memory 
T-cells, as a hallmark for good immunity (29) was measured by flow cytometric analysis of 
the number of CD8+ T-cells stained with H-2Db/E7
49-57
–specific tetramer (Fig. 1a).  
Very few tetramer positive (TM+) CD8+ T-cells were detectable when mice were injected 
with HPV16 E7
43-77
 in the absence of any stimulatory agent (PBS). A minor increase in the 
number of TM+ CD8+ T-cells was found when mice were vaccinated with peptide emulsified 
in IFA or its clinical grade counterpart Montanide ISA 51. In concordance with the limited 
capacity of poly I:C
12
U and R848 to trigger DC activation in vitro, no increase in the number 
of HPV16-specific CD8+ T-cells was found when these agonists were used in the vaccine 
(Fig. 1a). Additional experiments in which these adjuvants were administered either in an 
IFA depot or every 2 days, did not dramatically improve the outcome of vaccination (less 
than 3% TM+ CD8+ T-cells). This suggests that predominantly their insufficient capacity to 
properly mature DC is responsible for their failure to induce strong HPV16-specific CD8+ 
T-cell immunity.
The most potent adjuvants were MPL, CpG and agonistic CD40 antibody FGK-45 (Fig. 1a). In 
all three cases approximately 20% of the CD8+ T-cells stained with the H-2Db-E7
49-57
 tetramer, 
which is significantly higher than responses induced by peptide in PBS (mean=0.93%), IFA 
(mean=5.6%) or Montanide ISA 51 (mean=1.5%). Unexpectedly, PAM
3
CSK
4
 was not able 
to support the induction of a strong CD8+ T-cell response, despite its capacity to activate a 
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pro-inflammatory DC response in vitro. 
The differences between the potency of the adjuvants to stimulate HPV16-specific CD8+ 
T-cells became even more pronounced when the functionality of these CD8+ T-cells was 
analyzed by intracellular staining of antigen-specific IFNγ production (Fig. 1b). We focused 
on the three adjuvants (MPL, CpG and agonistic CD40 antibody FGK-45) that stimulated 
the largest expansion of CD8+ H-2Db-E7
49-57 
tetramer positive T-cells. The percentage of 
HPV16-specific IFNγ-producing CD8+ T-cells in the splenocyte cultures of CpG treated 
Figure 1. Efﬁcacy of DC agonists to induce HPV16-speciﬁc T-cell immunity. Groups of 6-16 C57BL/6 mice 
were vaccinated s.c. in the right ﬂank with a 35-mer HPV peptide, comprising an overlapping T-helper epitope 
and a CTL epitope, in combination with the indicated DC agonists. The used dose of the adjuvants were 50 µg 
PAM3CSK4, 20 µg Poly I:C12U (Ampligen), 10 µg MPL, 50 µg R848, 50 µg CpG or 100 µg FGK-45 per mouse 
(See M&M). After ten days the mice were sacriﬁced and the spleens harvested. (A) The number of HPV16 
E7-speciﬁc CD8+ T-cells by H-2Db-E749-57 tetramer analysis was determined after a 7-day incubation period of 
the splenocytes with E749-57-expressing cells (tumor cell line 13.2).  Mice vaccinated with the TLR agonists MPL 
and CpG as well as the agonistic CD40-speciﬁc antibody FGK-45 display a signiﬁcantly increased number of 
HPV16-speciﬁc CD8+ T-cells compared to mice vaccinated with peptide in IFA, Montanide or PBS (*, p<0.01). 
The functionality of the (B) HPV16-speciﬁc CD8+ T-cells and (C) HPV16-speciﬁc CD4+ T-cells was determined 
by intracellular cytokine staining for IFNγ. Signiﬁcant higher T-cell responses compared to the T-cell immunity of 
naïve mice are indicated with an asterisk (p<0.05). (D) Linear regression analysis showed a strong correlation 
between the percentage of HPV16-speciﬁc IFNγ-producing CD8+ T-cells and HPV16-speciﬁc IFNγ-producing 
CD4+ T-cells (r2=0.73; p<0.0001).
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mice (mean =19.5%) was similar to that found by the
 
tetramer analysis. Importantly, even 
though the induction of TM+ CD8+ T-cells was comparable to CpG treatment, the percentage 
of HPV16-specific IFNγ-producing CD8+ T-cells in the groups of mice vaccinated with MPL 
(mean=7.1%) or the agonistic CD40 antibody FGK-45 (mean=3.0%) was significantly lower 
(p<0.01). HPV16 E7-specific IFNγ-producing CD4+ T-cells were only detected in mice 
vaccinated with peptide in combination with CpG or MPL (Fig. 1c). 
Overall, the comparative analysis of DC agonists revealed a good correlation between the 
numbers of IFNγ-producing CD8+ and CD4+ T-cells induced (Fig. 1d), which is in line with 
the prevailing views on the importance of CD4+ Th1 immunity for efficient activation of 
CD8+ T-cell responses (reviewed in Ref. 4). The agonistic CD40 antibody FGK-45, although 
also very potent in the induction of high numbers of antigen-specific CD8+ T-cells, failed 
to trigger strong IFNγ production by E7-specific CD8+ T-cells (Fig. 1c). This failure is 
paralleled by the absence of an E7-specific CD4+ Th1 response (Fig. 1c), the induction of 
which may have been prohibited as a result of interference by the agonistic CD40 antibody 
with the CD40L signaling pathway.
In conclusion, the TLR 9 ligand CpG clearly acts as the most potent adjuvant for the peptide 
vaccine tested, in that it induces the strongest E7-specific Th1 and CTL responses. The peptide 
vaccine supplemented with TLR 4 ligand MPL similarly triggers such T-cell responses, albeit 
of a lower magnitude. This correlates with the in vitro capacity of these adjuvants to induce 
pro-inflammatory cytokine production and DC maturation at low doses. However, this 
latter capacity per se is not sufficient for strong in vivo adjuvanticity because PAM
3
CSK
4
, 
which is also very potent in the activation of pro-inflammatory DC, did not trigger a strong 
HPV16-specific T-cell response in vivo. 
Potent DC agonists have a sustained capacity to induce expansion of antigen-speciﬁc 
T-cells.
In order to study the apparent discrepancy between the capacity of some of the agonists to 
properly activate DC while failing to induce a strong HPV16-specific CD8+ T-cell response, 
we studied the proliferation and expansion of T-cells that are activated in vivo by peptide and 
the different adjuvants. For this we made use of a T-cell receptor transgenic OT-1 system 
(SIINFEKL-specific CD8+ T-cells). Since the OT-1 cells will recognize this injected cognate 
SIINFEKL peptide with the same T-cell receptor affinity and will respond all exactly the same 
upon triggering, differences in the OT-1 response will reflect the efficacy of the different DC 
activating agents co-injected with the peptide vaccine. By exploiting the CD45.1/CD45.2 
polymorphism, these CD45.1+ CD8+ T-cells (OT-1 cells) can be easily tracked in vivo 
when adoptively transferred into congenic CD45.2+ C57BL/6 mice. CFSE-labeled naïve 
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OT-1 cells were adoptively transferred into mice vaccinated with a 32-mer OVA peptide 
comprising the CTL epitope SIINFEKL. Subsequently, the proliferative response of OT-1 
cells in the vaccine-draining lymph node (DLN) and in the non-draining (mesenteric) lymph 
node (MLN) was analyzed after 5 days by flow cytometry (Fig. 2). 
The vaccines containing MPL, CpG or FGK-45 were able to trigger a strong and sustained 
proliferative response of OT-1 cells, as is indicated by the increase in height of the peaks of 
the divided T-cells (compare to peptide only). In contrast, OT-1 cells primed by either peptide 
alone or with peptide in combination with PAM
3
CSK
4,
 poly I:C
12
U or R848 did divide in the 
DLN, however, we did not observe accumulation of T-cells in higher dividing cell populations 
(i.e. the typical cell expansion peaks). Actually, after each division the height of the peak 
decreased, pointing at either migration of the divided cells to other parts of the lymphoid 
system or increased cell death. Analysis of the non-draining lymph node (i.e. MLN) revealed 
that the OT-1 cells primed by peptide and MPL or CpG sequester and migrate from the DLN 
to other lymphoid organs. In contrast, this was not observed when PAM
3
CSK
4,
 poly I:C
12
U 
or R848 were used (Fig. 2), suggesting that under these circumstances OT-1 cells divided but 
did not migrate or survive after antigenic triggering. A failure of PAM
3
CSK
4,
 poly I:C
12
U and 
R848 to support the sustained expansion of antigen-specific T-cells may explain why it failed 
to induce vigorous HPV16-specific T-cell responses in vivo (Fig. 1a). Moreover, the results 
using the 32-mer OVA peptide (without a T-helper epitope present) reinforces the observations 
made with the 35-mer HPV16 E7 peptide (containing a CTL and T-helper epitope), in that the 
observation of abortively expanded OT-1 cells (Fig. 2) was correlated with the disability to 
induce a strong CD8+ T-cell response as measured by tetramers (Fig. 1a) in mice treated with 
the long HPV peptide together with PAM
3
CSK
4,
 poly I:C
12
U or R848.  
Figure 2. In vivo capacity of adjuvants to induce and sustain the expansion of speciﬁc T-cells. C57BL/6 
mice were vaccinated s.c. in the right ﬂank with long OVA peptide with or without the indicated adjuvants. 
Subsequently, these mice received 1-2x106 CFSE-labelled CD45.1+ OT-1 T-cells i.v. Then, ﬁve days later the 
draining lymph node (DLN: inguinal LN) and the non-draining lymph node (MLN: mesenteric LN) were harvested 
and the obtained cells were analysed by ﬂow cytometry thereby acquiring 200,000 life cells. Histograms were 
plotted by gating on CD45.1+ and CD8a+ cells. Numbers in the graph indicate the percentage of cells that 
have divided at least once, as gated in M2. Data are representative for two mice per group in two different 
experiments.
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MPL and CpG, but not agonistic CD40 antibody FGK-45 mediated immune activation, 
confer in vivo killing capacity to vaccine-induced CD8+ T-cells.
The three most potent adjuvants (CpG, MPL and agonistic antibody FGK) were tested for 
their capacity to enhance the in vivo cytolytic activity of vaccine-induced HPV16 E7-specific 
CD8+ T-cells, as this is the key effector mechanism for destroying virus infected cells as 
well as for tumor eradication in many solid tumor settings. HPV16 E7
49-57
 or control peptide 
loaded target cells, labeled with CFSE at different fluorescent intensities to allow differential 
analysis, were simultaneously injected in a one to one ratio into immunized mice at day 9. 
After 24 hours, the recovery of these labeled target cells in the spleen was analyzed by flow 
cytometry and the percentage of in vivo killed target cells was determined (28). Whereas the 
spleens of naïve mice contained equal numbers of both target cell types, only the CFSEhigh E7 
peptide loaded cells were clearly killed in spleens of mice immunized with peptide vaccine 
containing CpG or MPL (Fig. 3). The highest percentages of HPV16 E7-specific cytotoxicity 
were found in mice vaccinated with peptide and CpG followed by mice vaccinated with 
peptide and MPL. The efficacy of vaccination with peptide and agonistic CD40 antibody 
FGK-45 was disappointing because there was no significant in vivo killing of specific target 
Figure 3. In vivo cytolytic function of vaccine-induced CD8+ T-cells. C57BL/6 mice were vaccinated with 
E7 peptide supplemented with MPL, CpG or agonistic CD40-speciﬁc antibody FGK-45. After 9 days, the mice 
received i.v. 2x106 CFSEhigh splenocytes pulsed with the target peptide (E749-57; RAHYNIVTF) along with 2x10
6 
CFSElow splenocytes pulsed with a control peptide (OVA; SIINFEKL). Spleens of these mice were harvested 24 
hrs. later and the relative numbers of CFSEhigh and CFSElow target cells were determined by ﬂow cytometry. Two 
independent experiments with 5 mice per group were performed. (A) Histograms of representative examples. (B) 
Percentage of speciﬁc in vivo killing of E7-labeled target cells. 
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cells observed in mice vaccinated with peptide and FGK-45. Overall, the magnitude of the 
E7-specific in vivo cytolytic response corresponded with that of the number of IFNγ-positive 
CD8+ T-cells detected by flow cytometry (Fig. 1b).
The CD8+ T-cell effector function in an in vivo cytolytic assay does not depend on T-cell 
homing, because the target cells were injected intravenously. Therefore, the effector function 
of the vaccine-induced T-cell response was also tested against a subcutaneous tumor. 
C57BL/6 mice bearing palpable tumors of syngenic HPV16E7-expressing TC-1 tumor cells 
were vaccinated twice, with a 14-day interval and in the flank contra-lateral to the tumor 
site, with the aforementioned formulations. The tumors in non-vaccinated mice grew out 
rapidly, whereas the outgrowth of tumors in mice treated with peptide vaccine containing 
MPL or FGK was slightly delayed (Fig. 4). Despite the fact that MPL conferred in vivo 
killing of peptide-pulsed target cells in half of the vaccinated mice (Fig. 3), it did not work as 
well in the more demanding setting of an experimental tumor model since tumor eradication 
was only occasionally (2/19 mice) observed. Importantly, treatment with the peptide vaccine 
supplemented with CpG resulted in a significant therapeutic efficacy, in that half of the 
mice (11/23) showed complete remission, whereas the other mice showed delayed tumor 
growth (Fig. 4). Thus, strong cytolytic activity was induced by the combination of the long 
HPV peptide and CpG or MPL, but not by agonistic CD40 antibody FGK-45, and this is 
in line with the fact that these two compounds were the most potent inducers of both a 
HPV16-specific CD8+ and CD4+ type 1 T-cell response (Fig. 1-3). 
Figure 4. Therapeutic efﬁcacy of vaccine-induced T-cell immunity in the TC-1 tumor model. C57BL/6 
mice were given 25,000 TC-1 tumor cells s.c. in the right ﬂank. At day ten, when tumors were palpable, mice 
were either left untreated (naïve) or received the vaccine in combination with one of the indicated DC activating 
adjuvants, s.c. in the left ﬂank. Mice received a second vaccine dose in the left ﬂank 14 days later. Tumor size 
was determined 2-3 times per week, and mice with tumors exceeding 1000mm3 were sacriﬁced. The percentage 
of mice surviving tumor challenge is shown for each of the groups. The graph consists of the combined data (n ≥ 
10 per experiment) of two different tumor experiments. Treatment with peptide and CpG resulted in a signiﬁcant 
therapeutic efﬁcacy when compared to no treatment (p<0,01), FGK (p<0,01) and MPL (p=0.02) as reﬂected by a 
complete remission in 11 out of 23 treated mice, and a clear delay of tumor growth in the other mice.
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Distinct effects on CD8+ T-cell responses of local versus systemic immunization with 
combinations of strong adjuvants.
The finding that vaccination with the best formulation, peptide and CpG, resulted in tumor 
eradication in 50% of the mice argues that further optimization of this vaccine formulation 
is desirable. We explored combinations of the three most potent agonists because these 
adjuvants trigger different immunostimulatory molecules present on DC and may act 
synergistically. Strikingly, our data show that the numbers of HPV16 E7 peptide-specific 
CD8+ T-cells induced by vaccines containing a given combination of DC agonists were at 
best comparable, but in general lower, than those induced by vaccines containing only one 
of these DC agonists (Fig. 5: e.g. compare MPL, FGK45 and MPL + FGK45). The strongest 
significant decrease in immunostimulatory capacity of the vaccine was observed when CpG 
was combined with agonistic CD40 antibody FGK-45 (Fig. 5). 
These experiments show that peptide vaccines containing both a TLR ligand and agonistic 
CD40 antibody FGK-45 were suboptimal with respect to the induction of strong, systemic 
CTL immunity. The difference between this outcome and that of previously reported analyses 
by Ahonen et al., (17) may be related to differences in the experimental set up. Our experiments 
involved local co-injection of peptide and DC agonists, and thereby targeting of antigen and 
Figure 5. Combinations of strong adjuvants result in decreased CD8+ T-cell immunity. C57BL/6 mice 
were vaccinated s.c. with the HPV16 E7 peptide vaccine and indicated (combinations of) DC agonists. After 
10 days, the spleens were harvested and the percentage of H-2Db-RAHYNIVTF tetramer+ CD8+ T-cells was 
determined by ﬂow cytometry, directly ex-vivo. The results of two independent experiments with 5 mice per group 
are depicted. (*) A signiﬁcant decrease in the number of tetramer+ CD8+ T-cells was observed when CpG was 
combined with MPL (CpG vs. combination, p=0.014) or FGK-45 (CpG vs. combination, p<0.01) and when MPL 
was combined with FGK-45 (MPL vs. combination, p=0.04).
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DC agonist to the DC in the DLN. In the experiments by Ahonen and co-workers, peptide 
antigen and DC agonists were administered through systemic routes. As such, DC in all 
secondary lymphoid organs will become activated and present the cognate peptide-epitope to 
antigen-specific T-cells and this may explain why they observe such a strong T-cell response 
in the spleen. In view of these essential differences, we immunized mice with our HPV16 
E7 peptide and (combinations of) DC agonists through the systemic route, and analyzed 
the E7-specific CTL numbers induced in the spleen. When using this method of vaccine 
delivery, we also observed strong synergy between CpG and the agonistic CD40 antibody 
FGK-45 (Fig. 6), exceeding that of what can be found after s.c. delivery by injection with 
either single compound (see Fig. 5). Our data clearly illustrate that the impact of DC agonists 
on vaccination efficiency depends on the manner in which the vaccine is administered. It is 
important to realize, that systemic administration of agonist CD40 antibodies, although acting 
synergistically with CpG, also results in splenomegalomy as a consequence of polyclonal 
B-cell activation and expansion. As this is a side effect one would try to avoid in human 
beings, it is important to take into account that local administration of agonistic CD40 
antibodies can negatively affect the outcome of vaccination.
Dendritic cell activating agonists
Figure 6. Increased numbers of antigen-speciﬁc T-cells in the spleen after systemic vaccination with 
2 different DC activating adjuvants. C57BL/6 mice were vaccinated either with FGK-45 i.p. followed by i.v. 
administration of the peptide with or without the adjuvant CpG after 4 hours. Six days later the spleens were 
harvested and subjected to H-2Db-RAHYNIVTF tetramer analysis, directly ex-vivo. The percentages of tetramer-
positive CD8+ T-cells measured for 10 mice per vaccination regime (in 2 independent experiments) are plotted. 
The combination of CpG and antagonistic CD40 antibody FGK-45 when administered systemically with the 
peptide vaccine resulted in a signiﬁcant increase (4-fold; p≤0.0005) in circulating TM+ CD8+ T-cells compared to 
the response of  either adjuvant alone.
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DISCUSSION
Full mobilization of CD8+ lytic effector cells crucially depends on proper activation of DC 
either by innate immunity triggers such as microbial ligands of TLR or by adaptive immunity 
triggers such as CD40 ligand (CD40L) on activated CD4+ Th cells. In infections, DC will 
be activated through both pathways whereas in tumor immunity DC activation relies on the 
interaction with CD4+ T-cells (reviewed in Ref. 4). We have tested 6 different commonly 
used ligands that are known to trigger TLR on antigen presenting cells as well as an agonistic 
CD40-specific antibody for their capacity to enhance the T-cell responses induced by 
subcutaneous vaccination. Our experiments showed that, although all these agonists were 
able to activate DC in vitro, several agonists failed to induce an effective T-cell response in 
vivo. This failure, such as it was observed for Poly I:C
12
U (Fig. 1), is presumably not due 
to differences in antigen uptake by activated DC since West et al., (34) described enhanced 
antigen uptake in several DC types activated by PAM
3
CSK
4
, Poly I:C
12
U, LPS and CpG. In 
addition, Datta et al., (32) showed that the ligands for TLR 3 and TLR 9 were able to boost 
cross presentation, while this was not the case for TLR 2, TLR 4 and TLR 5 ligands. Since 
Poly I:C
12
U is a rather weak stimulant in our model and MPL a strong stimulatory adjuvant 
it seems that other factors are responsible for the in vivo outcome. Moreover, the differential 
responsiveness of BM-DC to TLR ligands does not correlated with the TLR mRNA (measured 
by RT-PCR) expression by murine DC (8). The limiting factors of DC-activating agonists to 
elicit an effective T-cell response in vivo included high concentrations (e.g. Poly I:C
12
U and 
R848) required to mature  DC, disappointing T-cell expansions, poor systemic migration 
of activated T-cells, a failure to trigger an antigen-specific CD4+ Th1 cell response as well 
as failure to endow the expanded CD8+ T-cell population with full effector function. Of all 
the agonists tested, the use of CpG in the subcutaneously administered long peptide vaccine 
consistently resulted in a high number of antigen-specific fully activated CD8+ T-cells that 
are easily detected by tetramers, directly ex-vivo within 10 days after priming. This rapid 
induction of high numbers of CD8+ effector T-cells may be advantageous for situations 
where a quick and strong T-cell response is mandatory such as lethal viral infections but also 
for cytopathic virus infections with a high economical impact, for instance infections with 
new variants of influenza and the immunotherapy of cancer. 
CpG, MPL and the agonistic CD40 antibody FGK-45 triggered the production of 
pro-inflammatory cytokines by DC in vitro (Table 1) and supported a vigorous clonal expansion 
of adoptively transferred transgenic CD8+ T-cells in vivo (Fig. 2). A major difference between 
FGK-45 on one hand and CpG or MPL on the other hand was the failure of FGK-45 to endow 
vaccine-induced HPV16-specific CD8+ T-cells with full effector function. Mice vaccinated 
with peptide plus FGK-45 did not display the capacity to directly kill target cells present in 
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the spleen. In addition, no HPV16-specific CD4+ T-cells were detected in these spleens and 
the numbers of HPV16-specific IFNγ-producing CD8+ T-cells were lower when compared 
to peptide vaccination with CpG or MPL. However, the T-cells that did migrate to the spleen 
displayed a well preserved capacity to undergo secondary expansion as indicated by the 
high numbers of HPV16-specific TM+ CD8+ T-cells detected after one round of in vitro 
stimulation of spleen cells (Fig. 1a). But this does not explain the lack of effector function 
of these in lymph node resident CD8+ T-cells. Recently, Bachmann et al. reported that the 
presence of Th cells, but not CD40/CD40L interaction, was key to an effective antiviral 
cytotoxic response by CD8+ T-cells upon viral challenge (35), implying that CD4+ Th cells 
play a role that is beyond CD40/CD40L mediated DC-activation and involves the regulation 
of CD8+ T-cell effector function. Indeed, in our model the presence of HPV16-specific 
INFγ-producing CD4+ T-cells, which were detected in MPL and CpG vaccinated mice but 
not in FGK-45 treated mice, is associated with high numbers of HPV16-specific cytotoxic 
CD8+ T-cells (Fig. 1 and 3).  Previously, antibodies reacting with CD40L on T-cells were 
shown to block the interaction between DC and CD4+ T-cells (36). The failure of the CD40 
binding antibody FGK-45 to facilitate the induction and/or expansion of HPV16-specific 
CD4+ T-cells probably is the result of a similar interference by the agonistic CD40 antibody 
with the CD40-CD40L signaling pathway. 
Analysis of vaccine-induced expansion of OT-1 CD8+ T-cells in vivo, showed that the 
subcutaneous administration of peptide mixed with a TLR 2, 3, or 7/8 agonist failed to induce 
a continued expansion and accumulation of OT-1 cells in the DLN (Fig. 2). In contrast, the 
TLR 4 and 9 ligands as well as the agonistic CD40 antibody FGK-45 were able to drive 
the expansion of T-cells and this was reflected in the numbers of HPV16-specific CD8+ 
T-cells detected in mice vaccinated with the HPV16 vaccine in combination with either of 
these adjuvants (Fig. 1 and 2). Similar observations have been made by Lefrancois et al. 
who showed that short-lived optimal stimulations resulted in rapid but abortive proliferative 
T-cell responses whereas a sustained response initiation drives optimal clonal T-cell expansion 
(37). In some cases the failure of a TLR agonist to sustain the activation of T-cells may 
be overcome. For instance, application of the TLR 7 agonist imiquimod twice a day for 2 
days at a significantly higher dose (50-fold per application) than in our experiments can 
also trigger functional CTL responses (38). Similarly, intravenous (systemic) administration 
of a 10 fold higher dose of the TLR 3 agonist Ampligen induces an enhanced expansion 
of antigen-specific CD8+ T-cells, albeit that the magnitude of the response as well as the 
functional capacity of these CD8+ T-cells was significantly lower when compared to a low 
dose of subcutaneously administered CpG (39). In addition, we observed that, compared to 
the subcutaneous injection of the agonistic CD40 antibody FGK-45 (Fig. 5), the systemic 
Dendritic cell activating agonists
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administration results in a stronger CD8+ T-cell response (Fig. 6).  Furthermore, the systemic 
injection of CpG in combination with FGK-45 resulted in a HPV-specific CD8+ T-cell response 
that significantly exceeded the response of either compound alone (p≤0.0005, Fig. 6). These 
data indicate that a change in the dose and/or route of administration of the DC-activating 
agent can improve the priming of antigen-specific T-cells and this may have far-reaching 
consequences. For instance, in human beings the intravenous injection of the TLR 3 ligand 
poly(I:C) is associated with intolerable side effects at the doses that are effective in mice (40, 
41). Ampligen, which has a reduced toxicity compared to its parent compound poly(I:C), 
also has a reduced bioactive half-life and this is reflected by a reduced stimulating capacity 
in vivo. Application of high and/or frequent doses of the TLR 7 and 8 agonists, imiquimod or 
resiquimod, gives rise to stronger T-cell responses but also to severe local reactions including 
ulceration and excoriation in patients (42, 43). Similarly, repeated intravenous injections of 
agonistic CD40 antibody or CpG can cause splenomegaly and lymphoid follicle destruction 
(reviewed in Refs. 44 and 45). These apparent side effects may restrict the use of such 
compounds for direct injection into patients, although they may still be very useful for the in 
vitro activation of DC for adoptive transfer protocols (46).
Last but not least we observed that there was no difference in T-cell reactivity when peptide 
plus CpG was delivered either subcutaneously or systemically (Fig. 5 and 6). When CpG 
was combined with FGK-45 the systemic administration of this vaccine resulted in strong 
synergy as indicated by a 4-fold increase in circulating TM+ CD8+ T-cells (Fig. 6), which 
is in accordance with Ahonen et al. (17). Interestingly, s.c. injection of both compounds 
did not result in increased numbers of HPV16 E7 specific T-cells in the spleen but rather 
lowered this number, suggesting that s.c. delivery of two strong agonists might result in a 
lymph node shut down as observed for other DC activating agents (47Y, thereby precluding 
the migration to secondary lymph nodes within the optimal test period for each of the  single 
compounds (10 days). Potentially, a synergistic effect of these s.c. injected compounds may 
become evident at later time points than currently studied.
In conclusion, we have performed a head-to-head comparison of several DC agonists within 
a single long peptide vaccination model, using a multiple parameter analysis. The parameters 
used unerringly indicate to what extend these adjuvants are capable to induce a strong T-
cell immunity within a chosen setting. A failure to pass one of these check-points does not 
automatically label an agonist as a useless adjuvant. As illustrated by the differences in T-cell 
reactivity observed when CpG and FGK-45 are both locally or systemically injected (Figures 
5 and 6), it merely indicates that an alternative strategy should be sought to overcome the 
problem. The multiple parameter system presented here can be used as a general road map to 
develop therapeutic vaccines.
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Distinct uptake mechanisms but similar 
intracellular processing of two different 
TLR-peptide conjugates in Dendritic Cells
Abstract. Covalent conjugation of Toll-like receptor ligands (TLR-L) to synthetic 
antigenic peptides strongly improves antigen presentation in vitro and T lymphocyte 
priming in vivo. These molecularly well defined TLR-L-peptide conjugates, constitute 
an attractive vaccination modality, sharing the peptide antigen and a defined adjuvant in 
one single molecule. We have analyzed the intracellular trafficking and processing of two 
TLR-L-conjugates in dendritic cells (DCs). Long synthetic peptides containing an Ovalbumin 
cytotoxic T-cell epitope were chemically conjugated to two different TLR-Ls the TLR2 ligand, 
Pam(3)CysSK(4) (Pam) or the TLR9 ligand CpG. Rapid and enhanced uptake of both types of 
TLR-L-conjugated peptide occurred in DCs. Moreover, TLR-L conjugation greatly enhanced 
antigen presentation, a process that was dependent on endosomal acidification, proteasomal 
cleavage, and TAP translocation. The uptake of the CpG approximately conjugate was 
independent of endosomally-expressed TLR9 as reported previously. Unexpectedly, we found 
that Pam approximately conjugated peptides were likewise internalized independently of the 
expression of cell surface-expressed TLR2. Further characterization of the uptake mechanisms 
revealed that TLR2-L employed a different uptake route than TLR9-L. Inhibition of clathrin- 
or caveolin-dependent endocytosis greatly reduced uptake and antigen presentation of the 
Pam-conjugate. In contrast, internalization and antigen presentation of CpG approximately 
conjugates was independent of clathrin-coated pits but partly dependent on caveolae 
formation. Importantly, in contrast to the TLR-independent uptake of the conjugates, TLR 
expression and downstream TLR signaling was required for dendritic cell maturation and 
for priming of naïve CD8(+) T-cells. Together, our data show that targeting to two distinct 
TLRs requires distinct uptake mechanism but follows similar trafficking and intracellular 
processing pathways leading to optimal antigen presentation and T-cell priming.
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INTRODUCTION
Toll-like receptors (TLR) are germ-line encoded receptors expressed mainly on cells of 
the innate immune system, such as granulocytes, macrophages and dendritic cells (DCs). 
These receptors are important in sensing infectious agents through recognition of pathogen-
associated molecules, and act as a communicator between innate and adaptive immune 
responses. The receptors are expressed either on the cell surface or in the endosomal 
organelles. This compartmentalization of the TLR correlates with the type of ligands with 
which they interact. The TLRs expressed on the cell surface bind to extracellular components 
of the microorganisms (such as bacterial LPS to TLR4, bacterial lipopeptide to TLR2). 
In contrast, the TLRs found in the endosomes bind to ligands derived from intracellular 
molecules of the pathogen, such as unmethylated CpG DNA sequences to TLR9, and ssRNA 
to TLR7 (1). Studies have shown that ligands interacting with the latter type of TLRs are 
internalized independently of the TLRs (2). Upon engagement of the ligand to its receptor, 
a cascade of intracellular signaling events is initiated, which involves docking of different 
adaptor molecules such as MyD88, and TRAM to the TLR receptors and recruitment of 
proteins belonging to the IRAK-family, that ultimately culminate in the activation of the 
NF-kB transcription factor and gene transcription leading to production of pro-inflammatory 
cytokines (3).
DCs are both initiators and regulators of T cell responses (4). Dendritic cells constantly 
screen the environment for potential foreign antigens by a variety of mechanisms such as 
phagocytosis, macropinocytosis, caveolin-mediated or clathrin-dependent endocytosis. The 
manner of uptake dependent on the size and nature of material to be internalized (5, 6). As 
specialized antigen presenting cells, DCs have the capacity to efficiently process exogenous 
proteins and present the peptides in major histocompatibility complex (MHC) class I 
molecules, a process known as cross-presentation. In this scenario, exogenously derived 
antigens are internalized and translocated from the endosomal route into the cytosol, where 
the proteasome complex processes the antigen. The generated peptides are transported from 
the cytosol into the endoplasmic reticulum via the peptide transporter TAP (7), after which 
the peptides undergo further trimming and are finally loaded onto MHC class I molecules, 
which translocate to the cell surface, where the peptide is presented to CD8+ T-cells. 
The ability of DCs to cross-present peptides on MHC class I to CD8+ T-cells together with 
the capacity of TLR ligands to deliver maturation signals, have inspired efforts to explore 
the use of DCs as a vaccine vehicle in the fight against infectious diseases and cancer  (8, 
9). Covalent linkage of immunogenic peptides to the TLR9 ligand, CpG DNA or TLR2 
ligands, like Pam
3
CysSS and Pam
3
CysSK
4
 induces a more prominent T-cell response than 
administration of free TLR2-L or TLR9-L mixed with protein (2, 10-16). 
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To explore the mode of action of TLR-L antigen conjugates, we have designed well-defined 
synthetic vaccines, composed of peptides containing the model antigen Ovalbumin CD8+ 
cytotoxic T-lymphocyte (CTL) epitope (SIINFEKL) chemically linked to either the TLR2- 
ligand, Pam
3
CysSK
4
, or the TLR9 ligand, CpG. These conjugates were used to study the 
uptake, intracellular routing and processing. We show that not only TLR9-L conjugates but 
also the TLR2-L conjugates are taken up independently of TLR expression, albeit through 
two distinct internalization mechanisms. Down-stream processing route for MHC class I 
antigen presentation, however, were similar and requires endosomal acidification, TAP 
translocation, and proteasomal processing. Importantly, whereas the uptake of both types 
of TLR-L conjugates was independent of TLR expression, priming of specific CD8+ T-cell 
response required TLR signaling in dendritic cells.
MATERIAL AND METHODS
Mouse strains and chemicals. C57BL/6 (B6; H-2b) were obtained from Charles River 
Laboratories. TLR2-deficient mice were purchased from Jackson Laboratories, whereas 
the TLR9-deficient mice were obtained from S. Akira Osaka University, Osaka, Japan. 
Bone marrow from TAP-deficient mice and TAP/β2m-deficient mice strains were kindly 
provided by Prof. H.G. Ljunggren, Karolinska Institutet, Sweden. LPS of Escherichia coli 
(serotype026:B6), Monodansylcadavererine (MDC) and filipin were purchased from Sigma-
Aldrich (St. Louis, MO). Epoxomicin and chlorophenol red-ß-D-galactopyranoside (CPRG) 
were from Calbiochem.
Cell lines. Freshly isolated DCs were cultured from mouse bone-marrow cells as described 
elsewhere (17). D1 cell line, a long term growth factor-dependent immature splenic DCs 
line derived from B6 (H-2b) mice, was cultured as described (18). B3Z is a T-cell hybridoma 
specific for the H-2Kb CTL epitope SIINFEKL, which expresses a beta-galactosidase 
construct under the regulation of the NF-AT element from the IL2 promoter (19). EG7 
(EL4-OVA) (20) was cultured in complete medium with 400 μg G418 (Gibco).
Generation of Pam
3
CysSK
4
- or CpG-conjugated peptides and labeling. 
Table I shows the conjugates and peptides used in this study.
Chemicals. HCTU was purchased from IRIS Biotech GmbH (Germany) and 
Pam
3
Cys-OH was from Bachem. PyBOP (Benzotriazole-1-yl-oxy-tris-pyrrolidino-
phosphonium hexafluorophosphate) was purchased from MultiSynTech GmbH. Reactive 
fluorescent dyes BODIPY-FL N-(2-aminoethyl) maleimide, Alexa Fluor 488 C
5
 maleimide 
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and Alexa Fluor 488 carboxylic acid succinimidyl ester were purchased from Invitrogen. 
Fmoc-amino acids were from SENN Chemicals or from MultiSynTech GmbH. Tentagel based 
resins were bought at Rapp Polymere GmbH (Germany). All chemicals and solvents used in 
the solid phase peptide synthesis were from Biosolve. Chemicals, resins and solvents used in 
the solid phase DNA synthesis, except of Beaucage reagent and Control Pore Glass (CPG) 
support used to introduce 3’-thiol modification were from Proligo and used as received. 
3’-thiol modifier C3 S-S CPG and Beaucage reagent were purchased at Glen Research. All 
chemicals were used as received.
General methods. Mass spectra were recorded on a PE/SCIEX API 165 (Perkin-Elmer) 
mass spectrometer. Analytical LC/MS was conducted on a JASCO system using an Alltima 
C
18
 analytical column (4.6 x 150 mm, 5µ particle size, flow: 1.0 ml/min) detecting  at 214 
and 254 nm. Solvent system: A: 100% water, B: 100% acetonitrile, C: 1% TFA. Gradients 
of B in A were applied over 15 minutes, keeping C isocratic at 10%. Purifications of the 
synthetic peptides were conducted on a BioCAD “Vision” automated HPLC system 
(PerSeptive Biosystems, inc.), supplied with a Alltima C
18
 column (10 x 250 mm, 5µ particle 
size, running at 4ml/min). Solvent system: A: 100% water, B: 100% acetonitrile, C: 1% 
TFA unless stated otherwise. A Varian DMS 200 UV VIS spectrophotometer was used to 
measure UV absorption MALDI-TOF spectra were recorded on a Voyager-DE PRO mass 
spectrometer (Perseptive Biosystems, inc.).
Peptide synthesis. Fmoc based solid-phase peptide synthesis was performed on a CS 
Bio 336 automated instrument (CS Bio, California, USA) starting from either preloaded 
Fmoc-Leu-PHB-Tentagel resin or from Tentagel –RAM resin. The synthesis was performed 
on a 50 or 250 µmol scale according to established methods (21). HCTU was used as coupling 
reagent. All peptides (see Table I) were cleaved from the resin using trifluoroacetic acid 
(TFA)/triisopropylsilane (TIS)/H
2
O (95/2.5/2.5) for 2h at room temperature (RT), precipitated 
from diethyl ether, redissolved in 20% aqueous 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) 
and purified by RP HPLC and characterized using LC-MS and MALDI MS (see General 
methods).
Oligonucleotide synthesis. DMT based solid-phase phosphorothioate oligonucleotide (ODN) 
synthesis was performed on an Expedite automated instrument (Perseptive Biosystems) starting 
from Control Pore Glass support with the 3’-thiol modifier. The syntheses were performed on 
a 10 µmol scale according to established methods (22). Elongation was performed using DMT 
protected DNA monomers 5’-DMT-A(TAC)-OH, 5’-DMT-C(TAC)-OH, 5’-DMT-G(TAC)-
99
OH and 5’-DMT-T-OH under the agency of dicyanoimidazole (DCI). After each coupling, 
remaining free 5’-hydroxyls were blocked using a capping solution (tbutylphenoxyacetic 
anhydride (Tac
2
O)/1-methylimidazole in THF/pyridine), followed by sulphurization of the 
phosphite linkage to the phosphorothioate linkage using the Beaucage reagent. Next the 
5’-DMT protecting group was removed by trichloroacetic acid (TCA) after which elongation 
was continued. After final DMT removal the DNA oligomer was cleaved from the resin by 
25% ammonium hydroxide solution to give a 3’-disulfide modified ODN (ODN-SS-propyl-
OH). ODNs were purified on a Q-Sepharose column pre-equilibrated with 50mM NaOAc 
applying a gradient of 2M NaCl in 50mM NaOAc. Fractions containing the pure product 
were combined and dialysed three times with millipore water using dialysis tubing with 1 kD 
cut-off (Spectrum). Quantification was performed by UV absorbance at 260 nm. Sequences 
of the ODN prepared in this study were CpG: 5’-TCCATGACGTTCCTGACGTT-3’; 
GpC: 5’-TCCATGAGCTTCCTGATG-3’.
Maleimidopropionoyl peptides. Maleimidopropionoyl-OVA
247-264
 (Mal-OVA
247-264
) and 
Maleimidopropionoyl-OVA
247-264A5K
 (Mal-OVA
247-264A5K
). Fmoc-deprotected peptide resin 
(200 mg, 30 μmol) was suspended in 2 ml NMP, 3-maleimidopropionic acid (5 eq., 250 
μmol, 42.2 mg), HCTU (5 eq, 250 μmol, 103.2 mg) and DiPEA (5 eq., 250 μmol, 42 μl) were 
added subsequently. The mixture was shaken for 2 hours after which the resin was filtered, 
washed with NMP, DCM and dried. TNBS test indicated complete coupling. The products 
were processed as described in Peptide synthesis section.
ODN-peptide conjugates (CpG-OVA
247-264
). 3’- disulfide modified CpG- SS-propyl-OH 
(266 nmol) was converted to 3’-SH modified CpG-SH overnight with dithiothreitol (DTT) 
containing buffer (35 mg DTT, 26 mg NaOAc. 3H
2
O, 1 mL water). DTT was removed from 
the mixture using a PD-10 desalting column (Amersham) that was pre-equilibrated with 25 
ml of a 50mM phosphate buffer (25mM Na
2
HPO
4, 
25mM NaH
2
PO
4
, 1mM EDTA in water, 
continuously degassed with helium. Filtrate (3.25 ml) was directly transferred to a tube 
containing 5 mg of maleimidopropionyl peptide Mal-OVA
247-264
. The resulting solution was 
sonicated and placed under blanket of argon. The tube was sealed and shaken for 2 days at 
RT. The mixture was purified over a Superdex 75 gel filtration column using isocratic elution 
with  0.15 M triethylammonium acetate. Fractions containing the product were collected and 
lyophilised. Excess triethylammonium acetate was removed by lyophilization  from water 
(3 times). Quantification was performed by UV-absorbance (260 nm). 
CpG-OVA
247-264A5K 
and GpC-OVA
247-264 
were prepared as described for CpG-OVA
247-264 
starting 
from the corresponding ODNs and maleimidopropionyl peptides.
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Lipopeptides Pam
3
CysSK
4
-OVA
247-264 
. Fmoc-deprotected peptide resin (300 mg, 45 μmol) 
was suspended in 1.4 ml, 1/1 NMP/DCM. Pam
3
Cys-OH, (91 mg, 2 eq., 100 μmol) and 
PyBOP (80 mg, 3 eq., 150 μmol) were added. DiPEA (30 μl, 175 μmol) was added in two 
portions of 15 μl with an interval of 15 minutes and the mixture was shaken for 4 hours.5 The 
resin was washed with NMP, DCM and dried. TNBS test indicated complete coupling. The 
product was cleaved from the resin as described in Peptide synthesis section, dissolved in 
tBuOH/ACN/H
2
O 1/1/1 and purified on a Alltima CN column (10 x 250 mm, 5µ particle size) 
with gradient of B in A; C kept isocratic at 10% (A; 1/1 MeOH/H
2
O, B; ACN, C; 1% TFA 
in MeOH/H
2
O 9/1). Pam
3
CysSK
4
-OVA
247-264A5K
 and Pam
3
CysSK
4
C-OVA
247-264 
were prepared 
and purified as described above for Pam
3
CysSK
4
-OVA
247-264
 starting from the corresponding 
peptide resins.
Fluorescently labeled peptides and conjugates [Alexa488]OVA
247-264
. Fmoc-deprotected 
peptide resin (100 mg, 15 μmol) was treated twice with 2 ml of a capping reagent (0.5M 
Ac
2
O, 0.125M DiPEA in NMP). TNBS test indicated complete acetylation. The cleaved and 
purified peptide (1 mg) was dissolved into 50μl buffer (300mM NaHCO
3
 in 30% acetonitrile/
water) and Alexa Fluor 488 carboxylic acid succinimidyl ester (0.3mg) was added. Another 
50 μl of buffer was added and the mixture was let to shake overnight. The product was 
purified by RP HPLC (see General methods). 
CpG-[Alexa488]OVA
247-264
 and GpC-[Alexa488]OVA
247-264
 - Conjugate CpG-OVA
247-264
 
(296 nmol) or GpC-[Alexa488]OVA
247-264
 (296 nmol) was dissolved in 50 μl buffer (300mM 
NaHCO
3
, 30% ACN in H
2
O) and Alexa Fluor 488 carboxylic acid succidinimidyl ester (1.0 
mg) was added. The bright green mixture was let to shake overnight. The mixture was diluted 
5 times with H
2
O before subjection to RP-HPLC purification. (Alltima C
18
, gradient of B in 
A; C kept isocratic at 10%; A:H
2
O, B: ACN, C: 100 mM aq. NH
4
OAc).
Pam
3
CysSK
4
-C[BDP-FL]OVA
247-264
 -Lipopeptide Pam
3
CysSK
4
C-OVA
247-264
 (0.46 μmol, 
1.69 mg) and BODIPY-FL N-(2-aminoethyl)maleimide were transferred to a vial containing 
0.5ml of 50mM phosphate buffer (25mM NaH
2
PO
4
/25 mM Na
2
HPO
4, 
1mM EDTA
 
in 2/1/1, 
H
2
O/MeOH/ACN). The mixture was sonicated and let to shake for 60 hours under argon. The 
mixture was diluted 5 times with 40/30/30 H
2
O/ACN/tBuOH, 1% TFA before subjection to 
RP-HPLC purification as described for Pam
3
CysSK
4
C-OVA
247-264
. 
SK
4
-C[BDP-FL]-OVA
247-264
 - Synthesized as described for Pam
3
CysSK
4
-C[BDP-FL]OVA
247-
264
 using 50 mM phosphate in 3/2 H
2
O/ACN as  a ligation buffer and SK
4
-C-OVA
247-264
 as the 
peptide substrate.
Pam
3
CysSK
4
-C[Alexa488]OVA
247-264
 was synthesized as described for Pam
3
CysSK
4
-C[BDP-
FL]OVA
247-264
 using Alexa Fluor 488 C
5
 maleimide as the reactive dye.
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IL-12p40 ELISA. DCs (4x104) were plated into 96-well round bottom plate, and incubated 
for 24-48h with the compounds indicated in the figure legends. Supernatants were harvested, 
and tested for IL-12 p40/p70 content using a standards sandwich ELISA, as previous 
described (23).
Confocal microscopy. DCs were plated out into glass-bottom petrish dishes (MatTek) two 
days before the experiment. Cells were incubated either with the fluorescence labeled TLR-L 
peptide conjugate or the fluorescence labeled peptide at 37oC for different time-periods, at the 
concentrations indicated in the figure legends. In some experiments, as indicated, cells were 
coincubated with 1 μM Lysotracker for 5 min to stain endosomal/lysosomal compartments. 
In experiments with inhibitors, cells were pre-incubated for 30min either with 50μM MDC, 
or  10μg/ml filipin, followed by extensively washing before incubation with the TLR-L 
conjugate either alone (pretreatment) or in the presence of inhibitors (coincubation). Cells 
were then washed and imaged using an inverted Leica SP2 confocal microscope. Dual color 
images were acquired by sequential scanning, with only one laser line per scan to avoid 
cross-excitation. The images were processed using the software program ImageJ. 
Flow cytometry. For analyzing the effect of the different compounds on dendritic cell 
phenotypic profile, DCs were incubated with the different compounds at a final concentration 
of 1μM for 48 h. Subsequently, cells were harvested and resuspended in FACS buffer (PBS 
/ 0.1% BSA) and incubated for 20 min with the following panel of monoclonal antibodies 
FITC-anti-CD86 (clone GL-1), PE-anti-I-Ab (clone M5/114 15.2), PE-anti-CD40 (clone 
3/23), APC-anti-Kb (24). Cells were washed twice and fixed with 0.5% PFA before being 
subjected to flow cytometry measurements.
MHC-class I-restricted antigen presentation assay. DCs were incubated for 2 h, (unless 
stated otherwise in the figure legends), with 1) the parent peptide (DEVSGLEQLESIINF
EKLAAAAAK, OVA
247-264A5K
, or DEVSGLEQLESIINFEKL, OVA
247-264
), 2) the peptide-
conjugate, or 3) the mixture of the parent peptide and the Pam
3
CySK
4 
or CpG, at the indicated 
concentrations. Cells were washed five times with medium before the T-cell hybridoma B3Z 
cells were added and incubated for 16h at 37oC.
Antigen presentation of the Ovalbumin cytotoxic T-cell epitope, SIINFEKL (OVA
257-264
) 
in H-2Kb was detected by activation of B3Z cells measured by a colorimetric assay using 
chlorophenol red- -D-galactopyranoside as substrate to detect lacZ activity in B3Z lysates, 
as described (23).
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In some experiments cells were preincubated for 30 min with titrated amounts of epoxomicin 
ranging from 0.01-10μM epoxomicin or with 3mM NH
4
Cl, or preincubated for 60min with 
titrated amounts of monodansylcadaverine (25-50μM), or with filipin (10-20μg/ml) before 
adding the peptide compound still in the presence of the inhibitors. Cell viability was 
confirmed by tryphan blue exclusion at the indicated concentration range of inhibitors.
Priming of endogenous naïve CD8+ T-cells. To determine the endogenous CTL response, 
five nmol of the different compounds was injected s.c. into naïve C57BL/6 mice. After 10 days 
spleen cells were stimulated in vitro by plating 10x106 splenocytes with 1x106 mytomycin 
C (Kyowa) treated (50ug/ml 1 hour at 37 degrees) and irradiated (4000 rad) EG7 cell line 
(EL4-OVA), in the absence of additional cytokines. After seven days viable splenocytes were 
isolated over a ficoll gradient and stained for H-2Kb Tetramer (TM)-OVA
257-264
 and CD8b2 
(clone 53-5.8), and propidium iodide to exclude dead cells as described previous (23).
Intracellular cytokine staining. An aliquot of spleen cells after re-stimulation and ficoll 
purification (see above) were subjected to stimulation in vitro with or without 1 μg/ml 
OVA
257-264
 peptide (H2-Kb restricted SIINFEKL) overnight in the presence of GolgiPlug 
(BD Pharmingen, San Diego, CA, USA). Cells were then washed twice with FACS buffer 
and stained with PE-conjugated monoclonal rat anti-mouse CD8b2 antibody. Cells were 
subjected to intracellular cytokine staining using the Cytofix/Cytoperm kit according to 
the manufacturer’s instructions (BD Pharmingen, San Diego, CA, USA). Intracellular IFN-
γ was stained with APC-conjugated rat anti-mouse IFN-γ. All antibodies were purchased 
from BD Pharmingen. Flow cytometry analysis was performed using FACSCalibur with 
CELLQuest software (BD Biosciences, Mountain View, CA, USA). Splenocytes without 
peptide stimulation were used as a negative control. 
In vivo uptake studies. To monitor the uptake of the TLR-L conjugated peptides and the 
free peptide in vivo, mice were injected s.c. either with 5nmol of Alexa 488 Fluor labeled 
CpG~conjugated peptide, 5nmol of BODIPY-FL Pam~conjugated peptide, CpG mixed with 
Alexa 488 Fluor labeled peptide or Pam mixed with BODIPY-FL labeled peptide. Three 
days later, mice were sacrificed and a single cell suspension of the draining lymph nodes was 
stained for CD11c (clone HL3) before being subjected to flow cytometry analysis.
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RESULTS
To study the uptake, trafficking and processing of two distinct TLR-ligands peptide 
conjugates in dendritic cells for MHC class I presentation to CD8+ cytotoxic T-lymphocytes, 
we selected the TLR9 ligand CpG, and the TLR2 ligand Pam
3
CysSK
4 
(Pam), based on the 
fact that these two ligands interact with two distinct receptors located either in the endosomal 
compartment (TLR9) or on the plasma membrane (TLR2). As a model antigen we made use 
of peptides containing the CTL epitope (SIINFEKL, designated OVA
257-264
) derived from 
the Ovalbumin protein. Two different peptide length variants were synthesized, an extended 
peptide that required proteasome-dependent processing on both the N- and C-terminus to 
release the CTL epitope (DEVSGLEQLESIINFEKLAAAAAK) designated OVA
247-264A5K
, 
and a shorter peptide, of which C-terminal processing by the proteasome is not required 
(DEVSGLEQLESIINFEKL), designated OVA
247-264
. For example, peptide OVA
247-264A5K
, 
conjugated to Pam
3
CysSK
4 
is designated as Pam~OVA
247-264A5K
. 
Crucially, all of our compounds (listed in Table I) are produced synthetically, therefore 
chemically well defined, of high purity and of constant quality, avoiding potential 
contamination with other TLR-ligands such as LPS, which commonly occur in purified TLR 
ligand preparations.
Table I. List of compounds generated
Robust induction of naive CD8 speciﬁc T-cells mediated by the conjugates.
To establish the quality of our generated TLR-L-peptide conjugates, we first investigated 
the induction of an endogenous T-cell response, following s.c. injection of either TLR-L-
conjugated peptide or free peptide into naïve C57BL/6 mice. After 10 days, the induction of 
OVA
247-264
-specific CD8+ T-cells was analyzed. As is shown in Fig. 1A, the magnitude of the 
OVA
257-264
-specific T-cell response induction by either CpG~OVA
247-264A5K
 or Pam~OVA
247-
264A5K
 was significantly higher than that in mice injected with non-conjugated OVA
247-264A5K
 
erohporoulFeditpePdnagilRLTnoitaiverbbA
OVA 257–264 SIINFEKL
OVA 247–264 DEVSGLEQLESIINFEKL
OVA 247–264A5K DEVSGLEQLESIINFEKLAAAAAK
CpG-OVA 247–264 CpG DEVSGLEQLESIINFEKL
CpG-OVA 247–264A5K CpG DEVSGLEQLESIINFEKLAAAAAK
GpC-OVA 247–264 GpC DEVSGLEQLESIINFEKL
Pam3CysSK 4-OVA 247–264 Pam3CysSK 4 DEVSGLEQLESIINFEKL
Pam3CysSK 4-OVA 247–264A5K Pam3CysSK 4 DEVSGLEQLESIINFEKLAAAAAK
Alexa488 OVA 247–264 Ac-DEVSGLEQLESIINFEKL Alexa488
SK 4-C BDP-FL -OVA 247–264 SKKKKCDEVGLEQLESIINFEKL Bodipy-FL
CpG- Alexa488 OVA 247–264 CpG DEVSGLEQLESIINFEKL Alexa488
GpC- Alexa488 OVA 247–264 GpC DEVSGLEQLESIINFEKL Alexa488
Pam3CysSK 4-C Alexa488 OVA 247–264 Pam3CysSK 4 CDEVSGLEQLESIINFEKL Alexa488
Pam3CysSK 4-C BDP-FL OVA 247–264 Pam3CysSK 4 CDEVSGLEQLESIINFEKL Bodipy-FL
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Figure 1. Robust induction of naïve CD8+ speciﬁc T-cells mediated by the TLR L-conjugates. A, Naïve 
C57/B6 mice were injected with either Pam mixed with OVA247-264A5K (Pam mixed w. peptide), Pam~OVA247-264A5K 
(Pam~conjugate), CpG mixed with OVA247-264A5K (CpG mixed w. peptide), CpG~OVA247-264A5K (CpG~conjugate), 
or GpC~OVA247-264 (GpC~conjugate). After stimulation in vitro, cells were analyzed for the presence of CD8b2 
cells capable of interacting with H-2Kb-OVA257-264 tetrameric complexes. The y-axis displays the percentages of 
tetrameric positive cells out of total CD8b2+ cells. The % of tetrameric CD8b2+ cells (<1%) of the naïve mice 
(PBS injection only) has been subtracted from all the values. Right hand panel shows a representative FACS plot, 
cells were gated on CD8+ and the percentage given in the top of right quadrant are the percentages of tetramer 
positive cells of total CD8+ T cells. Unpaired Student’s t-test, *: P=0.04; **: P=0.0006; ***: P=0.001; n.s. : not 
signiﬁcant. B, IFN-γ production in speciﬁc T-cells was measured as described in material and methods. Shown 
are results gated on CD8+ events. Pam mixed with OVA247-264A5K (Pam mixed w. peptide), Pam~OVA247-264A5K 
(Pam~conjugate), CpG mixed with OVA247-264A5K (CpG mixed w. peptide), CpG~OVA247-264A5K (CpG~conjugate), 
or GpC~OVA247-264 (GpC~conjugate). Unpaired Student’s t-test, *: P=0.05; **: P=0.001; ***: P=0.0007; n.s: 
not signiﬁcant. Experiments were conducted with ﬁve mice per group. C. BMDCs were incubated either with 
CpG~OVA247-264A5K (black bars) or GpC~OVA247-264 (white bars) for 48h. Supernatant was harvested and the 
concentration of IL-12p40 was determined as out-lined in material and methods. Results are means of triplicates 
± SEM. Data are representative of three independent experiments.
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peptide mixed together with either free CpG or free Pam. To address whether the induction 
of specific T-cells depended on activation of the DCs, we injected GpC~OVA
247-264
 conjugate, 
which is a non-stimulatory oligonucleotide as shown by its lack of capacity to induce IL-
12 production by DCs (Fig. 1C). Injection of GpC~peptide conjugate into naïve mice 
led to a significantly lower induction of specific CD8+ T-cells than of CpG~conjugated 
peptide, but was still as high as the response obtained after mixing of peptide with the CpG 
(Fig. 1A). Importantly, only when a stimulatory TLR-L-conjugate was given the majority of CD8+ 
T-cells were able to produce interferon-γ  (Fig. 1B), indicating that signaling via the TLR is 
essential for the generation of large numbers of functional T-cells in vivo.
These results suggest that the enhanced induction of specific T-cells is primarily the result of 
efficient delivery of the TLR-L-conjugated peptide into the antigen-presenting cell. 
TLR-conjugates activate dendritic cells.
Next we analyzed the ability of the different conjugates to induce maturation of DCs. As 
evident from Table II, increased surface marker expression of CD40, CD86, MHC I, and 
MHC II, was observed in dendritic cells after treatment with the different TLR-L-conjugates 
to a similar extent as the free TLR-Ls. To confirm the involvement of the TLRs in DCs 
activation, we isolated bone-marrow derived dendritic cells (BMDCs) from WT mice, 
TLR2-deficient mice and TLR9-deficient mice and stimulated these cells with the different 
conjugates, followed by phenotypic characterization by staining for different surface 
markers associated with DCs maturation (25). No up-regulation of the cell surface markers 
CD86 and MHC class II was detected when BMDCs from TLR2-deficient mice or TLR9-
Table II. FACS analysis of cell surface expression of markers after TLR-L-conjugate induced DCs 
maturation.
Treatment
Mean fluorescence
CD40 CD86 MHC I MHC II
Untreated 8 21 923 277
172DN228editpeP
215124363195GpC
CpG mixed with peptide 48 134 ND 903
CpG conjugate 71 132 3229 725
723DN8361maP
Pam mixed with peptide 18 40 ND 346
Pam conjugate 14 35 1348 329
675275373164SPL
Dendritic cells were incubated for 48 h in the presence of 1µM of either OVA247-264 (peptide), CpG, CpG mixed 
OVA247-264 (CpG mixed with peptide), CpG~OVA247-264 (CpG~conjugate), Pam, Pam mixed with OVA247-264 (Pam 
mixed with peptide), Pam~OVA247-264 (Pam~conjugate) or with E.coli LPS (10µg/ml). Cells were stained with 
speciﬁc antibodies as described in material and methods, and subjected to ﬂow cytometry analysis. Indicated 
are the mean ﬂuorescence intensities of positive cells. The results were obtained from a single experiment, and 
are representative of four similar experiments. N.D indicates not done.
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deficient mice were stimulated with Pam~conjugated peptide or CpG~conjugated peptide, 
respectively (Fig. 2). This impaired up-regulation was not due to a general defect in the 
maturation signaling pathway, as stimulation with LPS could induce up-regulation of CD86 
and MHC II in BMDCs derived from both TLR2- and TLR9-deficient mice to a similar 
extent as observed for BMDCs derived from wild type mice. Taken together, these results 
demonstrate that the conjugates are as effective as free TLR ligand in activating the DCs, and 
show that the expression of the cognate TLR is required for activation of DCs by the TLR-
L-peptide conjugates.
Figure 2. TLR-dependent DCs activation. A, BMDCs from either WT or TLR9-deﬁcient mice (TLR9 KO) were 
incubated either with 1 µM CpG~OVA247-264A5K, or E.coli LPS (10µg/ml) for 48 h. Cells were stained with CD86 or 
MHC II antibodies as described in material and methods, and subjected to ﬂow cytometry analysis, B, BMDCs 
from either wild-type (WT) or TLR2-deﬁcient mice (TLR2 KO) were incubated either with 1 µM Pam~OVA247-264A5K, 
or E.coli LPS (10µg/ml) for 48 h, cells were treated as stated under (A). 
A
B
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Figure 3. Efﬁcient antigen uptake mediated by the TLR-L-conjugates. A, Confocal images of the dendritic 
cell line D1 incubated for 15 min with either BODIPY-FL labeled Pam~OVA247-264 (Pam~conjugate) or BODIPY-FL 
labeled peptide OVA247-264 (peptide) at different concentrations. Arrows indicate accumulation of Pam~conjugates. 
B, Quantiﬁcation of mean intensity ﬂuorescence (MFI) of ﬂuorescence inside numbered cells selected 
from Fig. 3A. C, DCs were incubated with either Alexa 488 Fluro labeled CpG~OVA247-264 (CpG~conjugate), 
Pam~OVA247-264 (Pam~conjugate), or OVA247-264 peptide for 30 minutes, all compounds were used at 2.5 µM. D, 
DCs were incubated with either Alexa 488 Fluro labeled CpG~OVA247-264 (CpG~conjugate) or GpC~OVA247-264 
(GpC~conjugate) for 30min at a ﬁnal concentration of 5µM. All scale bars in A, B, C and D 20 µm. E, Mice were 
injected s.c. with either Alexa 488 Fluro labeled peptide OVA247-264 mixed with CpG, or Alexa 488 Fluor labeled 
CpG~OVA247-264, 72 hr later mice were sacriﬁce and draining lymph node cells were stained for CD11c. The y-axis 
displays the percentages of Alexa488 positive cell out of total CD11c+ cells. F, Mice were injected s.c. with either 
BODIPY-FL labeled peptide OVA247-264 mixed with Pam, or BODIPY-FL labeled Pam~OVA247-264, 72 hr later mice 
were sacriﬁce and draining lymph node cells were stained for CD11c. The y-axis displays the percentages of 
BODIPY-FL positive cell out of total CD11c+ cells. Experiments were conducted twice with similar results. 
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Efﬁcient uptake of CpG – and Pam-conjugated antigen peptides by dendritic cells.
Having demonstrated that TLR signaling was important for DC activation and priming of 
T-cells, we decided to compare the down-stream cellular mechanism used by the two types 
of TLR-L with respect to uptake, routing, and cellular processing. Therefore the efficiency of 
antigen uptake of conjugated versus non-conjugated peptide by DCs was determined. DCs 
were incubated with either Pam~conjugated peptide, or free peptide. Both compounds were 
labeled with a fluorophore (attached on the peptide backbone), which allowed us to monitor 
the internalization of these compounds by confocal microscopy analysis. Introduction of the 
fluorophore (either Alexa 488 or BODIPY-FL) into the conjugates did not alter the ability 
of the conjugates to activate DCs as comparable level of the IL-12 cytokine was produced 
by the fluorescent conjugates and the dark conjugates (unpublished data). As indicated by 
the increased intensity of fluorescence inside the cells, the Pam~conjugated peptides were 
taken up far more efficient than the non-conjugated peptide (Fig 3A). Interestingly, the 
Pam~conjugated peptide was found to accumulate in hot spots (indicated by arrows in Fig. 
3A), whereas a more diffuse pattern was observed in DCs incubated with the peptide alone. 
Quantification of the mean fluorescence intensity (MFI) revealed a more than 4-fold higher 
fluorescence in DCs incubated with the Pam~conjugate compared to DCs incubated with the 
peptide (Fig. 3B). Similarly, CpG~conjugated peptide was internalized more efficiently than 
the unconjugated peptide by DCs (Fig. 3C). In addition, the non-stimulatory GpC~conjugate 
(MFI 63±7.3) was internalized to a similar extent as the stimulatory CpG~conjugate (MFI 
72±9.1) (Fig. 3D). 
These comparisons indicate that the fluorescent TLR-L conjugates are taken up much more 
efficiently by DCs than unconjugated peptides in vitro. To examine the uptake efficiency 
in vivo, mice were injected with either Alexa 488 Fluor labeled CpG~conjugate or peptide 
labeled with Alexa 488 Fluor mixed with dark CpG. Three days later draining lymph node 
cells were stained for the DCs surface marker CD11c. In line with the in vitro results, a 
significantly higher proportion of CD11c+ cells had taken up the CpG~conjugated peptide 
(2.5%), when compared to the population of DCs that ingested unconjugated peptide (0.3%), 
or non-injected mice (0.1%; Fig. 3E). A similar tendency was observed upon comparison of 
BOPIPY-FL labeled Pam~conjugate with peptide labeled with BODIPY-FL mixed with dark 
Pam, (Fig.3F). Collectively, these results indicate that it is the covalent linking of the peptide 
to the TLR-L that is responsible for the enhanced uptake by the DCs.
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Conjugates translocate to endosomal/lysosomal compartment independently of TLR 
expression.
Our antigen uptake studies revealed that also the TLR9-L-conjugate was taken up more 
efficient despite that TLR9 is not surface expressed. Therefore to evaluate the relevance of 
TLR expression for the enhanced uptake, bone-marrow dendritic cells (BMDCs) purified 
from wild-type (WT), TLR2-/-, and TLR9-/- mice were incubated with Alexa 488 Fluor 
labeled TLR-L-conjugates. As shown in Fig. 4A and Fig. 4C BMDCs from TLR9-/- mice 
internalized CpG~conjugates to a similar extent as BMDCs from wild type mice, as reported 
previously (2).
Surprisingly, similar experiment carried out with Pam-conjugate and BMDCs from WT mice 
and TLR2-/- mice showed that also the Pam-conjugate, despite the fact that the receptor for 
Pam (TLR2) is located on the cell surface (1, 26), were internalized equally well by both 
types of DCs (Fig. 4B and Fig. 4D). 
To monitor the intracellular localization of the conjugates, we performed a co-localization 
study between the conjugates (green) and the endosomes (red). As seen in Fig. 4E both the 
CpG~ and Pam~conjugates are co-localized partially with an endosomal tracker (lysotracker), 
in a pattern characteristic for the endosomal vehicles. Moreover, no overall difference in the 
uptake kinetic or in the trafficking of the compounds could be detected when comparing 
BMDCs from wild-type mice to mice deficient for either TLR9 or TLR2 expression 
(unpublished data). These results indicate that TLR expression is not required for uptake and 
that the conjugate relocates to the endosomal compartment. 
Conjugation of peptide leads to pronounced enhancement in antigen presentation in 
vitro.
Having established that the conjugates were taken up much more efficiently than the 
free peptide harboring the OVA CTL epitope SIINFEKL, we next addressed the effect of 
conjugation of peptide to TLR-L on antigen presentation. DCs were loaded with either 
the CpG~conjugated peptide, Pam~conjugated peptide, the CpG or Pam mixed with the 
peptide, or the peptide alone (Fig. 5A and 5B) before incubation with the peptide-specific 
T-cell hybridoma B3Z cells that recognize the H-2Kb, SIINFEKL CTL epitope (27). As the 
concentration of the compounds decreased, antigen recognition was rapidly lost when DCs 
were incubated either with the peptide alone, or with the peptide mixed with CpG but not 
when the CpG~conjugated peptide was used. This indicates that the conjugation of peptides 
to TLR-L enhance antigen presentation (Fig. 5A). Likewise, an increased antigen presentation 
was observed for the Pam~conjugated peptide (Fig. 5B). In this case the difference in antigen 
presentation between conjugate and non-conjugate was even more prominent. Incubation 
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Figure 4. TLR-conjugates translocate to the endosomal compartment independently of TLR expression. 
A, BMDCs from wild type mice or TLR9 deﬁcient mice were incubated for 30 min with Alexa 488 Fluor labeled 
CpG~OVA247-264 (5µΜ), B, BMDCs from wild type mice or TLR2 deﬁcient mice were incubated for 30 min 
with Alexa 488 Fluor Pam~OVA247-264. (2.5µM). Scale bars in A and B 15 µm. C, Quantiﬁcation of uptake of 
CpG~conjugate in BMDC from wild type (WT) and TLR9 deﬁcient mice (TLR9 KO) was done on ten random cells 
selected from similar pictures as depicted in Fig.4A. D, Quantiﬁcation of uptake of Pam~conjugate in BMDC from 
wild type (WT) and TLR2 deﬁcient mice (TLR2 KO), was performed on ten random cells selected from similar 
pictures as depicted in Fig.4B. E, BMDCs were incubate with Alexa 488 Fluor labeled CpG~OVA247-264 (5µΜ), or 
Pam~OVA247-264 (2.5µM) in combination with 1µM Lysotracker-DND99, before imaging. Images were acquired by 
sequential scanning, with only one laser line per scan to avoid cross-excitation. Scale bars 10 µm, and 5 µm in 
enlarged images right panel. 
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Figure 5. TLR-L conjugates strongly enhance antigen presentation. A, The dendritic cell line, D1 was 
incubated with either the OVA247-264 peptide (gray bars), OVA247-264 peptide mixed with CpG (white bars), or 
CpG~conjugated to OVA247-264 (black bars). After 2h, cells were washed and B3Z cells were added and co-
cultured for 24h, before their activation was measured. B, D1 cells were incubated under the same conditions as 
indicated under (A), but in the presence of either the OVA247-264 peptide (gray bars), OVA247-264 peptide mixed with 
Pam (white bars), or Pam-conjugated OVA247-264 peptide (black bars). Results are means of triplicates ± SEM. C, 
BMDCs were incubated for various time period with either OVA247-264A5K (gray bars) CpG mixed with OVA247-264A5K 
peptide (white bars), or CpG~OVA247-264A5K (black bars), or D, with OVA247-264A5K peptide (gray bars), Pam mixed 
with OVA247-264A5K (white bars), or Pam~OVA247-264A5K (black bars) before co-culturing with B3Z T-cell hybridoma as 
outlined in material and methods.
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with a mixture of free TLR-L (Pam or CpG) and the peptides resulted in a decreased antigen 
presentation by DCs, when compared to loading with peptide alone or with conjugated 
peptide. This might be related to decreased uptake, since it has previously been reported that 
the endocytotic capacity of DCs declines upon encountering maturation signals (28, 29). 
To gain insight in the kinetics of antigen presentation, DCs were incubated for various time 
periods with either TLR-L-conjugated peptide, peptide mixed with TLR-L, or peptide alone. 
As shown in Fig. 5C and 5D, it required 24h-48h of continuous presence of peptide mixed 
with CpG or Pam, or of peptide alone to reach the level of antigen presentation acquired 
already after 2h of incubation with the conjugated peptide, as measured by an equal ability 
to stimulate the peptide-specific B3Z hybridoma T-cells. Thus, conjugation greatly improves 
the swiftness of presentation of antigen by DCs for stimulation of T-cells. 
The confocal microscopy results indicated that uptake of the conjugates occurred 
independently from the expression of the respective TLRs. Therefore we next evaluated 
the impact of TLR expression upon antigen presentation. To this end BMDCs from WT, 
TLR2-/-, and TLR9-/- mice loaded with the conjugates were incubated in vitro together, and 
subsequently incubated with the peptide-specific T-cell hybridoma B3Z cell line. In line with 
the confocal uptake studies, BMDCs derived from WT, the TLR2- or TLR9-deficient mice 
strains were recognized to the same extent (Fig 6A and 6B). 
Disruption of clathrin formation and caveolea clustering blocks antigen presentation of 
TLR-L-conjugates.
DCs can take up exogenous antigens via different mechanisms such as clathrin-mediated 
endocytosis, fluid phase endocytosis, and macropinocytosis (30). To define the pathways by 
which the TLR-L-peptide conjugates were internalized, DCs were pre-treated with different 
inhibitors before loading with the TLR-L conjugates. Macropinocytosis inhibitor 5-(N,N-
dimethyl) amiloride (29) had no effect on antigen presentation (unpublished data). On the 
other hand pretreatment with filipin, a sterol-binding agent that disrupt caveolea structures 
(31) and thereby lipid-raft formation, reduced antigen presentation of both Pam~conjugates 
as well as CpG~conjugates in a dose dependent manner, whereas antigen presentation of 
the CTL epitope OVA
257-264
 was only marginal affected (Fig. 6C). As lipid raft formation is 
involved both in clathrin-dependent endocytosis as well as caveolae dependent internalization 
(32), we analyzed the impact of monodansylcadaverine (MDC), a specific inhibitor of clathrin 
formation (33, 34) upon antigen presentation. Interestingly, whereas antigen presentation of 
CpG~conjugated peptides was not affected by MDC, antigen presentation of Pam~conjugated 
peptides was abrogated in a dose dependent fashion (Fig. 6D). To further explore the distinct 
uptake mechanisms used by the two types of conjugates, confocal microscopy was performed 
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Figure 6. Antigen presentation of TLR-L-conjugates does not require TLR expression, but is dependent 
on receptor-mediated endocytosis. A, BMDCs from wild type mice (black bars) or TLR9 deﬁcient mice (white 
bars) were incubated for 2 h with CpG~OVA247-264, and processed for antigen presentation as described in 
material and methods. B, BMDCs from wild type mice (black bars) or TLR2 deﬁcient mice (white bars) were 
incubated for 2h with Pam~OVA247-264 and processed for antigen presentation. C, DCs were left untreated, 
or pre-treated for 60min with various concentrations of ﬁlipin, or with various concentration of MDC D, 
before addition of 0.5µM CpG~OVA247-264A5K (gray bars), 0.5µM Pam~OVA247-264A5K (white bars), or 0.01µM 
OVA257-264,  (black).   Cells were incubated with the peptides for 3hr in the presence of inhibitors, before 
processed as outlined in material and methods section. Actual OD-values in Fig. 6C in the absence of ﬁlipin was: 
CpG~conjugate=0.5; Pam~conjugate=1.4; OVA257-264= 2.0. Actual OD-values in Fig. 6D in the absence of MDC 
was: CpG~conjugate=0.5; Pam~conjugate=1.0; OVA257-264= 1.4. Background OD-level of cells incubated without 
peptides were below 0.1 in both experiments.
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on DCs treated with the two inhibitors. As evident from Fig. 7 both MDC and filipin 
abolished the internalization of the Pam-conjugate in terms of mean fluorescence per cell, 
whereas inhibition of clathrin-formation had a less pronounced effect on internalization of 
the CpG~conjugate (Fig. 7C). On the other hand, inhibition of caveolin-formation by filipin 
reduced the mean fluorescence of cells incubated with the CpG~conjugate. The selective 
effect of the inhibitors was not due to a direct effect on one conjugate, as preincubation of 
cells with the inhibitor, followed by extensive washing before incubation with the conjugates 
(indicated as preincubation in Fig. 7) in the absence of inhibitors, led to similar results. Thus 
these results indicate that the two TLR-L-conjugates are internalized by distinct uptake 
receptors.
Figure 7. Effect of Filipin and MDC on internalization of the TLR-L conjugates. DCs were left untreated, or 
pretreated for 30min with 10µg/ml ﬁlipin, before adding Alexa488 labeled CpG~conjugate A or BODIPY-FL labeled 
Pam~conjugate B either in the presence of ﬁlipin (coincubation) or in the absence of ﬁlipin (pretreatment) for 
30min at 37oC before being subjected to confocal microscopy analysis. DCs were left untreated, or pretreated for 
30min with 50µM MDC, before adding Alexa488 labeled CpG~conjugate C or BODIPY-FL labeled Pam~conjuate 
D either in the presence of MDC (coincubation) or in the absence of MDC (pretreatment) for 30min at 37oC, 
before being subjected to confocal microscopy analysis. Shown is the mean ﬂuorescence intensity per cell based 
on quantiﬁcation of ten random selected cells.
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Antigen presentation depends upon endosomal acidification, proteasome activity, and 
TAP translocation.
Next, we examined the impact of different proteases upon antigen presentation. To address 
this issue, we made use of the C-terminal extended peptides (OVA
247-264A5K
), which require 
both N-and C-terminal processing to release the SIINFEKL CTL peptide-epitope. DCs were 
pre-treated either with epoxomicin, which inhibits the proteasome or NH
4
Cl that increases 
the pH in the acidic endosome/lysosome environment and thereby inhibiting the proteases 
that depend on acidification (35-38), before incubation with either of the conjugates. As 
evident from Fig 8A and Fig.8B when DCs were pretreated with the lysosomotropic agent, 
NH
4
Cl, a decrease in antigen presentation was seen ranging from 45% inhibition for the 
Pam~conjugates to 70% for the CpG~conjugated peptide. Similar, inhibition of the proteasome 
activity resulted in an overall decrease in antigen presentation of both the CpG~conjugated 
and Pam~conjugated peptide (up to 50% inhibition) in a dose dependent manner (Fig. 8C). 
To ascertain that the inhibitory effect observed was not due to an overall decrease in the 
surface expression of MHC class I, DCs that had been pretreated with either epoxomicin or 
NH
4
Cl were incubated with the minimal CTL epitope OVA
257-264
. As expected, the inhibitors 
did not cause major affect upon antigen presentation of exogenous loaded OVA
257-264
 peptide 
(Fig. 8B and Fig. 8C). 
Following proteasomal processing, CTL peptide-epitopes need to be translocated into the 
luminal side of endoplasmic reticulum via the transporter complex TAP, in order to be loaded 
onto MHC class I molecules. To address the involvement of TAP for cross-presentation of the 
TLR-L-conjugates, BMDC from either wild-type mice, or TAP-deficient mice were loaded 
with the TLR-L conjugates or the minimal CTL epitope OVA
257-264
. As evident in Fig. 8D, 
antigen presentation of both the TLR2L- and TLR9L-conjugates depended upon TAP activity, 
as the presentation was abrogated in TAP-deficient mice. Importantly, antigen presentation of 
the minimal CTL epitope OVA
257-264 
was not affected in the TAP-deficient DCs, showing that 
the observed TAP-dependence of the conjugates was not due to an overall reduced surface 
expression of MHC class I in the TAP-deficient DCs. In contrast, when using BMDC from 
mice deficient in both TAP and β2-microglobulin expression (TAP-/- beta2m-/-), completely 
lacking MHC class I surface expression (39), antigen presentation was completely lost for 
all peptides (Fig. 8D). 
Collectively, these results indicate that endosomal acidification, proteasomal activity and 
TAP translocation are required for antigen presentation of the TLR-L peptide-conjugates, 
and suggest that the peptide (conjugate) translocate via the endosomal compartment into the 
cytosol where the peptide undergoes proteasomal processing before being loaded onto MHC 
class I molecules in the endoplasmic reticulum.
Toll-like receptor ligands conjugated to peptides
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Figure 8. Antigen Presentation depends upon endosomal acidiﬁcation, proteasomal activity and TAP 
translocation. DCs were left untreated, or pre-treated for 60min with various concentrations of 3mM NH4Cl A , 
or epoxomicin B, before addition of 0.5µM CpG~OVA247-264A5K (squares), 0.5µM Pam~OVA247-264A5K (triangle), or 
0.01µM  OVA257-264 (circle). Cells were incubated with the peptides for 3hr in the presence of inhibitors, before 
processed as outlined under material and methods. (-) indicate untreated; (+) indicate with NH4Cl. Results are 
means of triplicates ± SEM. C, BMDC from wild-type (WT) mice, TAP-deﬁcient mice (TAP-/-), or mice deﬁcient in 
TAP and β2m (TAP-/- β2m-/-) were pre-loaded either with CpG-conjugates, Pam-conjugate, or OVA257-264 , before 
being processed as outlined under material and methods. 
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DISCUSSION
In this study we analyzed the cellular uptake and trafficking of two distinct TLR ligand-antigen 
conjugates that ultimately lead to the induction of an efficient CTL response. Strikingly, one 
single s.c. immunization with conjugate in saline induced an impressive systemic expansion 
of antigen-specific CD8 T-cells (Fig. 1). Thus, conjugation resulted in a stronger systemic 
response than what was observed for the mixed vaccines.
Our immunofluorescence analysis revealed that conjugates of both types of TLR-ligands 
were taken up very efficiently compared to unconjugated peptides (Fig. 3). Internalization 
was a very rapid process since uptake studies showed that already within 15-30 min, 
the major part of the conjugates could be found in endosome/lysosome compartments 
(Fig. 4, and unpublished data). For this we have used fluorescent conjugates, these may have 
slightly different properties from that of the unmodified conjugates, which could influence 
the uptake and function. However, the fluorescent conjugates induced DCs maturation to a 
similar extent as the unmodified conjugates (unpublished data). In line with our findings, 
CpG linked to FITC labeled Ovalbumin protein was recently shown to translocate to 
LAMP-1 positive endosomal-lysosomal compartments (10). Further support of enhanced 
uptake mediated by the conjugates was provided from our in vivo uptake analysis, which 
revealed a 6-8-fold increase in uptake of the CpG-conjugated peptide by CD11c+ cells, and a 
2-fold increase in uptake of the Pam-conjugated peptide by CD11c+ cells compared to uptake 
of non-conjugated peptide (Fig. 3E and Fig. 3F). We found that CpG~conjugated peptides 
were internalized independently from the expression of TLR9 and could also support antigen 
presentation in vitro independently of TLR9 expression (Fig.4). Accordingly, Wagner and 
co-workers (2) showed that cross-presentation of OVA linked CpG occurred independently 
from TLR9 expression, but that TLR9 expression nevertheless was essential for activation 
of the DCs. At first sight these findings might seem paradoxical, however, TLR9 are mainly 
expressed in the endoplasmic reticulum, followed by recruitment to the endosomes upon 
dendritic cell maturation (40). 
Unexpectedly, considering the cell surface expression of TLR2, we found that internalization 
of the Pam~conjugate was taken up independently from the expression of TLR2. BMDCs 
isolated from TLR2 deficient mice internalized the Pam~conjugate to a comparable level 
as BMDCs from wild-type mice, and antigen recognition was unaffected in BMDCs from 
TLR2-deficient mice. This could not be attributed to a side effect mediated by the peptide 
part, since TLR2-independent internalization was also observed when incubating the cells 
with free Pam (unpublished data). Importantly, inhibition of clathrin-dependent endocytosis 
or caveolea formation abrogated both uptake and antigen presentation of Pam-conjugates 
(Fig. 6 and Fig. 7), whereas internalization of CpG-conjugates was independent of clathrin-
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coated pits, but dependent on caveolae formation. These results indicate that other (distinct) 
receptors than the TLRs are involved in the uptake of the TLR-conjugates, although the exact 
nature of these receptors remains to be established. Other TLR2 ligands have been reported 
to be internalized independently from the expression of TLR2. Outer membrane protein A, a 
conserved major component of the outer membrane of Enterobacteriaceae family that triggers 
cytokine production in macrophages and DCs (41), was recently shown to be internalized by 
the scavenger receptor LOX-1, independently from the expression of TLR2 (42). Moreover, 
lipoteichoic acid (LTA) has also been reported to be internalized independently from TLR2 
expression (43), although the receptor involved in the uptake of LTA still remains to be 
identified. Therefore the contribution of TLR2 and other receptors expressed on the cell 
surface, to the uptake of Pam and other TLR ligands remains to be established.
Optimal presentation of the peptide antigen cargo in the conjugates required endosomal 
acidification (Fig.8). Although it can not be ruled out that the fusion of early endosomal 
vesicles with late endosomal vesicles is hampered by the lysosomotropic agent NH
4
Cl (37, 
44-46).These results imply that endosomal proteases, such as cathepins (45, 47), might 
be involved in the processing of the TLR-L-peptide conjugate. Furthermore, proteasomal 
cleavage was required since proteasome inhibition greatly decreased antigen presentation 
of the TLR-L-conjugates (Fig.8C). As proteasomes are mainly located in the cytosol (48, 
49), our results indicate that the peptide/conjugate, after being released in the endosomal 
compartment, translocate to the cytosol to undergo proteasomal processing (45). In this regard, 
it was recently reported that the translocon complex SEC61 could be involved in facilitating 
the translocation of peptide from the endosomes to the cytosol (50). Moreover, abrogation of 
translocation of peptides from the cytosol to the endoplasmic reticulum completely abrogated 
antigen presentation of both types of TLR-L-peptide conjugates (Fig 8D). Aside from being 
internalized efficiently, we found that all of the TLR-L conjugates retained their capacity 
to activate DCs to a comparable level as the free TLR-L, both in terms of production of 
the Th1-favoring cytokine, IL-12 (unpublished data) and up-regulation of DCs maturation 
surface markers (Table II). Importantly, TLR expression was required for DCs activation, 
since BMDCs lacking TLR2 or TLR9, were not able to up-regulate co-stimulatory molecules 
upon stimulation with either Pam~conjugate or CpG~conjugate, respectively (Fig. 2). In 
addition, conjugation of the non-stimulatory GpC oligonucleotide to the peptide antigen 
resulted in inefficient CTL priming (Fig.1) showing that the DCs activation of TLR-L peptide 
conjugates is essential. Therefore, intracellular signaling of TLR is crucially important for 
effective CTL priming by the conjugates.
In summary, we demonstrate that well-defined synthetic TLR-L-peptide conjugates induce 
a robust and systemic response of specific T-cells due to the combined action of enhanced 
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antigen uptake, improved MHC class I antigen presentation, and dendritic cell maturation. 
Our data show that targeting to two different TLRs requires distinct uptake mechanism, 
independent of TLR expression, but follows similar trafficking and intracellular processing 
pathways leading to optimal antigen presentation and T-cell priming. The chemical properties 
of these conjugates, which ensure that the same DCs that takes up the antigen receives 
simultaneously a proper maturation signal is likely to be the mechanism behind the superior 
activity of the peptide-conjugates. Accordingly, Medzhitov and co-workers recently reported 
that synchronous entrance of TLR-L and antigen enhanced MHC class II presentation, 
although in their system antigen and TLR-L was delivered on microspheres in a non-covalent 
manner (51). The collective features of our TLR-L peptide conjugates, together with their 
convenient manufacture and handling, makes synthetic peptide-TLR-ligand conjugates an 
attractive novel vaccine modality.
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Spontaneous tumor rejection by
cbl-b deficient CD8+ T cells.
Abstract. The concept of tumor surveillance implies that specific and non-specific components 
of the immune system eliminate tumors in the early phase of malignancy. Understanding the 
biochemical mechanisms of tumor immunosurveillance is of paramount significance because 
it might allow one to specifically modulate spontaneous anti-tumor activity. Here we report 
that inactivation of the E3 ligase Cbl-b confers spontaneous in vivo rejection of tumor cells 
that express Human Papilloma Virus antigens. Moreover, cbl-b-/- mice develop significantly 
fewer UVB-induced skin malignancies and reject UVB-induced skin tumors. CD8+ T cells 
were identified as key players in the spontaneous tumor rejection response. Loss of Cbl-b not 
only enhances anti-tumor reactivity of CD8+ T cells but also occurs in the absence of CD4+ 
T cells. Mechanistically, cbl-b-/- CD8+ T cells are resistant to Treg mediated suppression and 
exhibit enhanced activation and rapid tumor infiltration. Importantly, therapeutic transfer of 
naïve cbl-b-/- CD8+ T cells is sufficient to mediate rejection of established tumors. Even up 
to one year after the first encounter with the tumor cells, cbl-b-/- mice carry an “anti-cancer 
memory”. These data identify Cbl-b as a key signaling molecule that controls spontaneous 
anti-tumor activity of cytotoxic T cells in different cancer models. Inhibition of Cbl-b is a 
novel approach to stimulate long-lasting immunity against cancer. 
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INTRODUCTION 
More than 100 years ago, it was discovered that tumors regress in patients injected with 
bacterial extracts (1), suggesting that immune cells might be capable to eliminate cancer cells  
in the early phase of malignancy (2, 3). In many cases, tumor growth and lack of anti-cancer 
immunity can be ascribed to the fact that tumor cells do not provide sufficient T cell stimulation 
or induce tolerance in the tumor reactive T cell population (4-7). Several attempts have been 
made to break such tumor tolerance and to specifically enhance anti-tumor immunity by 
modulating immune cells (8, 9). However, immunotherapy is still difficult because most 
therapies result in severe side-effects, require large amounts of immune cells, or depend on 
extensive genetic manipulations of effector cell populations. Thus, identification of a key 
dominant “tolerogenic” factor in T cells that directly controls activation of tumor-reactive 
cytotoxic T cells in vivo might circumvent these limitations of T cell immunotherapy. 
The Casitas B-cell Lymphoma-b protein, Cbl-b, is a member of the mammalian family of 
Cbl E3 ubiquitin ligases (10). Proteins of this family contain an N-terminal tyrosine kinase 
binding domain, a RING finger, a C-terminal proline-rich sequence, and can thus function 
as both E3 ligases and molecular adaptors (10). Studies of Cbl-b-deficient mice have 
revealed an essential role for this molecule in T cell tolerance induction. Cbl-b-/- T cells show 
effective activation in the absence of costimulation, resulting in spontaneous autoimmunity 
or enhanced susceptibility to autoantigens (11-14). Moreover, Cbl-b sets the threshold for 
T cell activation to “weak” antigens (11, 15, 16) and controls immunotolerance in multiple 
experimental systems in vitro and in vivo (13, 14, 17, 18). Thus, Cbl-b functions as a negative 
regulator of antigen-specific T cell activation and is a critical mediator of T cell anergy. Based 
on these findings, we hypothesized that Cbl-b-regulated T cell activation may hold the key to 
our understanding of induction and/or maintenance of T cell responses to cancer cells. 
RESULTS 
Cbl-b mutant mice spontaneously reject tumors.
To determine whether Cbl-b contributes to anti-cancer immunity in vivo we tested the TC-1 
cancer model in cbl-b deficient mice. TC-1 cells are c-H-ras transformed C57BL6-syngeneic 
fibroblasts expressing the Human Papilloma Virus (HPV) 16 derived oncoproteins E6 and E7 
as tumor relevant T cell antigens (19). High risk HPV infection is a major cause of cervical 
cancer in women, with a high mortality rate, and the HPV-16 E6 and E7 oncoproteins are 
almost invariably expressed in early cervical cancer (20). Importantly, HPV vaccinations can 
protect against cervical cancer, indicating that immunoreactivity against HPV antigens plays 
a key role in cancer prevention and therapy (21).
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Figure 1. Spontaneous tumor rejection in cbl-b-/- mice. A, Kinetics of TC-1 tumor cell growth in cbl-b+/- (n=6) 
and cbl-b-/- (n=7) mice. 2.5x105 TC-1 cells were injected into the ﬂanks of 8-12 week old littermate mice and 
tumor volume was measured with a caliper [mm3] over time [days]. Of note, only mice that developed a palpable 
tumor were included into the experimental cohorts. B, Kaplan-Meyer survival curves of cbl-b+/+ (n=18), cbl-b+/- 
(n=11), and cbl-b-/- (n=28) mice inoculated with 2.5x105 TC-1 tumor cells. Data are pooled from four different 
experiments. C, Representative histology of TC-1 tumors isolated on different days (d7, d14, and d21 after 
inoculation) from cbl-b+/+ and cbl-b-/- mice. H&E staining. Arrows point at tumor mass. Bars indicate 1mm. D, 
Macroscopic appearance of TC-1 tumors in 5 different cbl-b+/+ and 5 different cbl-b-/- mice on day 21 (d21) after 
inoculation. 
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In mice, injection of HPV16 E6 and E7 expressing TC-1 tumor cells into syngenic recipients 
results in rapid tumor growth that can be abrogated by vaccination with an E7-peptide-
based vaccine (22, 23). We therefore injected TC-1 subcutaneously into the left flank of 
wild type (cbl-b+/+), cbl-b heterozygous (cbl-b+/-), and cbl-b deficient (cbl-b-/-) mice. In all 
recipients, tumor growth was first macroscopically observed at approximately 3 to 5 days 
after inoculation of 2.5x105 tumor cells (Fig. 1A). As reported previously in naïve C57BL/6 
mice (24), the tumors continued to grow progressively and with similar kinetics in all cbl-
b+/+ and cbl-b+/- mice analyzed (Fig. 1A,B). The histology of tumors, the kinetics of tumor 
growth, and tumor incidences were comparable between cbl-b-/-, cbl-b+/-, and cbl-b+/+ mice in 
the first two weeks after tumor inoculation (Fig. 1C and not shown). Intriguingly, around 2 
weeks after TC-1 inoculation, naïve cbl-b-/- mice spontaneously rejected the tumors (Fig. 1A). 
Tumor mass progressively reduced in cbl-b-/- mice and became undetectable between days 
25 and 35 after the initial inoculation of tumor cells (Fig. 1C). At 3 weeks post-inoculation, 
the average size of a wild type tumor was 835 mm3 (+/- 227,9 mm3 s.e.m.; n= 5) compared 
to an average size of 14 mm3 (+/-7,6 mm3 s.e.m.; n= 5, p < 0,003) in cbl-b-/- recipients (Fig. 
1D). Over 80% of cbl-b-/- mice completely rejected the tumors and remained tumor free 
throughout the experimental observation period that in some cases was longer than one year 
(Fig. 1B and data not shown). Progressive tumor growth in cbl-b-/- mice was observed in a 
few cases, but only after a longer latency period when compared to tumor growth in wild type 
mice (Fig. 1A,B). It should be noted that we injected a tumor cell number (2.5x105) into our 
experimental cohorts that is 10 times higher than the dose that is lethal for wild type mice. 
(24) These surprising data show that naïve cbl-b mutant mice can spontaneously reject a very 
high dose of aggressive TC-1 tumor cells.
Spontaneous tumor rejection in cbl-b mutant mice is mediated by CD8+ T cells. 
To explore the underlying mechanisms of spontaneous tumor rejection in the cbl-b knockout 
mice, we assessed proliferation and cell death of tumor tissue. Tumor cell proliferation was 
comparable in both cbl-b+/+ and cbl-b-/- mice on day 7, day 14 (Fig. 2A) and day 21 (not 
shown) suggesting that loss of Cbl-b expression in the host environment does not affect cell 
cycle progression of the tumor cells. By contrast, whereas cell death within early tumors (day 
7 after inoculation) appeared comparable among the different cohorts, we observed markedly 
increased apoptosis in day 14 tumors taken from cbl-b-/- mice (Fig. 2B). We next determined 
the numbers of lymphoid cells in tumor-bearing cbl-b+/+ and cbl-b-/- mice. We did not observe 
alterations in CD11b+, CD11c+, NK1.1+ cells or Gr1+ granulocytes, nor in relative numbers 
of CD4+ or CD8+ T cells in the draining inguinal lymph nodes, non-draining contra-lateral 
inguinal lymph nodes, or the spleen (not shown). Immunohistochemistry (not shown) and 
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FACS analysis (Fig. 2C) of total tumor tissue revealed that CD4+ and CD8+ T cells infiltrate 
the tumors in both wild type and cbl-b-/- mice. However we observed markedly increased 
ratios of CD8+ within the tumors of cbl-b-/- mice compared to wild type mice (Fig. 2C). Of 
note, we observed tumor infiltration of CD8+ cells as early as day 8 after TC-1 inoculation in 
cbl-b-/- mice (Fig. S1A,B). In line with increased CD8+ T cell infiltration of tumors, we also 
detected elevated levels of the CD8+ T cell chemokine RANTES (25) in tumors growing in 
cbl-b-/- mice (not shown). These data show that loss of  Cbl-b expression in mice results in 
increased tumor cell death, increased infiltration of CD8+ T cells into the tumor tissue, and, 
most importantly, spontaneous tumor rejection.    
To investigate whether CD8+ T cells from wild type and cbl-b-/- mice were reactive to the 
tumor specific antigens, we analyzed IFNγ production by CD8+ T cells isolated from the 
spleen (not shown) and lymph nodes (Fig. 3A) of tumor-bearing mice upon re-stimulation 
with the MHC class I (H2Db) restricted E7 tumor-specific peptide antigen. In the draining 
lymph nodes of TC-1 challenged wild type mice, we consistently observed a low frequency 
of E7-reactive CD8+ IFNγ producing T cells. Importantly, in all tumor-bearing cbl-b-/- mice 
analyzed, the frequency of IFNγ producing CD8+ T cells was markedly increased in response 
to stimulation with the E7 peptide (Fig. 3A). Of note, we also observed E7 tumor specific, 
IFNγ producing CD8+ T cells, albeit at lower numbers, in the non-draining contra-lateral 
inguinal lymph nodes of cbl-b-/- mice. These data show that spontaneous tumor rejection in 
cbl-b mutant mice is associated with rapid CD8+ T cells infiltration into the tumor and hyper-
activation of tumor-specific cytotoxic T cells.
To examine whether CD8+ T cells are indeed essential for the spontaneous rejection of TC-1 
tumor cells in cbl-b mutant mice, we depleted CD8+ cells using specific antibodies prior to 
the tumor injection. Following confirmation of CD8+ T cell depletion (Fig. S2), cbl-b-/- and 
cbl-b+/+ mice were injected with TC-1 tumors and tumor growth was monitored for up to 
one year. Tumors grew progressively in the cbl-b+/+ control mice and the kinetics of tumor 
expansion in the CD8+ T cell depleted group was comparable to the control cohort (Fig. 
3B). In the cbl-b-/- mice, tumors were spontaneously rejected in the control group with some 
cases of late-onset of tumor growth (Fig. 3B; see also Fig. 1A,B). Importantly, CD8+ T cell 
depleted cbl-b-/- mice displayed progressive and lethal tumor growth (Fig. 3B). 
In most experimental models of tumor rejection, CD4+ T cell help is required for effective 
anti-tumor immunity (26, 27). Similarly, it has been shown that the vaccination induced 
anti-TC-1 tumor response depends on CD4+ T cell help (22). To address the role of CD4+ T 
cells in spontaneous tumor rejection, we efficiently depleted CD4+ cells in cbl-b-/- and cbl-
b+/+ mice (Fig. S2) followed by TC-1 inoculation. As expected, depletion of CD4+ T cells 
in wild type mice did not change the kinetics or frequencies of tumor growth. Surprisingly, 
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Figure 2. Inﬁltration of CD8+ T cells into tumors from cbl-b-/- mice. A, Immunohistochemistry for proliferation 
marker Ki67 in TC-1 tumor samples from cbl-b+/+ and cbl-b-/- mice at 7 and 14 days after tumor inoculation 
(2.5x105). Original magniﬁcations X 50. Size bars represent 100μm. B, Increased cell death in tumor tissue 
from cbl-b-/- mice 14 days after TC-1 tumor cell injection. Cell death was determined by TUNEL. Representative 
images of individual mice on day 7 and 14 are shown. Original magniﬁcations X 50. Size bars represent 100μm. 
C, Analysis of tumor inﬁltrating lymphocytes 17 days (left panels) and 21 days (right panels) after TC-1 inoculation 
into cbl-b+/+ and cbl-b-/- mice. Single cell suspensions were analyzed by ﬂow cytometry using antibodies reactive 
to CD8 and CD4. Numbers indicate percentages of cells within the R1 and R2 gates. 
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ablation of CD4+ T cells in cbl-b-/- mice did not affect their capacity to spontaneously reject 
the tumor (Fig. 3B) indicating that CD4+ T cells are not required for rejection of TC-1 tumors 
in our experimental system. These data show that CD8+ T cells play an essential role in the 
spontaneous rejection of TC-1 tumors in cbl-b mutant animals. 
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Figure 3. CD8+ cells mediate spontaneous tumor rejection independent of CD4+ T cell help.  A, INFγ 
production of CD8+ T cells isolated from draining and non-draining inguinal lymph nodes of tumor-bearing 
cbl-b+/+ and cbl-b-/-  mice (n= 5) and naïve control mice (n=3). Data are from day 21 after tumor inoculation. 
Puriﬁed CD8+ T cells were re-stimulated for 60h with the HPV16-derived peptide E749–57, stained for intracellular 
IFNγ, and analyzed by ﬂow cytometry. Numbers indicate percentages of INFγ+CD8β+ T cells. B, Kinetics of TC-1 
tumor cell growth in cbl-b+/+ (top panels; n=6) and cbl-b-/- (bottom panels; n=7) mice left untreated or following 
depletion of CD4+ or CD8+ T cell subsets. 2.5x105 TC-1 cells were injected into the ﬂanks of 8-12 week old mice 
and tumor volume was measured with a caliper [mm3] over time [days]. Only mice that developed a palpable 
tumor were included into the experimental cohorts.
Therapeutic transfer of naïve cbl-b-/- CD8+ T cells is sufﬁcient to mediate spontaneous 
rejection of established tumors. 
Our data show that cbl-b mutant mice spontaneously reject TC-1 tumors via CD8+ T cells. 
We then wanted to ask whether cbl-b-/- CD8+ cells could also be used to treat a previously 
established cancer. To address whether cbl-b-/- CD8+ cells function therapeutically, we set 
up an adoptive transfer model. In this model, T and B cell deficient rag2 mutant mice were 
injected with 2.5x105 TC-1 tumor cells followed by infusion of 3x106 and 2x106 purified 
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Figure 4. Therapeutic transfer of naïve cbl-b-/- CD8+ T cells is sufﬁcient to mediate spontaneous rejection 
of established tumors. A, rag2-/- mice were subcutaneously injected with 2,5x105 TC-1 cells. At day 3 and day 6 
post tumor cell injection, puriﬁed CD8+ cells from naïve cbl-b-/- and cbl-b+/+ mice were adoptively transferred (i.v.) 
into the tumor bearing rag2-/- mice (arrows). n=5 per group. The rag2-/- control group (n=4) received tumor cells, 
but no donor T cells. Upper panels show representative tumor sizes at the end of the experiment. Lower panels 
indicate the kinetics of tumor growth. B, Relative percentages of CD3+CD8+cbl-b+/+ and CD3+CD8+cbl-b-/- T cells 
in the blood of adoptively transferred rag2-/- mice carrying TC-1 tumors. Representative ﬂow cytometry data show 
CD3+CD8+T cell populations on day 7 after the second T cell transfer (day 13 after the ﬁrst TC-1 injection). 
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Figure 5. Tumor escape and long lasting anti-tumor memory in cbl-b-/- mice. Escape of cbl-b-/- mice-derived 
TC-1 tumors. Tumor cell lines were generated from A, TC-1 tumors growing in cbl-b+/- mice or B, generated 
from late-onset TC-1 tumors growing in cbl-b-/- mice. Tumor cells were injected (2,5 x 105) into 8-12 weeks old, 
naïve, Cbl-b expressing control mice and cbl-b-/- recipients. Kinetics of tumor growth was analyzed over the 
indicated time period. Graphs represent data from two pooled experiment of cbl-b+/+ and cbl-b+/- (n=10 for both 
cell lines) mice and cbl-b-/- mice (n=7 for cbl-b+/--derived tumor cells and n=10 for cbl-b-/--derived tumor cells). Of 
note, the kinetics of tumor growth was comparable between cbl-b+/+ and cbl-b+/- mice. C,D. Anti-tumor memory. 
Cbl-b-/- mice, that had received 2,5 x 105 TC-1 cells at 8-12 weeks of age and stayed tumor free after rejection 
of the initial cancer, were kept under observation for 1 year post TC-1 injection. These experienced (exp) 
cbl-b-/- mice together with age-matched naïve cbl-b-/- and age-matched naïve cbl-b+/+ and cbl-b+/- control mice 
were re-challenged with a 10 times higher dose of TC-1 cells (2,5 x 106). C, Appearance of representative tumors 
from each experimental group. Tumors were imaged 23 days after injection of 2.5x106 TC-1 cells. D, Kinetics of 
TC-1 tumor cell growth in age- matched naive cbl-b+/+ and cbl-b+/- control mice (n=5), naïve cbl-b-/- mice (n=6), 
and experienced (exp) cbl-b-/- mice (n=6). 2.5x106 TC-1 cells were injected into the ﬂanks of 14 month old mice 
and tumor volume was measured with a caliper [mm3] over time [days]. Of note, only mice that developed a 
palpable tumor were included into the experimental cohorts. 
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CD8+ T cells from naive cbl-b+/+ and cbl-b-/- donors on days 3 and 6, respectively, after initial 
tumor cell challenge. In this experimental system tumors grow progressively in a wild type 
environment followed by 2 therapeutic vaccinations with freshly purified, polyclonal, and 
naive CD8+ T cells from syngenic donors. Tumor growth was monitored for a period of 
6 weeks (Fig. 4). The kinetics and extent of TC-1 tumor growth was comparable between 
rag2-/- control mice and rag2-/- mice infused with wild type CD8+ T cells (Fig. 4A). In contrast, 
tumor growth was markedly reduced and delayed in rag2-/- mice that received cbl-b-/- CD8+ 
T cells as a therapeutic vaccine (Fig. 4A). Moreover, although the same numbers of cells 
were transferred from wild type and cbl-b-/- donors, we observed a marked increase in the 
numbers of CD8+ cbl-b-/- T cells in the blood of rag2-/- hosts (Fig. 4B). These data show 
that therapeutic transfer of naïve cbl-b-/- CD8+ T cells is sufficient to mediate spontaneous 
rejection of established tumors.  
Tumor escape in cbl-b-/- mice.
Recent results suggested that the dominant mechanism of spontaneous tumor growth is 
induction of immunotolerance rather than immuno-escape of the tumor cells (28). However, 
Cbl-b appears to be a critical regulator of antigen-specific T cell tolerance and it has been 
shown in multiple systems that cbl-b-/- T cells cannot be anergized. (13, 17) Since some 
cbl-b-/- mice developed a late onset tumor (Fig. 1A,B; Fig. 3B), we therefore addressed the 
mechanism by which Cbl-b can confer spontaneous tumor rejection. To test whether the 
late onset of tumor growth in cbl-b-/- mice was the consequence of tumor-intrinsic “evasive” 
mechanisms rather than host-intrinsic “immunotolerance”, we established cell lines from 
TC-1 tumors that showed late onset growth in cbl-b-/- mice. If tumor cells originating from 
cbl-b-/- mice trigger immunotolerance in a particular host mouse, then these tumors should 
again be rejected in cbl-b-/- mice that have survived a previous challenge of TC-1 cells 
(experienced cbl-b-/- mice). If tumors developed due to an escape mechanism intrinsic to 
the cancer cell, then these tumors should also progress when transferred into experienced 
cbl-b-/- mice. As a control we also established tumors that grew in cbl-b+/- mice. As expected, 
tumors isolated from cbl-b+/- mice rapidly formed large tumors in wild type mice, but were 
rejected when transferred into cbl-b-/- hosts (Fig. 5A). Importantly, TC-1 tumors isolated from 
cbl-b-/- mice grew progressively in both cbl-b+/+ and cbl-b-/- recipients. These results indicate 
that tumor growth in cbl-b-/- mice is a consequence of tumor escape rather than induction of 
immunotolerance. 
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Cbl-b-/- mice carry long-lasting anti-cancer memory.
Our data so far showed that CD8+ T cells from cbl-b mutant mice can directly mediate and are 
sufficient for spontaneous tumor rejection. Moreover, mechanistically we failed to observe 
induction of immunotolerance in TC-1 challenged cbl-b-/- mice. To expand these findings 
to additional therapeutic benefits of a potential T cell vaccine, we studied the anti-tumor 
memory response. To investigate whether aged cbl-b mutant mice, that rejected tumors and 
remained tumor free (“experienced cbl-b-/- mice”), have a long lasting memory in response 
to the tumor, we re-challenged age matched naïve wild type, naïve cbl-b-/-, and experienced 
cbl-b-/- mice (1 year after the first challenge) with a hundred times the lethal dose of 
TC-1 cells. At such a tumor cell concentration, all age-matched wild type and cbl-b+/- control 
mice rapidly developed tumors (Fig. 5C, D). Tumor development was abrogated in old 
naïve cbl-b-/- mice, but all animals tested developed late onset tumors, indicating that the 
spontaneous anti-tumor response in cbl-b-/- is dependent on the tumor load. Intriguingly, one 
year after the first challenge we observed that experienced cbl-b knockout mice were able to 
reject the tumors even at the 100 times lethal tumor dose (Fig. 5D). Moreover, three weeks 
after tumor challenge, tumors appeared significantly smaller in the re-challenged experienced 
cbl-b knockout mice compared to naïve knockout mice and naïve heterozygous control mice 
(Fig. 5C). It should be noted that incidence and severity of autoimmune organ infiltration 
were comparable between aged naïve and TC-1 challenged cbl-b mutant mice at one year 
after the first tumor challenge (not shown) suggesting that even such long-lasting anti-tumor 
reactivity did not enhance the incidence or severity of autoimmunity (11, 12). Thus, even up 
to one year after the first encounter with the tumor cells, cbl-b-/- mice carry an anti-cancer 
memory. 
Cbl-b-/- CD8+ T cells are less sensitive to CD4+CD25+ regulatory T-cell suppression.
It has been reported that CD4+CD25+FoxP3+ T-regulatory (T-reg) cells suppress CD8+ 
effector cell immunity in cancer (29). Moreover, Tregs play a role in vaccination-mediated 
rejection of TC-1 tumors (30). Further it has been shown that cbl-b deficient CD4+ T-cells are 
resistant to CD4+CD25+ Treg suppression (17). However, whether loss of Cbl-b also confers 
such resistance to CD8+ T cells has never been established. We therefore first examined the 
numbers of Tregs in TC-1 tumors from cbl-b+/+ and cbl-b-/- mice. At two weeks after TC-1 
inoculation, the total numbers of CD4+CD25+ and CD8+ tumor infiltrating cells were similar 
in wild type mice (Fig. 6A). Tumors isolated from cbl-b-/- mice contained slightly increased 
(~2 fold) numbers of infiltrating CD4+CD25+ cells. FoxP3 immunostaining of tumor-derived 
CD4+CD25+ cells showed that ~ 55% of these cells express FoxP3 both in cbl-b+/+ and cbl-b-
/- mice (Fig. 6A and Fig. S3A). The number of tumor infiltrating CD8+ cells was dramatically 
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increased in TC-1 bearing cbl-b-/- mice as compared to wild type controls (Fig. 6A). Of note, 
the total number of tumor cells and tumor sizes were comparable in the cbl-b+/+ and cbl-b-/- 
mice analyzed (Fig. S3B). These results show that Tregs infiltrate TC-1 tumors in both cbl-
b+/+ and cbl-b-/- mice; however, loss of Cbl-b dramatically changes the ratio of CD8+ T cells 
to Tregs within the tumors.  
We next examined whether loss of Cbl-b might change the function of Tregs towards CD8+ 
effector cell proliferation. Suppression of wild type CD8+ effector cells was comparable 
between cbl-b+/+  and cbl-b-/- Tregs (Fig. 6B,D and Fig. S4). In addition, similar to control 
CD4+CD25+ Tregs, cbl-b-/- Tregs did not proliferate upon anti-CD3 stimulation in vitro 
(Fig. S4). Thus, cbl-b-/- regulatory CD4+CD25+ T-cells are bona fide suppressors towards 
wild type and cbl-b-/- responder CD8+ T-cells and loss of Cbl-b has no apparent effect on 
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Figure 7. cbl-b-/- mice show signiﬁcantly decreased susceptibility to spontaneous UVB induced skin 
cancer. A, Kaplan Meier curves of tumor-bearing cbl-b+/+ (n=18) and cbl-b-/- (n=21) mice during chronic 
UVB irradiation. Tumor incidence in the cbl-b-/- cohort was signiﬁcantly reduced as compared to cbl-b+/+ mice 
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growth in one wild type (left panels) and one cbl-b-/- mouse (right panels). Tumor growth is shown over time in 
the same two mice (days after ﬁrst UVB irradiation is indicated) Note progressive reduction of tumor mass in the 
cbl-b-/- mouse. Inserts are higher magniﬁcations of tumors. Histology conﬁrmed epithelial origin of the tumors in 
control and cbl-b-/- mice. C, Confocal images of cbl-b-/- and cbl-b+/+ skin tumor sections stained for CD8+ cells by 
immunoﬂuorescence. Original magniﬁcations x 400.Scale bars represent 25 μm. 
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Treg functions. However, cbl-b deficient effector CD8+ T-cells were resistant to suppression 
by wild type as well as cbl-b-/- Tregs at Treg: effector ratios that significantly suppressed 
proliferation of wild type CD8+ T cells. At a 2:1 Treg:CD8+ effector cell ratio we, however, 
still observed suppression, albeit at lower levels as in cbl-b-/- effector CD8+ T cells 
(Fig. 6C,D and Fig. S4). These data show that cbl-b-/- CD8+ effector cells are resistant to Treg 
suppression.
cbl-b-/- mice show resistance to spontaneous UVB-induced skin cancer.
Our results show that genetic ablation of Cbl-b confers spontaneous in vivo rejection of TC-1 
tumor cells following subcutaneous inoculation. We therefore wanted to test whether Cbl-b 
also controls tumor resistance in a spontaneous tumor model relevant for human cancer, i.e., 
UVB triggered skin cancer in mice. UVB irradiation is the most important risk factor for the 
induction of non-melanoma skin cancer (31, 32). In addition in has been shown, that induction 
of immunosuppression by UVB is a skin cancer promoting factor (31). To determine the role 
of Cbl-b in the generation of UVB-induced cutaneous malignancies we chronically irradiated 
cohorts of cbl-b+/+ and cbl-b-/- mice with UVB on their shaved backs. Tumor development was 
recorded over time (Fig. 7A and Fig. S5A,B). In both cbl-b+/+ and cbl-b-/- mice the first visible 
progressively growing tumors appeared around day 300 after the initial UVB treatment 
suggesting that tumor onset is comparable between control and cbl-b mutant animals. Most 
UV-induced skin tumors were located on the ears and backs of the mice (Fig 7B). However, 
cbl-b-/- mice exhibited markedly reduced susceptibility to photocarcinogenesis compared to 
wild type mice: whereas 15 of 18 wild type mice developed 2-3 visible tumors each, only 
6 out of 21 cbl-b-/- mice developed visible skin cancer and in only one case did we observe 
more than one tumor per cbl-b-/- mouse (Fig. 7A). 
Intriguingly, whereas in cbl-b+/+ mice skin tumors grew progressively in all cases observed 
(Fig. S5A), the initial phase of tumor growth in cbl-b-/- mice was followed by a marked 
reduction in tumor mass (Fig. 7B and Fig. S5B). Note that one cbl-b-/- mouse was 
euthanized for histology and therefore tumor progression or reduction could not be followed 
(Fig. S5B). In line with our TC-1 data, the number of tumor infiltrating CD8+ T cells was 
dramatically increased in the UVB-induced skin tumors of cbl-b-/- mice as determined by 
immunofluorescence (Fig. 7C). Furthermore, using TUNEL staining, we detected increased 
numbers of apoptotic cells in skin tumors of cbl-b-/- mice compared to cbl-b+/+ skin tumors 
(Fig. S6A). Numbers and ratios of T-cells as well as expression of surface markers (CD44, 
CD43, CD69, CD28, CTLA4, CD3, CD8, CD4, CD127, CD62L, CD25, FoxP3) in the 
draining lymph nodes were comparable among tumor-bearing cbl-b+/+ and cbl-b-/- mice (not 
shown). To address whether, similar to our TC-1 tumor model, CD8+ T cells are also the 
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critical cell type involved in the surveillance of UVB-induced skin cancer, CD8+ cells were 
depleted in UVB treated cbl-b-/- mice that had received UVB irradiation but never developed a 
tumor. Remarkably, only 10 day after starting the depletion by injection of the CD8 depleting 
antibody (Fig. S6B) 50% of UVB treated (and previously cancer free) cbl-b-/- mice (n=4) 
developed rapidly growing tumors while all IgG isotype control-treated UVB treated cbl-b-/- 
mice (n=4) remained tumor free (Fig.  8A, B, see page 138). In conclusion, our results show 
that cbl-b deficient mice exhibit reduced skin cancer and are able to reject spontaneous, 
UVB-induced skin tumors. 
DISCUSSION
Various schemes for immunological treatment of tumors have been described including 
genetic alterations of tumors with cytokines or co-stimulatory molecules, or the generation of 
tumor specific cytotoxic T cells (33-35). However, immunotherapy is still difficult because 
most tumors are insufficiently recognized, do not elicit a robust immune response, or induce 
immunotolerance (4, 5, 36). Several attempts have been made to break tumor tolerance and 
enhance tumor immunity using transgenic models, transplantation of T cells or dendritic 
cells, or novel vaccination regimens against known tumor antigens (8, 9). Moreover, many 
immunotherapies are limited due to severe side-effects and the availability of tumor-reactive 
immune cells and combination therapies (7, 37) .
Our results show that inactivation of a single negative regulator of T cell signaling confers 
anti-cancer activity in vivo using two distinct tumor models relevant for human cancers. This 
anti-tumor activity occurs spontaneously and tumor growth is completely eradicated in 
virtually all cbl-b mutant mice in the TC-1 tumor model as well as in our spontaneous UVB-
induced skin cancer model. In the TC-1 model we could show that anti-tumor memory is 
maintained for more than one year in cbl-b-/- mice. Thus, we have identified a dominant 
“tolerogenic” factor that actively represses activation of tumor-specific T cells in vivo. 
Although we explored the role of Cbl-b in two distinct tumor models, further studies are 
required to determine whether Cbl-b is indeed a key molecule that confers anti-tumor immunity 
in additional cancer types including tumor models with defined high or low immunogenicity. 
Moreover, it will be interesting to explore whether cbl-b-/- CD8+ T cells cooperate with other 
cell types in tumor rejection.
Mechanistically, deletion of cbl-b might affect anti-cancer immunity at several levels. One 
rate limiting factor for successful anti-tumor immunity is the induction of Tregs in cancer. 
Interestingly, whereas loss of Cbl-b does not affect Treg mediated suppressor functions towards 
CD8+ T cells, cbl-b-/- CD8+ effector T cells display resistance to proliferative suppression. 
Thus, similar to previous reports that Cbl-b may regulate suppression of CD4+ effector cells 
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(17, 18), we have identified a novel function of Cbl-b in Treg mediated suppression of effector 
CD8+ T cells. Our results also indicate that Cbl-b must regulate additional mechanisms 
involved in tumor rejection by CD8+ T cells. For instance, the expansion and proliferation of 
CD8+ T cells is increased in cbl-b-/- mice and we observed a rapid onset and elevated numbers 
of tumor infiltrating effector CD8+ T-cell in TC-1 tumors as well as our spontaneous skin 
cancer model. These results would be in line with enhanced penetration of T cells into the 
tumors possibly as a result of enhanced activation.  Moreover, our preliminary data suggest 
that CD8+ T cells from cbl-b-/- mice exhibit increased sensitivity to dendritic cells loaded with 
TC-1-derived tumor antigens. We propose that Cbl-b affects multiple regulatory circuits in 
anti-tumor immunity.  
Importantly, established TC-1 tumors can be treated by the transfer of non-transgenic, “naïve” 
CD8+ cbl-b-/- T cells that have previously never encounter the tumor antigen. Loss of Cbl-b 
in the CD8+ compartment alone is both necessary and sufficient to induce potent anti-tumor 
immunity, thereby perhaps providing a direct means of targeting tumors via CD8+ T-cell 
responses even in the context of ineffective co-stimulation, impaired CD4+ T cell help, or 
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Treg immunosuppression. Thus, inactivation of Cbl-b might be a potent new strategy for 
anti-cancer immunotherapy on multiple levels to augment the effectiveness of tumor specific 
CD8+ T cells in humans. 
MATERIAL AND METHODS 
Mice. cbl-b mutant mice have been previously described (11) and were crossed onto a 
C57BL/6 background for more than 10 generations. C57BL/6 wild type mice and rag2-/- 
mice were obtained from our in house breeding stock. cbl-b+/- littermates showed the same 
results as wild type mice. Only female mice were used in all experiments since TC-1 cells are 
derived from female mice. All mice were maintained under specific pathogen-free conditions 
and used in accordance with institutional guidelines (Permission from Magistrat 58 of the 
City of Vienna).
Tumor cells, dendritic cell culture, antibodies, and peptides. TC-1 cells have been 
previously reported and were generated by co-transformations of primary C57BL/6 mouse 
lung fibroblasts with an activated c-H-ras oncogene and the HPV-16 E6 and E7 oncoproteins 
(19). TC-1 cells were maintained in IMDM medium containing 10% FCS, 100 IU/ml penicillin, 
and 2 mM glutamine, supplemented with G418 (0.5mg/ml), Na pyruvate (1mM) and 30µM 
2-ME. The HPV16-derived and H-2Db restricted peptide E749-57 (RAHYNIVTF) was used 
for all re-stimulation experiments (23). Antibodies against mouse CD3ε (clone 145-2C11), 
CD4 (RM4-5), CD8β.2 (53-5.8), CD8α (53-6.7), TCR-β (H57-597), CD11b (M1/70), CD11c 
(HL3), CD16/32 (2.4G2), GR1 (RB6-8C5), NK1.1 (PK136), IFNγ (XMG1.2), CD44 (IM7), 
CD62L (Mel-14), CD25 (PC61), CTLA-4 (UC10-4F10-11), CD43 (1B11), CD69 (H1.2F3), 
CD28 (37.51), and CD127 (clone SB/199) were purchased from BD Pharmingen. The anti-
Ki67 antibody was purchased from Novacastra. The anti-mouse FoxP3 antibody (clone FJK-
16s) was obtained from eBioscience. Hybridomas for production of the depleting antibodies 
to CD4 (clone GK1.5) and CD8 (clone 2.43) were grown in serum free medium and purified 
using a proteinA/proteinG column. Cells were analyzed by four-color flow cytometry on a 
FACScaliburTM cytometer (Becton Dickinson, BD) using the CELLQuestTM software. 
In vivo TC-1 tumor cell growth. TC-1 cells were injected s.c. into the shaved left flank of 
8-12 weeks old female mice. In all experiments, at day zero 2,5x105 TC-1 tumor cells were 
injected s.c. whereas for tumor memory experiments, 2,5x106 TC-1 tumor cells were s.c. 
injected. CD8+ cells or CD4+ cells were depleted by injection of 50 µg of depletion antibodies 
i.p. per mouse at day-4 and day-2 prior to tumor inoculation (day 0). At day-1 complete 
depletion of respective cell subsets was confirmed by FACS analysis. The depletion was 
repeated weekly throughout the experiment. In all experimental groups, tumor growth was 
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monitored three times per week by measuring tumor length, width and height with a caliper. 
Mice were euthanized when tumor volume reached 1cm3. For tumor escape/immunotolerance 
experiments, tumors were isolated from cbl-b+/- or cbl-b-/- mice. Cells were passaged in vitro 
for one month and aliquots were kept. Prior to use for experiments cells were passaged 6 
times. These newly established TC-1 tumor cell lines cells were then injected into 8-12 
week old, ‘naïve”, cbl-b+/+ or cbl-b-/-  recipients and tumor growth was analyzed as described 
above. All experimental procedures performed on mice were in accordance with institutional 
guidelines. 
UVB-induced photocarcinogenesis. Within the solar spectrum, the UV-B range (290–320 
nm) is responsible for carcinogenesis and immunosuppression. Therefore, a bank of four 
Philips UV-B TL40W/12 sunlamps was used, which have an emission spectrum from 280 to 
350 nm, with a peak at 306 nm. These lamps deliver an average dose of 8 W/m2, as measured 
with an IL-1700 UV detector and a SED 24 (no. 3124) filter (both from International Light). 
The mice were placed on a shelf 20 cm below the light bulbs for irradiation. The cage order 
was systematically rotated before each treatment to compensate for uneven lamp output along 
the shelf as described previously (38, 39). Female mice were shaved with electric clippers 
once per week on the entire dorsum. Beginning at 10 wks of age, mice were irradiated three 
times per week with 2.5 kJ/m2 for the first 4 wks, followed by 5 kJ/m2 for 4 wks, 7.5 kJ/m2 
for 4wks and finally for 6 month with 10 kJ/m2. All mice were monitored weekly for tumor 
development by two independent investigators for additional four months. The location and 
growth of each tumor exceeding 2 mm in diameter was recorded. The method of Kaplan 
and Meier was used to describe the probability of tumor development in the carcinogenesis 
study. Immunhistochemistry of UV-induced tumors was performed on cryostat sections (3 
µm) fixed in acetone according to standard methods. Slides were incubated in the appropriate 
dilution of anti-CD8 (clone 53-6.7; Becton Dickinson) and an Alexa-488 labeled secondary 
antibody (Molecular Probes) and examined using a Zeiss 200M confocal microscope and the 
LSM510Meta software. Statistical differences for the development of tumors between the 
two strains of mice were determined using a log-rank test.
Therapeutic CD8+ T-cell transfer into rag2-/- mice. CD8+ cells were purified from spleens 
and lymph nodes of naïve cbl-b-/- and cbl-b+/+ mice by positive selection using Magnetic 
beads against CD8 (Miltenyi Biotec) following the manufactures recommendations (purity 
was over 90% as determined by CD8β and CD3 double staining). Three and six days after 
tumor cell injection 3 x 106 and 2 x 106 CD8+ cells were adoptively transferred into the tumor 
bearing   rag2-/- mice, respectively. Tumor growth was monitored three times per week.
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Re-stimulation and intracellular cytokine staining. Cells were isolated from spleens and 
lymph nodes of tumor bearing cbl-b-/- and cbl-b+/+ mice as well as naïve controls of each 
genotype and CD8+ T cells were purified using positive magnetic bead sorting (Miltenyi 
Biotec). CD8+ cells (2x105/well) were stimulated in vitro for 3 days with HPV16-E749–57 
peptide-loaded splenocytes (10µg/ml peptide; 20Gy irradiated; 2x105 APCs per well) in 
complete medium. Golgi plug was added for the last 4h and the cells were stained for CD8β and 
CD3 surface expression. Following fixation, intracellular IFNγ levels were then determined 
using a cytoperm/cytofix kit from BD Pharmingen (according to the manufacturer’s protocol). 
Cells were analyzed by FACS (BD).
Histology and immunohistochemistry. Tumors were dissected and frozen in OCT for 
cryosections or fixed with 3.7% formaldehyde prior to paraffin embedding. For histological 
analysis, 5 µm thick sections were cut and stained with hematoxylin and eosin (H&E) 
using standard protocols. TUNEL (Roche) and Ki67 stainings were performed on paraffin 
embedded sections. Tumor infiltrating CD8β+ and CD4+ were detected on frozen sections by 
immunofluorescence. FoxP3 staining was performed on frozen sections and on PolyPrepTM 
slides (sigma) coated with FACS-sorted CD4+CD25+ cells by immunocytochemistry. Confocal 
images were taken using a Zeiss LSM510 Microscope.
Treg suppressor assays. Different concentrations of sorted CD25+CD4+ Treg cells from naïve 
cbl-b+/+ and cbl-b-/- mice were co-cultured with CD8+ effector T cells (5*104/well) isolated 
from wild-type and cbl-b-/- mice in the presence of 2*105 irradiated (3,000 rads), T depleted 
splenocytes and 1 μg/ml of purified mouse anti-CD3ε in 200μl Iscove’s modified Dulbecco’s 
medium supplemented with 10% FCS in 96-well round-bottomed plates. Proliferation was 
measured by scintillation counting following a pulse with 1 μCi of [3H]thymidine per well for 
the last 12 h of a 72h -hour incubation period.
ACKNOWLEDGMENTS. 
We thank Vukoslav Komnenovic, Ivan Botto, Johannes Tkadletz, Gabi Stengl and Pawel 
Pasierbek for technical support, and all members of the Penninger laboratory for helpful 
discussions. JMP is supported by grants from EuroThymaide (EU), the Austrian FWF (SFB 
on immunotolerance), IMDEMI (EU), EuroRA (EU), the Austrian National Bank, IMBA, and 
the Austrian Ministry of Sciences. SL is a EuroThymaide fellow. KL and SB are supported by 
the Interdisciplinary Center of Clinical Research (IZKF, grants Lo2/65/04 and Lo2/17/07), 
the Innovative Medical Research Fund (IMF, grant Lo110603) and the German Research 
Cbl-b and anti-tumor immunity
142
Association (DFG, grant BE1580/7-1). MSB is supported by the Dutch Cancer Society grant 
UL 2003-2817. Competing interest: JMP has shares in a company that attempts to develop a 
Cbl-b inhibitor. 
REFERENCES 
1. Pardoll, D.M. 1993. New strategies for enhancing the immunogenicity of tumors. Curr Opin Immunol 5:719-
725.
2. Burnet, F.M. 1970. The concept of immunological surveillance. Prog Exp Tumor Res 13:1-27.
3. Dunn, G.P., L.J. Old, and R.D. Schreiber. 2004. The immunobiology of cancer immunosurveillance and 
immunoediting. Immunity 21:137-148.
4. Staveley-O’Carroll, K., E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. 
Levitsky. 1998. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. 
Proc Natl Acad Sci U S A 95:1178-1183.
5. Speiser, D.E., R. Miranda, A. Zakarian, M.F. Bachmann, K. McKall-Faienza, B. Odermatt, D. Hanahan, R.M. 
Zinkernagel, and P.S. Ohashi. 1997. Self antigens expressed by solid tumors Do not efficiently stimulate naive 
or activated T cells: implications for immunotherapy. J Exp Med 186:645-653.
6. Yu, X., R. Abe, and R.J. Hodes. 1998. The role of B7-CD28 co-stimulation in tumor rejection. Int Immunol 
10:791-797.
7. Phan, G.Q., J.C. Yang, R.M. Sherry, P. Hwu, S.L. Topalian, D.J. Schwartzentruber, N.P. Restifo, L.R. Haworth, 
C.A. Seipp, L.J. Freezer, K.E. Morton, S.A. Mavroukakis, P.H. Duray, S.M. Steinberg, J.P. Allison, T.A. Davis, 
and S.A. Rosenberg. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated 
antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100:8372-8377.
8. Lollini,P.L., F. Cavallo, P. Nanni, G. Forni.2006. Vaccines for tumour prevention. Nat Rev Cancer 6:204-216.
9. Townsend, S.E., and J.P. Allison. 1993. Tumor rejection after direct costimulation of CD8+ T cells by B7-
transfected melanoma cells. Science 259:368-370.
10. Thien, C.B., and W.Y. Langdon. 2001. Cbl: many adaptations to regulate protein tyrosine kinases. Nat Rev Mol 
Cell Biol 2:294-307.
11. Bachmaier, K., C. Krawczyk, I. Kozieradzki, Y.Y. Kong, T. Sasaki, A. Oliveira-dos-Santos, S. Mariathasan, 
D. Bouchard, A. Wakeham, A. Itie, J. Le, P.S. Ohashi, I. Sarosi, H. Nishina, S. Lipkowitz, and J.M. Penninger. 
2000. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 
403:211-216.
12. Chiang, Y.J., H.K. Kole, K. Brown, M. Naramura, S. Fukuhara, R.J. Hu, I.K. Jang, J.S. Gutkind, E. Shevach, 
and H. Gu. 2000. Cbl-b regulates the CD28 dependence of T-cell activation. Nature 403:216-220.
13. Jeon, M.S., A. Atfield, K. Venuprasad, C. Krawczyk, R. Sarao, C. Elly, C. Yang, S. Arya, K. Bachmaier, L. 
Su, D. Bouchard, R. Jones, M. Gronski, P. Ohashi, T. Wada, D. Bloom, C.G. Fathman, Y.C. Liu, and J.M. 
Penninger. 2004. Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity 21:167-
177.
14. Heissmeyer, V., F. Macian, S.H. Im, R. Varma, S. Feske, K. Venuprasad, H. Gu, Y.C. Liu, M.L. Dustin, and A. 
Rao. 2004. Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins. Nat 
Immunol 5:255-265.
15. Krawczyk, C.M., R.G. Jones, A. Atfield, K. Bachmaier, S. Arya, B. Odermatt, P.S. Ohashi, and J.M. Penninger. 
2005. Differential control of CD28-regulated in vivo immunity by the E3 ligase Cbl-b. J Immunol 174:1472-
1478.
16. Gronski, M.A., J.M. Boulter, D. Moskophidis, L.T. Nguyen, K. Holmberg, A.R. Elford, E.K. Deenick, H.O. 
Kim, J.M. Penninger, B. Odermatt, A. Gallimore, N.R. Gascoigne, and P.S. Ohashi. 2004. TCR affinity and 
negative regulation limit autoimmunity. Nat Med 10:1234-1239.
17. Wohlfert, E.A., M.K. Callahan, and R.B. Clark. 2004. Resistance to CD4+CD25+ regulatory T cells and TGF-
beta in Cbl-b-/- mice. J Immunol 173:1059-1065.
18. Wohlfert, E.A., L. Gorelik, R. Mittler, R.A. Flavell, and R.B. Clark. 2006. Cutting edge: deficiency in the E3 
ubiquitin ligase Cbl-b results in a multifunctional defect in T cell TGF-beta sensitivity in vitro and in vivo. J 
Immunol 176:1316-1320.
19. Lin, K.Y., F.G. Guarnieri, K.F. Staveley-O’Carroll, H.I. Levitsky, J.T. August, D.M. Pardoll, and T.C. Wu. 
1996. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II 
presentation of tumor antigen. Cancer Res 56:21-26.
143
20. zur Hausen, H. 1996. Papillomavirus infections--a major cause of human cancers. Biochim Biophys Acta 
1288:F55-78.
21. Harper, D.M., E.L. Franco, C. Wheeler, D.G. Ferris, D. Jenkins, A. Schuind, T. Zahaf, B. Innis, P. Naud, 
N.S. De Carvalho, C.M. Roteli-Martins, J. Teixeira, M.M. Blatter, A.P. Korn, W. Quint, and G. Dubin. 2004. 
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus 
types 16 and 18 in young women: a randomised controlled trial. Lancet 364:1757-1765.
22. Zwaveling, S., S.C. Ferreira Mota, J. Nouta, M. Johnson, G.B. Lipford, R. Offringa, S.H. van der Burg, and 
C.J. Melief. 2002. Established human papillomavirus type 16-expressing tumors are effectively eradicated 
following vaccination with long peptides. J Immunol 169:350-358.
23. Feltkamp, M.C., H.L. Smits, M.P. Vierboom, R.P. Minnaar, B.M. de Jongh, J.W. Drijfhout, J. ter Schegget, C.J. 
Melief, and W.M. Kast. 1993. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects 
against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23:2242-2249.
24. Diehl, L., A.T. den Boer, S.P. Schoenberger, E.I. van der Voort, T.N. Schumacher, C.J. Melief, R. Offringa, 
and R.E. Toes. 1999. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte 
tolerance and augments anti-tumor vaccine efficacy. Nat Med 5:774-779.
25. Lavergne, E., C. Combadiere, M. Iga, A. Boissonnas, O. Bonduelle, M. Maho, P. Debre, and B. Combadiere. 
2004. Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell 
infiltration. J Immunol 173:3755-3762.
26. Cavallo, F., R. Offringa, S.H. van der Burg, G. Forni, and C.J. Melief. 2006. Vaccination for treatment and 
prevention of cancer in animal models. Adv Immunol 90:175-213.
27. Melief, C.J., R.E. Toes, J.P. Medema, S.H. van der Burg, F. Ossendorp, and R. Offringa. 2000. Strategies for 
immunotherapy of cancer. Adv Immunol 75:235-282.
28. Willimsky, G., and T. Blankenstein. 2005. Sporadic immunogenic tumours avoid destruction by inducing T-
cell tolerance. Nature 437:141-146.
29. Turk, M.J., J.A. Guevara-Patino, G.A. Rizzuto, M.E. Engelhorn, S. Sakaguchi, and A.N. Houghton. 2004. 
Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp 
Med 200:771-782.
30. Di Paolo, N.C., S. Tuve, S. Ni, K.E. Hellstrom, I. Hellstrom, and A. Lieber. 2006. Effect of adenovirus-mediated 
heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on 
antitumor immune responses. Cancer Res 66:960-969.
31. Beissert, S. 2002. Use of mutant mice in photoimmunological and photocarcinogenic investigations. Methods 
28:130-137.
32. Woodhead, A.D., R.B. Setlow, and M. Tanaka. 1999. Environmental factors in nonmelanoma and melanoma 
skin cancer. J Epidemiol 9:S102-114.
33. Gattinoni, L., D.J. Powell, Jr., S.A. Rosenberg, and N.P. Restifo. 2006. Adoptive immunotherapy for cancer: 
building on success. Nat Rev Immunol 6:383-393.
34. Pardoll, D. 2003. Does the immune system see tumors as foreign or self? Annu Rev Immunol 21:807-839.
35. Figdor, C.G., I.J. de Vries, W.J. Lesterhuis, and C.J. Melief. 2004. Dendritic cell immunotherapy: mapping the 
way. Nat Med 10:475-480.
36. Wick, M., P. Dubey, H. Koeppen, C.T. Siegel, P.E. Fields, L. Chen, J.A. Bluestone, and H. Schreiber. 1997. 
Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic 
anergy. J Exp Med 186:229-238.
37. Dudley, M.E., J.R. Wunderlich, P.F. Robbins, J.C. Yang, P. Hwu, D.J. Schwartzentruber, S.L. Topalian, R. 
Sherry, N.P. Restifo, A.M. Hubicki, M.R. Robinson, M. Raffeld, P. Duray, C.A. Seipp, L. Rogers-Freezer, K.E. 
Morton, S.A. Mavroukakis, D.E. White, and S.A. Rosenberg. 2002. Cancer regression and autoimmunity in 
patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854.
38. Kripke, M.L. 1977. Latency, histology, and antigenicity of tumors induced by ultraviolet light in three inbred 
mouse strains. Cancer Res 37:1395-1400.
39. Beissert, S., J.A. Bluestone, I. Mindt, M. Voskort, D. Metze, A. Mehling, T.A. Lugar, T. Schwarz, and S. 
Grabber. 1999. Reduced ultraviolet-induced carcinogenesis in mice with a functional disruption in B7-
mediated costimulation. J Immunol 163:6725-6731. 
Cbl-b and anti-tumor immunity
144
145
Design and development of
synthetic peptide vaccines
7
146
adapted from
Expert Review of Vaccines
2007 Aug;6(4):591-603.
Martijn S. Bijker1, Cornelis J. M. Melief1, 
Rienk Offringa1, Sjoerd H. van der Burg2
1Department of Immunohematology and Blood Transfusion, 
2Department of Clinical Oncology, 
at the Leiden University Medical Center, 
Albinusdreef 2, 2333 ZA Leiden, 
The Netherlands. 
147
Design and development of synthetic peptide 
vaccines: past, present, and future.
Abstract. Synthetic peptide vaccines aiming at the induction of a protective CD8+ T cell 
response against infectious or malignant diseases are widely used in the clinic but despite 
their success in animal models they yet do not live up to their promise in humans. This review 
assesses the development of synthetic peptide vaccines, weighs it against the immunological 
concepts that meanwhile have emerged, and identifies the key issues that play a role in failure 
or success of a synthetic peptide vaccine. The current state-of-the-art peptide vaccine is a 
complete synthetic inflammatory product that is ingested by professional antigen presenting 
cells and stimulates both CD4+ and CD8+ T cells.
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SYNTHETIC PEPTIDE VACCINES: IMMUNITY VERSUS 
TOLERANCE
In the 1950s the host’s immune system was shown to reject tumors following the recognition 
of tumor-associated Ag (TAA) (1-4). Subsequently, Zinkernagel and Doherty discovered 
in 1974, that the recognition of target cells by CD8+ T cells was restricted by the Major 
Histocompatibility Class (MHC) I molecules (5). Townsend et al. then revealed that CD8+ 
T cells were able to sense short linear peptide sequences of 11-16 amino acid (a.a.) in 
length, generated by proteolytic degradation of the target antigens that were presented in 
the context of MHC class I molecules (6-8). Subsequently, the group of Rammensee and 
colleagues revealed that the exact MHC class I binding peptides (CD8+ T cell epitopes, 
Fig. 1A) recognized by CD8+ T cells were even smaller peptides - 8 amino acids (a.a.) (9-
11) - and that these peptides contained specific amino acids that anchored the peptide in the 
pockets of the MHC class I molecule (12). This knowledge resulted in the rapid identification 
of CD8+ T cell epitopes in both mice (13-16) and human beings (12) and in exploration of the 
use of  peptide vaccines against multiple diseases. 
The first peptide vaccine able to induce a Cytotoxic T lymphocyte (CTL) response in vivo, 
was reported by Aichele et al. (17) who injected mice with a peptide encoded by lymphocytic 
choriomeningitis virus (LCMV) (Fig. 1B). Peptide vaccination was also shown to induce 
a protective CTL response against lethal challenges with live viruses, such as LCMV (18) 
and Sendai virus (19), against a lethal challenge with Human Papilloma Virus (HPV) type 
16 positive tumor cells (20) or methylcholanthrene-induced sarcomas (21), and was shown 
to enhance the life-span of mice in a spontaneous lung carcinoma metastasis model (22) 
(Fig. 1B). However, not all peptide vaccines induced strong protective CTL responses. For 
instance, vaccination with peptides from the circumsporozoite protein from malaria (23), 
or GP100 (24) induced low levels of CTL responses while vaccination with Her2/neu 
peptides in patients induced only short-lived CD8+ T cell responses (25). In contrast, some 
peptide vaccines did not induce protective CTL responses (26-28) or even enhanced tumor 
cell growth due to the induction of CD8+ T cell tolerance (29,30). Despite these opposing 
outcomes, many synthetic peptide-based clinical trials have been initiated in cancer patients 
with disappointing immunological and clinical responses (reviewed in (31,32)). In this review 
we have explored the short-comings of these peptide-based vaccines and provide a basis for 
the rational design of improved peptide vaccines that are able to induce strong and sustained 
T cell responses. Since a complete overview of the results obtained by peptide vaccines in 
patients has recently be published by Mocellin et al. (31), we only refer to specific examples 
in this review. 
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HOW TO ENHANCE THE CD8+ T CELL RESPONSES
Increasing the peptide afﬁnity.
Many (self) minimal CTL peptides have relatively low binding affinity for the MHC class 
I complex and, therefore, are not able to induce a strong CD8+ T cell response. The affinity 
of the peptide (33-35) and the dissociation constant of the peptide (36) determine the time 
before the peptide:MHC complex is displaced from the cell surface. Site directed substitution 
of specific amino acid positions in these peptides (Fig. 1C, I) can therefore induce more 
stable peptide:MHC class I complexes and thereby enhance the immunogenicity of these 
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Figure 1. Design of peptide-based vaccines; choosing and designing the right peptide(s). A. Deﬁnition of 
CD8+ and CD4+ T cell epitopes. In a given protein sequence there can be multiple CD8+ (blue) and CD4+ (purple) 
T cell epitopes present that can bind to different MHC/HLA class I and II molecules, respectively. These CD8+ 
and CD4+ T cell epitopes can be located at distinct positions in the protein sequence, or could be (partially) 
overlapping; striped blue/purple bars. B. Peptide vaccines can come in many ﬂavors, for instance: I) minimal CTL 
or Th peptides; II) multiple minimal CTL and/or Th peptides; III) minimal CTL and Th peptides that are N- and 
C-terminally extended; IV) single peptides that contain both a CTL and a Th epitope that (partially) overlap; or 
V) a set of overlapping peptides that cover the whole protein sequence, containing all possible CD8+ and CD4+ 
epitopes of the protein. C. Engineered peptide vaccines with enhanced immunogenicity. In order to enhance 
the immunogenicity of a peptide vaccine several strategies can be undertaken: I) the afﬁnity of a MHC/HLA 
class I binding peptide can be altered/enhanced by changing certain amino acids (red star); II) minimal CTL and 
Th peptides can be physically linked to form long Th-CTL or CTL-Th fusion peptides; or III) different forms of 
peptides can be conjugated to TLR ligands.
ProteinA
B
CD8+ CD4+
Minimal CTL or Th peptide
Multiple minimal CTL and/or Th peptides
Overlapping CTL and Th peptides
I
III
II
IV
V
Extended minimal CTL or Th peptides
Extended peptides covering the whole 
protein sequence containing multiple
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CTL binding peptide with enhanced affinityI
Fusions of minimal CTL and Th peptides
(Th–CTL or CTL–Th)
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peptides (33,37-39). As a result, injection of these modified peptides could confer protection 
against a subsequent lethal tumor challenge in mice (40,41) as well as increase the magnitude 
of the CD8+ T cell  response in melanoma patients (42,43).
Another approach to enhance the immunogenicity of MHC class I restricted peptides is to 
design a super-agonist peptide able to interact more efficiently with the T cell receptor of 
CD8+ T cells (Fig. 1C, I), as demonstrated with the Melan-A/Mart-1
27-35
 epitope (44). Site 
directed substitution of certain a.a. in the minimal CTL peptides could therefore be a genuine 
strategy to enhance the magnitude of peptide vaccine induced T cell responses. However, in 
some cases alteration of peptides resulted in the induction of T cell responses with TCRs not 
able to cross-react with the wild type peptide (45,46), indicating the limitations in applying 
such a strategy. 
Inclusion of CD4+ T cell peptide-epitopes; a helping hand for the Cytotoxic 
T Lymphocyte.
Central to the induction of strong and sustained CTL immunity is the presentation of minimal 
CTL peptides by matured DC which endow the responding CD8+ T cells with the necessary 
signals that allow them to become functionally active (47). In addition, CD8+ CTL require 
the presence of cytokines such as IL-2 that support them to rapidly expand. Lack of DC 
maturation or supporting cytokines may result in a vaccine-induced CD8+ T cell response 
that is transient and weak, even when peptides with strong MHC binding affinity are used. A 
proper way to increase the magnitude and long-term efficacy of the CD8+ T cell response is 
through the provision of help by CD4+ T helper cells (Fig. 1B).
The helping role of CD4+ T cells is versatile. Upon activation, the CD4+ T cell can secrete 
the cytokine IL-2 (48), which is an important growth factor for (CD8+) T cells; CD4+ T cells 
can activate the DC via CD40-CD40L interactions (49-51) that can subsequently license the 
CD8+ T cell to kill its target cell and CD4+ T cells can program CD8+ T cells via the Antigen 
Presenting Cell (APC) to become memory cells (52). 
This important role for the CD4+ T cell in the induction of a protective CD8+ T cell response 
by peptide vaccination against LCMV became apparent after it was realized that the peptide 
vaccine used by Aichele et al. (17) comprised both a CD8+ T cell epitope and a CD4+ T cell 
epitope (53) (Fig. 1B, IV). In vivo depletion of the CD4+ T cell population almost completely 
abrogated the vaccine-induced protective effect against LCMV (53). In addition, CD4+ 
T-cell help was shown to be indispensable for the induction of long lasting immunity against 
tumors. Eradication of MHC class II-negative FBL erythroleukemia cells was only observed 
when the mice were injected with a vaccine that only contained a tumor-specific Th peptide 
(54) (Fig. 1B, I). Indeed vaccination with an exclusive Th peptide protected mice against 
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MHC class II-negative virus induced tumors (Fig. 1B, I), but optimal protection was achieved 
by vaccination with both a minimal Th peptide and a dominant minimal CTL peptide (28) 
(Fig. 1B, II). This principle of providing help was endorsed in a phase I clinical trial in which 
patients were vaccinated with minimal CTL peptides of melanoma-associated tyrosinase 
antigen. Tyrosinase peptide specific IFNγ-producing T cells were detected only if the patients 
simultaneously received the non-specific helper protein keyhole limpet hemocyanin (KLH) 
in addition to the minimal tyrosinase CTL peptide vaccine (55).
Further improvements in peptide vaccines were achieved by directly linking the 
minimal Th peptide to the minimal CTL peptide to form a single linear hybrid peptide 
[PbCS(57-70)-(251260)] (Fig. 1C, II) showed enhanced CTL responses in a mouse model 
for malaria (23). Similar observations were reported for peptide vaccines aiming at the 
induction of Human Immunodeficiency Virus-specific CTL (56) and Herpes Simplex 
Virus-specific CTL (57). However, not all the combinations of minimal Th and CTL peptide 
linkage showed enhanced reactivity. For instance, in a phase I clinical trial with stage IV 
patients, a gp100 specific T cell response was only observed in patients that had received the 
minimal CTL peptide gp100 and not in patient vaccinated with the gp100 minimal peptide 
that was C-terminally extended with a Th peptide derived from tetanus (58). The reason for 
the absence of gp100 specific T cells could be the additional amino acid sequence located 
at the C-terminus of the CTL epitope. Changing of the natural occurring C-terminal amino 
acid sequence can  change the processing by the proteasome and thus liberation of the CTL 
epitope (59,60). 
Interestingly, a number of peptide vaccines able to induce strong CD8+ T cell responses, 
not only comprised the minimal CD8+ T-cell epitope but also a CD4+ T cell epitope, e.g. 
LCMV (53), HPV (61), and mutant p53 (21) (Fig. 1B, IV). Co-localization of CD4+ and 
CD8+ epitopes has also been described in proteins that are target antigens in human beings, 
e.g. NY-ESO (62), Synovial Sarcoma X-2 breakpoint protein (63), and Mart-1/Melan-A 
(64). An elegant approach was undertaken by Knutson et al. who identified Her2/neu CD4+ 
T cell epitopes that comprised a (HLA-A2+) CD8+ T cell epitope within the same peptide 
sequence (65) (Fig. 1B, IV). In contrast to their clinical trial in which only a CD8+ T-cell 
epitope was used (25), vaccination with the peptides, comprising both CD4+ and CD8+ T-cell 
epitopes, resulted in the induction of long-lived Her2/neu specific CD8+ T cell responses. 
Thus, a simple approach to induce strong and long-term CD8+ T cell reactivity is the inclusion 
of CD4+ T cell epitopes in peptide vaccines. 
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Antigen-related or non-related CD4+
 
T cell help.
Addition of a minimal Th peptide enhanced the capacity of peptide vaccines to induce 
strong malaria-specific CTL responses (23,66) and protected mice against a subsequent 
tumor challenge (28,67,68). As yet it is not clear whether the CD4+ T cell epitope that is 
incorporated in the vaccine should be derived from the same (tumor) Ag or pathogen as 
the CD8+ T cell epitope. It has been argued that for optimal results both epitopes should be 
encoded in the same pathogen or tumor (28) (Fig. 1B, II, IV, V), while others have shown that 
this is irrelevant (23,55,67,69). This issue can only be solved when the intrinsic properties 
of CD4+ T-cell epitopes (Fig. 1A) - i.e. binding affinity or antigenic origin - are taken into 
account. It can be envisaged that CD4+ (viral) T cell peptides with high binding affinity 
for the MHC class II molecule will be more helpful to a developing CD8+ T cell response 
than the use of CD4+ T cell peptides which have a low binding affinity for MHC class II, as 
was the case for the non-related MHC class II I-Ab-restricted epitope of Ovalbumin (28). 
Similarly, CD4+ T cell epitopes derived from proteins to which partial tolerance exist may be 
less powerful with respect to the induction of a strong helper T cell response (70). 
Help can also be provided in the form of an agonistic CD40 Ab that triggers the CD40 
receptor on APC (49). Using CD40 agonistic Ab, a prophylactic vaccine consisting of 
the minimal CTL peptide of HPV16 E7 protein could be converted in to a vaccine with 
therapeutic anti-tumor potency (71) (Fig. 2, I). Furthermore, the use of agonistic CD40 Ab 
allowed eradication CD40 negative tumors in tumor-bearing mice (72). This depended on 
the activation of tumor-antigen presenting CD11c+ APC in the draining Lymph Node (LN) 
(73). However, this type of “help” requires complete tumor or virus eradication, because 
it is associated with an acute wave of effector CTLs. In case of chronic disease, additional 
injections (of aCD40 Ab) are required.
This latter argument also applies to the use of non-related CD4+ T cell epitopes in peptide 
vaccines. Although such CD4+ T cell epitopes can effectively induce a CD4+ T cell response 
that helps the development of an acute wave of CTL, this CD4+ T cell response is rather useless 
in re-activating the CTL response upon secondary challenge or to sustain CTL responses in 
case of chronic infection/diseases, simply because the cognate Ag for these CD4+ T cells is 
lacking. Provision of both the minimal (non-related) Th and (related) CTL peptides in IFA 
- that induces long-term Ag presentation of both peptides simultaneously in the dLN (74) - 
might however, sustain APC activation and thereby CTL reactivity and might to some extent 
circumvent this problem. Note, however that the vaccination with Ag-related minimal Th 
peptides will ensure reactivation of these Ag-specific CD4+ T cells, that subsequently provide 
help to the Ag-specific CD8+ T-cell response upon re-challenge. 
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Length of the peptide.
Unexpectedly, the length of the peptide used for vaccination strongly influences the magnitude 
of the induced CD8+ T cell response (Fig. 1B, III-IV). In a head-to-head comparison, a 35 
amino acid long peptide containing the HPV16 E7
49-57
 CD8+ T cell epitope induced a robust 
CD8+ T cell response capable of eradicating an established tumor, while the minimal CTL 
peptide (9 a.a. long) could not (75). One of the underlying mechanisms is that extension of 
these minimal CTL peptides to a longer peptide, increased the duration of Ag presentation 
in vivo and thereby enhanced the magnitude of the CD8+ T cell response and reviewed in 
(reviewed in (76) and C).
Additionally, the presentation of the CTL epitopes from the extended peptides requires Ag 
processing by professional APC, whereas the minimal CTL peptide can bind exogenously 
to MHC class I molecules. This might also explain why many of the first reported, so called 
“short synthetic peptides” performed so well. These “short synthetic peptides” were indeed 
relatively short when compared to whole antigens, but still were not the exact MHC class 
I binding peptides that - based on these animal models - are nowadays used in vaccine 
trials in humans. Actually, the vaccines used in these animal models could reach up to 27 
amino acids in length (17-20,77-80) (Fig. 1B, III-IV) and, as such, should be qualified as 
Ag-processing dependent peptides that are more immunogenic than their exact MHC class I 
binding counterparts (75).
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Figure 2. Additional immune interventions to enhance vaccine efﬁcacy. In order to enhance the 
immunogenicity and efﬁcacy of a peptide vaccine additional immune interventions can be applied. Ab: Antibody; 
APC; Antigen-presenting cell; TLR Toll-like receptor; Treg; T-regulatory cell.
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Using adjuvants to enhance immune reactivity.
The most devastating signal a T cell can receive is that through interaction of its T-cell 
receptor and a MHC-peptide complex presented on a non-activated and non-matured APC. T 
cell activation in the absence of co-stimulatory molecules or pro-inflammatory cytokines will 
generally result in the induction of tolerance (reviewed in (81)). The main hallmark of good 
vaccines is that they closely mimic the most successful natural triggers of DC activation. 
Therefore peptide vaccines have to be formulated with different kinds of adjuvants that 
enhance the magnitude, survival and polarization of the vaccine-induced T cells. 
A very common vehicle and adjuvant for vaccination is oil-in-water emulsion (reviewed in 
(82)). The best known are: Complete Freund’s Adjuvant (CFA), Incomplete Freund’s Adjuvant 
(IFA), and Montanide ISA-51. Besides CFA – that contains heat killed Mycobacterium 
tuberculosis – the other two adjuvants only contain mineral oil and their adjuvant effect is 
based on the formation of a depot from which Ag is slowly released into the system. Another 
promising adjuvant is Immuno Stimulatory Complexes (ISCOMs) ((83) and reviewed in (84)). 
ISCOMs are cage-like structures that are comprised of antigen, cholesterol, phospholipid, 
and saponin that targets the antigen and adjuvant components of the vaccine to both the 
endosomal and cytosolic pathways for antigen presentation.
Other ways to strongly activate DC are the use of Toll Like Receptor (TLR) ligands. These 
ligands mimic certain structures commonly found on the outside and inside of pathogens 
that can deliver danger signals upon binding to the TLR at the surface or inside the APC. 
Examples of the most common naturally occurring danger signals are: pathogen-derived 
RNA or DNA, lipoproteins/peptides, lipopolysaccharide (LPS), and peptidoglycan (reviewed 
in (85)). Inclusions of synthetic analogous of these TLR ligands into vaccines provide an 
ultimate way to enhance vaccine induced T cell responses via the activation of TLR on 
professional APC. So far many different TLR ligands have been exploited in vaccine studies 
in mice ((75,86) and Chapter 4+5). In human beings, monophosphoryl lipid A (a detoxified 
form of LPS)  - that triggers TLR4 - was proven to be safe as a clinical vaccine adjuvant in 
combination with a recombinant protein vaccine against malaria (87). The use of CpG 7909 
– a TLR9 ligand – in combination with a Melan-A minimal CTL peptide in IFA not only 
enhanced the magnitude of Melan-A specific CD8+ T cells compared to the minimal CTL 
peptide vaccine without CpG, it also changed the phenotype of these CD8+ T cells from IFNγ 
producing cells to IFNγ producing cells that were also granzyme and perforin positive (88).
Direct coupling of the TLR ligands to Ag forms a next generation of vaccines (Fig. 1C, III). 
A pioneer study by Rammensee showed that the use of peptide linked to lipopeptides induced 
the same high affinity T cells as live influenza virus (89). Others have shown that coupling 
enhances Ag uptake by professional APC ((90) and Chapter 5), enhances Ab and T cell 
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responses (91,92) and induces a more vigorous and protective T cell response to pathogens, 
with similar efficacy as a live vaccines (93). While the use of TLR ligands, and especially 
multiple TLR ligands (94,95), generally provides a potent APC stimulating environment 
needed for the induction of effector T cell responses, they may also unleash unwanted T-cell 
responses. For instance, in mice the use of TLR2 ligand (Pam3Cys) induces proliferation of 
Treg cells (96) and systemic application of CpG elicits potent regulatory responses by acting 
on a discrete, minor population of splenic DCs (97). 
PHARMACOKINETICS OF PEPTIDE VACCINES DETERMINE 
OUTCOME
Of all the vaccinations with minimal CTL peptides (Fig. 1B), many resulted in the induction 
of a detectable but weak CD8+ T cell response and some peptide vaccines were even reported 
to induce T cell tolerance. Multiple (systemic high dose) vaccinations with the minimal CTL 
peptide GP
33-41
 of LCMV in IFA resulted in CD8+ T cell tolerance (27) or deletion of GP
33-41
 
specific transgenic CD8+ T cells (26). This induction of CD8+ T cell tolerance has been 
attributed to the multiple high doses of peptide, which likely over-activated/stimulated the 
responding CD8+ T cells and subsequently induced apoptosis (27).
However, Toes et al. reported in an adenovirus tumor model that already a single injection 
with a low dose of the strong MHC class I binding CD8+ T cell peptide-epitopes of adenovirus 
(Ad5E1A or Ad5E1B) in IFA tolerized adenovirus-specific CD8+ T cells and enhanced tumor 
cell outgrowth (29,30). This result is not restricted to vaccination with these Ad5E1A or 
Ad5E1B minimal CTL peptides, as this also occurred after vaccination with the highly 
immunogenic Ovalbumin
257-264 
minimal CTL peptide (Chapter 2). 
Mechanism of peptide vaccine induced tolerance.
The tolerogenic feature of Ad5E1A has been attributed to the fact that the Ad5E1A minimal 
CTL peptide very rapidly distributes throughout the whole body in contrast to, for instance 
an immunogenic minimal CTL peptide, like HPV16 E7 (98). Of note, the Ad5E1A minimal 
CTL peptide displays a very strong binding affinity to its cognate MHC class I molecule, 
whereas the HPV16 E7 minimal CTL peptide displays only intermediate affinity to the MHC 
class I molecule (33). We realized that the injection of these high affinity minimal MHC class 
I binding peptides resulted in the binding to cell surface expressed MHC class I molecules 
of passenger lymphocytes in the dLN and showed that these lymphocytes export the peptide 
to more distant lymph nodes (Chapter 3). The slow release and thereby long duration of Ag 
presentation induced by the IFA adjuvant – more than 100 days (74) – in combination with 
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minimal CTL peptides presentation in non-inflammatory LN by non-professional APC, will 
provide an optimal environment to induce CD8+ T cell tolerance (99,100), or the deletion 
of specific CD8+ CTL when peptide vaccine-activated CD8+ T-cells present the minimal 
CTL peptide themselves- fratricide (101). These data suggest that the injection of modified 
minimal CTL peptides displaying a strongly increased peptide binding affinity for MHC 
class I molecules in an oil-in-water adjuvant such as IFA or Montanide ISA51, might work 
counterproductive.
Prevention of peptide vaccine induced tolerance.
The studies described above indicate that the pharmacokinetics of the peptides used for 
vaccination are important to evaluate the capacity of a peptide vaccine to induce an effective 
immune response. In addition, help in the form of agonistic CD40 Ab (Figure 2,I) initially 
enhanced the magnitude of the Ad5E1A-specific (102) CD8+ T cell responses induced by 
peptide in IFA vaccines, however, this treatment did not prevent the tolerization of the 
responding CD8+ T cells at later stages (74). While the aCD40 antibody will be cleared rapidly 
from the system and as such is not able to activate the APC, the CD8+ T cell continuously 
receives signals by the minimal CTL peptide leaking out of the IFA depot for more then 
100 days (74) presented by non-activated APC. Importantly, the provision of continuous 
help by co-injection of a minimal Th peptide (Fig. 1B, II) in IFA, rescues CD8+ T cells from 
tolerance, indicating that CD4+ T cell help is not only important in enhancing the CD8+ T cell 
response as has been reported previously (23), but also in preventing the induction of CD8+ T 
cell tolerance (Chapter 2). These results teach us that both the APC activating signals and the 
T-cell activating signals (peptide) should be matched both in time and location. 
MULTI-EPITOPE VACCINES TO PREVENT IMMUNE ESCAPE
Many vaccination trials are performed with only a single minimal CTL peptide designed to 
fit only one HLA class I molecule and are therefore not widely applicable to many patients 
of different genetic backgrounds (Fig. 1B, I). Such a strategy not only narrows down the 
overall force that can be undertaken against an infected/transformed cell but also constrains 
the efficacy of the vaccines in the case of Ag loss variants or specific down regulation of HLA 
class I molecules by the target cell. 
This was exemplified by the sequential HLA and Ag loss variants of subsequent metastases 
of melanoma in a patient reported by Yamshchikov et al. (103). The first escape-variant 
showed selective loss of three HLA class I molecules. The second metastasis displayed 
the specific down-regulation of a HLA molecule involved in the presentation of a Mart-1 
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specific peptide, while still presenting a tyrosinase-derived epitope. Accordingly, Lehmann 
et al. reported that CTL lines that recognized the first metastasis did not cross react with the 
second metastasis, due to the selective loss of the HLA molecules to which the CTL lines 
were restricted (104). New CTL clones which specifically recognized the second metastasis 
were directed to a different HLA class I molecule and to a different antigen compared to the 
first metastasis. 
Multiple peptide-epitopes vaccines.
The most effective strategy for vaccination is the use of multiple CTL and Th epitopes of 
a given protein Ag so that they can be presented by many different HLA (Class I and II) 
molecules, reducing the chance of outgrowth of Ag and/or HLA class I loss variants. This 
can be achieved by vaccination with the whole Ag as a vaccine; either by overlapping long 
peptides that span the whole protein (Fig. 1B, V); or by using recombinant or synthetic 
proteins (Fig. 1A). Furthermore, attacking the cell via multiple Ag, would further enhance 
the strength and as such the success of the vaccine. 
For instance, the therapeutic use of overlapping peptides (27-34 a.a. long, Fig. 1B, V) spanning 
the entire Cottontail Rabbit Papilloma Virus (CRPV) E6 and E7 proteins was reported to 
induce regression of established warts induced by CRPV and a reduction of the CRPV viral 
load (105). A similar vaccine consisting of overlapping peptides (27-34 a.a.) spanning the 
sequence of HPV16 E6 and E7 induces CD4+ and CD8+ T cell responses in cervical cancer 
patients (Melief and Van der Burg, unpublished data). Also longer peptides, ranging from 
44-182 a.a. in length were effective in inducing strong Ab and T cell responses in mouse 
and human malaria model systems (106-110). In addition, linking of two long HPV16 E7 
peptides to create the synthetic protein (98 a.a. long) of HPV16 E7 was shown to be highly 
effective in clearing an established tumor (111). 
Besides the use of multiple antigens to target virally infected cells or tumor cells, the choice 
of proteins may contribute to the clinical success of vaccination. It is likely that proteins less 
susceptible to mutations (structural proteins of HIV) or proteins that are needed to maintain 
the oncogenic form of the cell would provide better target antigens. Examples would be 
anti-apoptotic proteins such as survivin (112), bcl-2 (113), bcl-xL (114), and Mcl-1 (115). 
Accordingly, telomerase reverse transcriptase (hTERT) (116) or proteins that are involved in 
resistance to chemotherapeutic agents such as TRAG-3 (taxol resistance gene) (117) might 
constitute appropriate target antigens for T-cells to attack malignant cells. 
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EXPERT COMMENTARY
Minimal CTL peptide vaccinations are widely used against multiple forms of cancer and 
other diseases. However, these peptide-based vaccines have so far induced little to no clinical 
or immunological responses (reviewed in (31,32)). We are convinced that the translation 
of  peptide vaccination from early pre-clinical mouse studies (17-20,27,77-80,118) to 
human clinical studies was flawed by an imperfect understanding of the mechanisms that 
play a role in successful peptide vaccination. First, while studies in human subjects almost 
always explore the efficacy of vaccines consisting of the exact HLA class I binding peptides 
(Fig. 1B, I), most of the groundbreaking studies which showed that “short synthetic peptide” 
vaccines could be effective in pre-clinical mouse studies, used peptides that were not exact 
MHC class I binding peptides. In general, the peptides were much longer and could reach 
up to 27 a.a. in length (17-20,77-80) (Fig. 1B, III-IV) and are therefore likely to be retained 
in the local draining lymph node where they are processed and presented by professional 
APC to CD8+ T cells ((75) and reviewed in (76)). Additionally, some of the “short synthetic 
peptides” contained also a CD4+ T cell epitope in the peptide sequence (17,53) (Fig. 1B, IV). 
These two factors – the predominant local presentation of peptides and the provision of CD4+ 
T-cell help (53,75)- which are lacking in most of the peptide vaccines used in human subjects, 
have greatly contributed to the enhanced efficacy of the early pre-clinical  “short synthetic 
peptide” vaccines tested in rodents. 
Second, the efficacy of many of the synthetic minimal CTL peptide vaccines that did seem 
to induce a proper CTL response, was assessed in prophylactic settings only (20,27,77,118). 
Importantly, the mice were lethally challenged when the CD8+ T cell response was at its 
maximum and, therefore, able to rapidly deal with the infection/tumor challenge (20,27,77,118). 
In patients, peptide vaccinations are given in a situation of established diseases, requiring 
first and foremost a need to build up a highly effective Ag-specific CD4+ and CD8+ T cell 
response, subsequently this immune response needs to be maintained for a long period of 
time to combat the disease. Notably, the early studies demonstrating that the use of minimal 
CTL peptide vaccines could induce tolerance when provided in oil-in-water formulations 
(IFA) (26,27,29,30) should have made us cautious in using minimal peptide-epitopes for 
vaccination. As we now know, the longer variants of these minimal CTL peptides provide 
a much safer form of vaccination (Chapter 2) (Fig. 1B. III). Moreover, since human beings 
display up to 8 different HLA class II molecules it is highly likely that these synthetic long 
CTL peptides (or proteins, Fig. 1A) contain CD4+ T cell epitopes for one or more HLA class 
II molecules (62,65) (Fig. 1B, IV-V) and this will ensure full activation of professional APC 
allowing optimal priming of CD8+ T cells (50,51). Covalent linking of synthetic TLR ligands 
to these synthetic peptide vaccines may be used to increase the magnitude of the CD8+ T cell 
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response ((90,91,93) and Chapter 5) (Fig. 1C, III). Hence, for design of a successful peptide 
vaccine, it is important to adhere to a number of principles shown in Table 1. 
Table 1. Basic principles for peptide vaccination
Multiple epitopes Vaccine containing multiple epitopes induces a broad 
(CD4+ and CD8+) T cell repertoire that reduces the 
chance of immune escape variants
(62,65,103-105, 
142-144)
Broad 
applicability
A (peptide) vaccine should be applicable for patients 
irrespective of their HLA type
(105)
Ag targeting to 
professional APC
Vaccines should contain peptides that predominantly 
target professional APC in order to prevent the 
possibility that T cells become tolerized by peptide 
presentatin on non-professional APC
(75,81) and 
Chapter 3,5
Extended 
duration of Ag 
presentation
Peptide vaccines should install sustained duration of Ag 
presentation in vivo for optimal (CD8+) T cell clonal 
expansion to occur
(145-147) and 
Chapter 2,3
Include CD4+ T 
cell help
Concomitant induction of CD4+ and CD8+ T cel 
responses enhances and maintains strond CD8+ T cell 
effector responses
(21,23,28,52-57, 
61-69,148-150) 
and Chapter 2 &4
Include strong 
APC activating 
signals
Provision of strong APC activating signals induces 
optimal activatin and expansion of effector T cells
(49-51,74,75,
85-95,102) and 
Chapter 3,4,5
Co-localization 
of Ag and APC 
activation
Ag presentation and APC activating signals should be 
closely matched in time and location
(89-93) and 
Chapter 2,3,5
FIVE-YEAR VIEW
In our opinion the use of synthetic vaccines comprising multiple CD4+ and CD8+ T-cell 
epitopes is only the start of the next generation of therapeutic vaccines (Fig. 1B, V). There 
is a need for additional regimens to further optimize the efficacy of the vaccine (Figure 2). 
A generic method to improve both the magnitude and the efficacy of the vaccine-induced 
T-cell response is to use longer peptides (75) (Fig. 1B, III-V). While most peptide 
vaccinations are already applied in oil-in-water adjuvants such as Montanide/ISA-51, 
occasionally supplemented with TLR-ligands such as MPL or CpG ((87,88) and reviewed in 
(31,85)), the inclusion of the immune potentiating TLR ligands will become general practice. 
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Furthermore, vaccines exploiting antigens covalently linked to TLR ligands ((91,93,119) and 
Chapter 5) (Fig. 1C, III) increase the magnitude of the T-cell response as well as polarize the 
vaccine-induced immune response into a type 1 helper T cell/CTL response and are therefore 
likely to find their way into the clinic. 
Vaccines are likely to be used in combination with the injection of T cell growth hormones such 
as IL-2 (43,120), IL-15 (121,122) or cytokines complexed to specific Abs or soluble receptors 
(123-125) resulting in enhanced in vivo efficacy, while greatly reducing the toxicity of these 
hormones (Figure 2, II). Pre-existing Ag-specific T regulatory T cells that can be boosted 
by the vaccine itself (126-128), should be removed first by for instance cyclophosphamide 
pre-treatment (129) or by the use of recombinant IL-2 linked to diphtheria toxin (DAB389IL-
2) (130,131) (Figure 2, III). This will provide the right environment to further improve 
vaccine induced T cell response. 
Notably, other emerging strategies to enhance this vaccine-induced T-cell response are 
injection of antibodies that either target specific members of the TNF receptor family, such as 
OX40 (132,133) and 4-1-BB (134) (Figure 2, I). Recently it was shown that successful peptide 
vaccines able to induce vast numbers of gp100-specific CD8+ T-cells in melanoma patients, 
failed to induce concomitant clinical responses (135). This lack of clinical efficacy could be 
alleviated by blocking the inhibitory signal given to T cells using blocking antibodies against 
CTLA-4 (136,137) (Figure 2, I). Note, however, that the use of aCTLA-4 might, in the case 
that self-proteins are the target antigen, also result in the induction of auto-immunity (137). 
Alternative strategies can be the use of PD-L1 blocking Ab (reviewed in (138)). Additionally, 
inhibition of immune regulatory proteins in T cells - such as Cbl-b - could further improve the 
expansion and effectiveness of the T cell responses (Chapter 6).
In contrast to the treatment of hematological cancers,  the homing of immune cells to solid 
tumors is essential but often fails to occur due to immunosuppressive mechanisms (139). 
Immunotherapy trials that combine vaccines together with modalities that are able to induce 
pro-inflammatory signals, either induced by chemotherapy (140), radiation, or by application 
of creams that contain TLR ligands on accessible lesions (141) are likely to be more successful 
in recruiting effector T cells (Figure 2, IV). 
We therefore expect that the first successful product will be a completely synthetic 
inflammatory product comprising multiple Ag determinants - provided as long peptides 
or synthetic/recombinant proteins (Fig. 1A) - that will be ingested by professional APC 
and following Ag processing stimulates both CD4+ and CD8+ T cells. This product that 
is likely to be given in combination with one or more therapeutic modalities that reduce 
immunosuppression and enhance T cell expansion as well as T cell homing.
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KEY ISSUES
• The lack of a profound insight in the mechanisms of peptide-induced CD8+ T-cell 
response by minimal CTL peptides, explains in part their failure to induce clinical 
responses in human vaccination trials. 
• The induction of a strong T-cell response by (peptide) vaccines requires that both Ag 
presentation and the APC activating signals have to be matched both in time  and in 
location.
• An inherent risk of (peptide) vaccines is that not only beneficial helper CD4+ T cells 
but also detrimental (pre-existing) regulatory T-cells are stimulated by vaccines. 
• The immunotherapy of cancer will be a multi-modality approach in which synthetic 
(peptide) vaccines will be combined with strategies to decrease immune suppression, 
enhance T-cell expansion, effector potential, and T-cell homing. 
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NEDERLANDSE SAMENVATTING
Met vaccinaties kunnen veel ziektes voorkomen worden, zoals de mazelen, de rode hond 
en de griep. Echter een vaccin voor het voorkomen van kanker is veel moeilijker om te 
maken. Dit komt omdat de meeste kankers verschillend van elkaar zijn. Het is niet mogelijk 
één vaccin te maken tegen verschillende soorten kankers. Vaccineren tegen kanker, kan dus 
pas wanneer je al kanker hebt, dit wordt therapeutische vaccinatie genoemd. Door middel 
van het injecteren van peptiden kun je het immuunsysteem activeren. Peptiden zijn stukjes 
eiwit. Wanneer peptiden gebruikt worden die specifiek zijn voor de kankercel, kun je het 
immuunsysteem activeren om zo de kanker op te ruimen. Gedurende mijn promotie onderzoek, 
heb ik het effect van de lengte van deze peptiden op de activatie van het immuunsysteem 
en de gepaard gaande antikanker respons onderzocht. Daarnaast heb ik onderzocht hoe 
we peptide vaccinaties verder kunnen optimaliseren door het toevoegen van verschillende 
soorten adjuvantia (immuun stimulerende stoffen) aan het vaccin. 
Het immuunsysteem
Het immuunsysteem bestaat uit een scala aan cellen met verschillende functies. Een van de 
belangrijkste cellen van het immuunsysteem zijn de professionele antigeen presenterende 
cellen (APC), waarvan de dendritische cellen (DC) de meest gespecialiseerde zijn. DC 
hebben lange uitlopers, dendrieten genaamd, waarmee ze pathogenen (virussen, bacteriën, 
of parasieten) of dode (kanker) cellen kunnen oppakken en internaliseren. De DC knipt 
vervolgens de eiwitten - van de pathogenen of de kankercellen - in kleine peptiden van 8-10 
aminozuren groot. Het peptide wordt samen met een ander eiwit – MHC – als een complex 
gepresenteerd. Het MHC heeft een groeve waar dit peptide precies in past. Het peptide, 
samen met het MHC wordt op het cel oppervlak als peptide:MHC complex gepresenteerd 
aan andere cellen van het immuunsysteem, de CD8+ T cellen. Wanneer de CD8+ T cel een 
peptide sequentie herkent op het oppervlak van de DC, wordt de CD8+ T cel geactiveerd 
voor dit specifieke peptide. De CD8+ T cel vermenigvuldigt waardoor er een groot leger aan 
CD8+ T cellen ontstaat wat specifiek is voor dat ene peptide. Vervolgens migreert de CD8+ T 
cel naar de door de pathogeen geïnfecteerde cellen of de kankercellen om deze vervolgens op 
te ruimen. CD8+ T cellen herkennen hun target cel aan de buitenkant. Iedere cel presenteert 
op het oppervlak, peptiden van alle eiwitten die zich in de cel bevinden als peptide:MHC 
complex. Indien een cel met een virus is geïnfecteerd of tot een kankercel is getransformeerd, 
worden dus ook peptiden van de eiwitten die daar betrokken bij zijn gepresenteerd. Zodra de 
CD8+ T cel het peptide:MHC complex herkent op de cel waarvoor het geactiveerd is, wordt 
deze cel opgeruimd.
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Peptide vaccinatie
Kanker specifieke peptiden die op de kankercel gepresenteerd worden als peptide:MHC 
complex, kunnen ook gebruikt worden voor vaccinatie. Het is per slot van rekening hetzelfde 
peptide waarmee de CD8+ T cel geactiveerd wordt om vervolgens de kankercel op te ruimen. 
Deze peptiden van 8-10 aminozuren lang worden korte peptiden genoemd. Het induceren 
van een antikanker respons met deze korte peptide is niet optimaal. Wanneer een peptide 
van 30 aminozuren lang wordt gebruikt voor vaccinatie - waar dezelfde sequentie van 
8-10 aminozuren in zit - blijkt de CD8+ T cel respons veel sterker te zijn dan wanneer het 
korte peptide voor vaccinatie wordt gebruikt. Het ontrafelen van dit fenomeen was een van 
het belangrijkste onderwerp van mijn promotie onderzoek
Dit proefschrift
Het effect van korte en lange peptiden vaccinaties hangt af van of het peptide in een waterige 
oplossing met een adjuvant (hoofdstuk 2) of in een olieachtige substantie - wat meestal in 
patiënten wordt gebruikt - wordt toegediend (hoofdstuk 3). De vorm van toediening bepaalt 
de duur van presentatie van de peptiden aan het immuunsysteem. Het peptide in het waterige 
vaccin wordt voor ongeveer 2 tot 10 dagen aan het immuunsysteem gepresenteerd (hoofdstuk 
2) terwijl de peptiden die in een olieachtige substantie worden toegediend voor meer dan 60 
dagen aan het immuunsysteem worden gepresenteerd (hoofdstuk 3). 
Bij het waterige vaccin zijn een aantal parameters belangrijk voor een antikanker respons 
(hoofdstuk 2). Dit zijn het aantal CD8+ T cellen geïnduceerd door het vaccin, het APC type 
dat het peptide presenteert en de sterkte van binding van het peptide aan het MHC. Een kort 
peptide dat niet zo goed bindt aan het MHC wordt maar 2 dagen door het immuunsysteem 
gepresenteerd aan de CD8+ T cellen. Hierdoor worden maar weinig CD8+ T cellen 
geïnduceerd en is er geen goede antikanker respons. Een langere duur van presentatie van 
10 dagen, wordt bereikt na vaccinatie met: een niet zo sterk MHC bindend lang peptide of 
met een sterk MHC bindend kort of lang peptide. Vaccinaties met deze peptiden induceren 
allemaal veel CD8+ T cellen. Echter de antikanker respons is het meest optimaal voor de 
beide langere peptiden. Deze peptiden worden namelijk door DC gepresenteerd, welke de 
meest professionele APC zijn in het immuunsysteem. Het sterk MHC bindend kort peptide 
wordt gepresenteerd door professionele en niet-professionele APC. Ondanks de inductie van 
veel CD8+ T cellen, zijn deze CD8+ T cellen niet goed in staat om de kanker op te ruimen. 
Het gebruik van lange peptiden voor vaccinaties tegen kanker lijkt dus altijd een sterkere 
immuunrespons te induceren dan het korte peptide.
Bij het olieachtige vaccin hebben we een kort en lang peptide dat sterk aan het MHC kan 
binden met elkaar vergeleken (hoofdstuk 3). De duur van presentatie speelt hierbij geen rol 
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aangezien beide peptiden voor meer dan 60 dagen gepresenteerd worden. De CD8+ T cel 
respons na vaccinatie met het korte peptide is kortdurend. Op dag 10 zijn de CD8+ T cellen 
te detecteren, op dag 30 zijn deze echter volledig verdwenen. Wanneer het lange peptide 
wordt gebruikt voor vaccinatie, zijn de CD8+ T cellen nog wel aanwezig op dag 30. Het 
verschil in het effect van korte en lange peptide vaccinaties ligt aan het APC type dat het 
peptide presenteert en aan de locatie waar het peptide wordt gepresenteerd. Het lange peptide 
wordt in de lymfeklier vlak bij de plek van vaccinatie door DC gepresenteerd. Echter bij het 
korte peptide zijn ook andere cellen betrokken bij de presentatie van het peptide, zoals B- en 
T cellen. Daarnaast wordt het korte peptide ook in het gehele lichaam door B- en T cellen 
gepresenteerd. Presentatie van het korte peptide door deze cellen kan leiden tot tolerantie 
of dood van de CD8+ T cel. Dit is precies wat we zien na vaccinatie met het korte peptide. 
Concluderend, wanneer een olieachtige substantie wordt gebruikt voor peptide vaccinatie, 
is alleen het lange peptide vaccin in staat om CD8+ T cellen te induceren die langdurig 
aanwezig blijven. Daarom is dit lange peptide vaccin beter om mee te vaccineren dan het 
korte peptide vaccin.
In hoofdstuk 4 staat het onderzoek beschreven van hoe een waterig lang peptide vaccin 
bestaande uit een peptide dat zowel CD8+ als CD4+ T cellen kan induceren, verbeterd kan 
worden door het toevoegen van een adjuvant. We hebben hiervoor verschillende soorten 
adjuvantia getest. Het onderzoek toonde aan dat de mate waarin het adjuvant de DC kon 
activeren niet bepalend was of er ook een goede CD8+ T cel respons werd geïnduceerd. 
Het aantal door het vaccin geïnduceerde CD8+ T cellen was ook hier belangrijk voor de 
antikanker respons maar niet doorslaggevend. Er waren drie adjuvantia die evenveel CD8+ T 
cellen induceerden, echter was maar één adjuvant goed in het induceren van CD8+ T cellen 
die ook de kanker konden opruimen. Belangrijke parameters van een goed antikanker vaccin 
zijn, dat het vaccin CD8+ T cellen induceerde die IFNgamma produceerden en dat het vaccin 
tegelijkertijd veel CD4+ T cellen activeerde.
In hoofdstuk 5 staat het onderzoek beschreven van het mechanisme waarom koppeling van 
een lang peptide aan een adjuvant, een betere CD8+ T cel respons induceert dan het niet 
gekoppelde vaccin. De reden hiervoor is dat door de koppeling meer peptiden in de DC terecht 
komen. Het adjuvant gedeelte van het complex wordt namelijk gebonden door receptoren op 
de DC. Hierdoor wordt dus tegelijkertijd het peptide door de DC opgenomen. De receptoren 
die betrokken waren bij de opname van het adjuvant bleken andere receptoren te zijn dan 
die verantwoordelijk zijn voor de activatie van de DC via dit adjuvant. Waarschijnlijk zijn 
algemene (‘scavenger’) receptoren betrokken bij de opname van deze adjuvantia.
In hoofdstuk 6 staat het onderzoek beschreven van de antikanker respons in muizen die het 
cbl-b gen missen. De onderzoeksvraag was of afwezigheid van het cbl-b gen, en daardoor het 
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eiwit, de antikanker T cel respons zou versterken. Afwezigheid van cbl-b leidt tot CD8+ T 
cellen die hypergevoelig zijn. Deze muizen waren in staat om spontaan grote hoeveelheden 
kanker cellen op te ruimen zonder dat ze gevaccineerd hoefden te worden. Het remmen van 
cbl-b in CD8+ T cellen tijdens een (peptide) vaccinatie in kanker patiënten zou daarom een 
additionele therapie kunnen zijn voor het induceren van een betere antikanker respons.
Samenvattend hebben we met dit onderzoek beter inzicht gekregen in hoe korte en lange 
peptiden vaccins werken. Daarnaast hebben we laten zien waarom lange peptiden vaccins 
een betere CD8+ T cel respons induceren dan korte peptiden vaccins. De keuze van het 
adjuvant speelt ook een cruciale rol in de effectiviteit van het vaccin en het koppelen van het 
adjuvant aan het lange peptide kan het effect van het vaccin verder versterken. Deze data zijn 
van groot belang voor het verdere ontwikkelen van toekomstige peptiden vaccins.
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